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GLOSSARY OF TERMS 
GP10 A prescription.  
 
Away Team The Pharmacist/manager and member of support staff from sites participating 
in the SPSP-PPC collaborative. 
 
Home Team Other staff working in the sites participating in the SPSP-PPC collaborative. 
 
Dosette Box Provided by Community Pharmacy/Dispensing practices, these are boxes with 
small compartments that show clearly which pills need to be taken at what time 
of day.  
 
Triple Whammy Combinations of diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), ACE 
inhibitors (ACEI) and/or angiotensin receptor antagonists (ARA) that may impair 
renal function. 
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INTRODUCTION 
The Scottish Patient Safety Programme-Pharmacy in Primary Care (SPSP-PPC) Collaborative 
i. Background to the SPSP  
The Scottish Patient Safety Programme (SPSP) is a national quality improvement initiative which 
launched in 2008. NHS Scotland collaborated with the Institute of Healthcare Improvement (IHI) on 
the programme, and the theoretical basis of the implementation process was depicted by Paul Carlile 
and Clay Christensen, who developed a driver diagram with actionable guidance on how to meet the 
ŽǀĞƌĂƌĐŚŝŶŐĂŝŵƚŽ “/ŵƉƌŽǀĞ^ĂĨĞƚǇŽĨ,ĞĂůƚŚĐĂƌĞ^ĞƌǀŝĐĞƐŝŶ^ĐŽƚůĂŶĚ ?(1). Within the acute sector a 
number of successes were achieved: a 7% reduction in hospital standardised mortality rates, a 70% 
reduction in Clostridium Difficile infectŝŽŶƐŝŶĐĞ ? ? ? ?ĂŶĚĂŶĂǀŽŝĚĂŶĐĞŽĨ ? ? ? ? ? ? “ďĞĚĚĂǇƐ ?ŝŶƚǁŽ
years for those over 65 years old (2).  
As an output of the NHS Quality Strategy 2010 (3), the SPSP migrated into primary care, and the 
programme is now led by NHS Healthcare Improvement Scotland (HIS). Following a two year pilot 
phase within General Practices (GP practices), national rollout aimed for 95% of primary care teams 
to participate in [1] achieving reliability on the safe prescribing and monitoring of Warfarin, 
Methotrexate and Azathioprine, [2] developing reliable care systems for medication reconciliation and 
[3] developing the safety culture of general practices. This was facilitated by contractual changes to 
the 2013/2014 Quality Outcomes Framework, which continued into subsequent contracts (4). The 
^W^WŝŶ'WƉƌĂĐƚŝĐĞƐŚĂƐďĞĞŶĚĞƐĐƌŝďĞĚĂƐĂ “ƐŝŐŶŝĨŝĐĂŶƚƐƵĐĐĞƐƐ ?ďǇĂĐŚŝĞǀŝŶŐĨŽĐƵƐĞĚ ?ĐŽ-ordinated 
action on safety concerns (5). Tools developed were effective in identifying previously undetected 
patient safety incidents, and positive outcomes were observed with improvements of patients 
Warfarin INR control (6, 7). 
ii. Introduction to the SPSP-PPC 
As outlined in Prescription for Excellence, the SPSP programme extended into the community 
pharmacy setting as the SPSP-Pharmacy in Primary Care (SPSP-PPC) collaborative in 2014 (8). This is 
ĂůƐŽ ŝŶ ĂůŝŐŶŵĞŶƚ ǁŝƚŚ ƚŚĞ E,^ YƵĂůŝƚǇ ^ƚƌĂƚĞŐǇ  ? ? ? ? ? ĂƐ ƚŚĞƌĞ ŝƐ Ă ƐƚƌŽŶŐ ĞŵƉŚĂƐŝƐ ŽŶ Ă  “ǁŚŽůĞ
ƐǇƐƚĞŵ ?ĂƉƉƌŽĂĐŚ(3) ?/ŶƚĞƌŶĂƚŝŽŶĂůůǇ ?ĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚƐ ?ƌŽůĞƐĂƌĞĞǆƉĂŶĚŝŶŐƚŽďĞŝŶĐƌĞĂƐŝŶŐůǇ
integrated within primary care (9-11). Within the United Kingdom (UK), this transition has already 
resulted in the introduction of services such as community pharmacy minor ailment schemes, with 
positive pharmacists and patient views (12-14). 
iii. Aim of the SPSP-PPC  
The overarching aim of the SPSP-WWŝƐƚŽ “ŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐĂĨĞƚǇďǇƐƚƌĞŶŐƚŚĞŶŝŶŐƚŚĞĐŽŶƚƌŝďƵƚŝŽŶ
ŽĨĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐǇĂŶĚŝŵƉƌŽǀŝŶŐĐŽŵŵƵŶŝĐĂƚŝŽŶƐǁŝƚŚŝŶƚŚĞƉƌŝŵĂƌǇĐĂƌĞƚĞĂŵ ? ?dŚĞ^W^W-
PPC seeks to achieve this through the formation of a collaborative and use of established improvement 
tools and approaches focused on three areas of interest: High Risk Medicines, Safety Culture and 
Medicines Reconciliation.   
iv. Programme Overview  
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The programme is led by two National Leads. Four NHS Health Boards became involved following a 
competitive application process. These were: 
x NHS Greater Glasgow and Clyde (NHS GG&C) 
x NHS Highland 
x Health Board 
x NHS Grampian 
For each NHS Board, two Health Board Leads were recruited - a Clinical Lead and a Board Facilitator. 
Also via a competitive process, twenty-seven community pharmacy sites were selected to participate 
(NHS GG&C n=10, NHS Highland, n=5, NHS Grampian n=5, NHS Fife n=7), and two dispensing practices 
(Highland n=2). See Figure 1 below for brief demographic details.  
 
 
 
 
 
 
 
 
 
 
 
 
NB The image shows 9 community pharmacies in Greater Glasgow and Clyde as one pharmacy withdrew 
participation midway through the pilot 
 
The Health Board Leads provided local support to the community pharmacies and dispensing 
practices, and supportive site resources included an SPSP Launch Folder and access to the SPSP-PPC 
Knowledge Network website (15).  
A Steering Group was set up and met approximately every two months to share information on the 
progress in the four Health Boards. In addition to the National and Local Health Board Leads, the 
Steering Group comprised of representatives from the SPSP-PPC Evaluation Team (from the University 
of Strathclyde and NHS Education for Scotland), Patient Representative, Project Officers, Data and 
Measurement Advisors and NHS Senior Management.  
 
v. SPSP-PPC Change Packages 
Figure 1: SPSP-PPC study sites with demographics 
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High Risk Medicines Care Bundles: 
Within the UK, studies show 6.5% of hospital admissions are attributed to adverse effects of High Risk 
Medicines (HRM) - including Warfarin and Non-steroidal anti-inflammatory drugs (NSAIDs) (16). 
Resultantly, the SPSP-PPC collaborative developed and implemented High Risk Medicine Care Bundles 
for patients on Warfarin and NSAIDs. A Care Bundle can be defined as a set of structured interventions 
that improve patient outcomes and health services process (17). Within the sites, the Care Bundles 
focus on clinical assessment and patient education  W involving identification of patients on these high 
risk medicines, clinical assessment and asking of series of question to ensure patient understanding.  
Two of the participating health boards chose to focus on Warfarin (NHS Grampian and NHS Fife), and 
two on NSAIDs (NHS GG&C and NHS Highland). Across the four Health Boards, different Care Bundles 
were developed each with different aims (aims in Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 presents the Care Bundles questions, and the guidance and rationale for each can be found 
in Appendix 1.    
 
 
 
 
 
 
 
 
 
NHS Highland 
Aim
 ?To reduce harm 
from NSAIDs.
NHS GG&C Aim
 ?To reduce the co-
prescribing of 
High Risk Drug 
Combinations 
(NSAIDS + other 
medication) by 
90% by 30th June 
2016.
NHS Grampian 
Aim
 ?To improve 
education and 
understanding for 
90% of patients / 
carers whose 
warfarin is 
dispensed from a 
participating 
Community 
Pharmacy by July 
2016.
NHS Fife Aim
 ?That 95% of all 
patients being 
dispensed 
warfarin have an 
active High Risk 
Medicines 
Intervention in 
their community 
pharmacy. 
Figure 2: Health Board High Risk Medicines Care Bundle Aims 
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Community Pharmacy Safety Climate Survey (SafeQuest-CP): 
Within the UK, findings have suggested community pharmacy staff perceive a blame culture when 
reporting incidents (18).   The safetǇĐƵůƚƵƌĞŽĨĂŶŽƌŐĂŶŝƐĂƚŝŽŶŝƐƚŚĞƉƌŽĚƵĐƚŽĨ “individual and group 
values, attitudes, competencies, and patterns of behaviour that determine the commitment to, and 
the style and proficiency of, an organisation's health and safety programmes ? (19).   To measure the 
underlying safety climate within community pharmacy and raise awareness of the importance of a 
positive safety culture, a psychometrically validated questionnaire was developed to measure safety 
climate perceptions in community pharmacy (20). This was called SafeQuest-CP, and includes 5 
domains (Figure 4): 
NHS Highland 
NSAID Care 
Bundle
 ?Has the patient been informed to take it with or after food?
 ?Has the patient been informed to report any GI side effects to their pharmacist or GP?
 ?Is the patient aware of the Medicine Sick Day Rules?
 ?Is the patient in a high risk group requiring gastroprotection? If yes, has gastroprotection 
been prescribed? 
 ?Is the patient prescribed the triple whammy combination? If yes, has the triple whammy 
combination been highlighted to the prescriber?
NHS GG&C 
NSAID Care 
Bundle
 ?Have you checked that the patient is concordant with taking their NSAID?
 ?Have you checked if the patient is experiencing adverse drug reactions or side effects?
 ?Has gastroprotection been prescribed for high risk patients?
 ?For patients identified as taking other high risk drugs, has this risk been highlighted to the 
prescriber?
 ?If the prescriber was contacted, was the resulting review communicated back to the 
pharmacy?
 ?Has this change been discussed by the pharmacist with the patient/carer?
NHS Fife 
Warfarin Care 
Bundle
 ?Does the patient have an up to date Oral Anti-Coagulant Therapy (OAT) record book 
(indication, duration of treatment and therapeutic range)?
 ?Does the patient carry an up to date alert card (indication, duration of treatment and 
target range)?
 ?Does the patient know what to do if they have missed a dose of warfarin?
 ?Is the patient aware that they should inform the team responsible for their warfarin care 
of any significant changes that may affect their warfarin? E.g. Newly prescribed medicines, 
certain OTC medicines and changes to food/alcohol.
 ?Is the patient aware of what to do if they are suffering from signs and symptoms of 
over/under-coagulation?
 ?Is the patient aware that they should have an INR test 3 days after starting a course of 
antibiotics?
NHS Grampian 
Warfarin Care 
Bundle
 ?Is the yellow OAT record booklet up to date / current including completed information 
(indication, duration of treatment and therapeutic range)?
 ?Is the OAT alert card up to date / current including completed information (indication, 
duration of treatment and target range)?
 ?Is the patient / carer aware that the Yellow OAT record booklet is taken to EVERY 
healthcare intervention?
 ?Is the patient / carer aware that they should carry the Alert Card at all times?
Figure 3: Health Board High Risk Medicines Care Bundle Questions 
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Figure 4: Domains of SafeQuest-CP Questionnaire 
 
The SPSP-PPC pharmacies piloted the use of this questionnaire in routine practice, which involved 
annual participation in the SafeQuest-CP questionnaire online, followed by an in-house reflective 
meeting to discuss the results, which are benchmarked against the SPSP-PPC sites generated average.  
Appendix 2 details the questionnaire items for SafeQuest-CP. SafeQuest-CP is now accessible online 
(21).  
Medicines Reconciliation Care Bundle: 
Medicine reconciliation errors during the transition of care has previously been highlighted. One 
report by the Royal Pharmaceutical Society of Great Britain in 2009 revealed that between 46-60% of 
patients had discrepancies in their discharge medication (22). The Medicines Reconciliation Care 
Bundle (Figure 5) aims to ensure that patients discharged from hospital with a change in medication 
have their medicines accurately reconciled by their community pharmacy. The Health Board Leads 
collaborated to develop a single care bundle for testing across the four Health Boards. Participation in 
the care bundle involves Immediate Discharge Letters (IDLs) being sent to the community pharmacy, 
ĂŶĚĨŽůůŽǁŝŶŐĐŽůůĂďŽƌĂƚŝŽŶǁŝƚŚ'WƉƌĂĐƚŝĐĞƐ ?ƚŚĞƐƚĂĨĨƚŚĞŶƌĞĐŽŶĐŝůĞƐƚŚĞƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐĂƚŝŽŶǁŝƚŚ
the patient, ensuring they have adequate understanding of any changes made. Appendix 3 details of 
the Medicine Reconciliation Care Bundle.  
 
Figure 5: Medicines Reconciliation Care Bundle Questions 
 
Overview of the Collaborative Approach  
Building on the earlier SPSP experience the SPSP-PPC collaborative involved the use of Quality 
Improvement (QI) methodology and the Breakthrough Series Collaborative Model. At Project Steering 
Medicines 
Reconciliation Care 
Bundle
 ?Is there a record that the GP10 prescription has been reconciled 
with a minimum of two sources?
 ?Have identified differences been discussed with the prescriber?
 ?Have the changes been explained to the patient/carer?
 ?Has the patient/carer been counselled on their medicines? 
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Group level, driver diagrams, care bundles and run charts were utilised. At the sharp end, site staff 
were ƚƌĂŝŶĞĚ ƚŽ ƵƐĞ YƵĂůŝƚǇ /ŵƉƌŽǀĞŵĞŶƚ ƚŽŽůƐ ? ƐƵĐŚ ĂƐ ƚŚĞ  ‘WůĂŶ-Do-Study-Đƚ ?(PDSA) cycles, to 
implement the programme to adapt it to their local context. Additionally, collaborative learning and 
development was encouraged at various Local and National Learning Events.  
Collaborative models bring individuals together in a structured way to focus on the quality of aspects 
within an area of the health service, and are being increasingly used in both the UK and the United 
States of America (USA) (23). Typically, they encourage people to share experiences and involve 
learning about improvement methods, best practice and change ideas (23). 
The Breakthrough Series (BTS) Collaborative Model is one example of a collaborative model, which 
was initially developed in the early 90s by the IHI and has been refined following its application in 
various contexts, including within UK primary care settings (24). It offers a model for structured 
learning sessions, allowing for collaborative learning, broken up by actions periods where changes are 
tested in practice. A systematic review in 2008 analysed the outcomes of 12 controlled design studies 
to measure the effects of the collaborative method (25).  The BTS Collaborative model was used in 
seven of these, and despite limited evidence it was concluded that there was moderate positive 
outcomes. This collaborative model was utilised for the SPSP-PPC, as depicted below in Figure 6.  
 
Figure 6: The SPSP-PPC Breakthrough Series Collaborative Model 
 
dŚƌĞĞEĂƚŝŽŶĂů>ĞĂƌŶŝŶŐǀĞŶƚƐ ?E> ?ĂŶĚƚǁŽ>ŽĐĂů>ĞĂƌŶŝŶŐǀĞŶƚƐ ?>> ?ǁĞƌĞĂƚƚĞŶĚĞĚďǇƐŝƚĞ “ǁĂǇ
dĞĂŵƐ ? ?dŚĞ “ǁĂǇdĞĂŵ ?ĐŽŵƉƌŝƐĞĚŽĨƚǁŽƌĞƉƌĞƐĞŶƚĂƚŝǀĞƐĨƌŽŵĞĂĐŚƐŝƚĞ ?ŵĂŝŶůǇƚŚĞŵĂŶĂŐĞƌĂŶĚ
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a member of support staff.  &ŽůůŽǁŝŶŐĂƚƚĞŶĚĂŶĐĞĂƚƚŚĞƐĞĞǀĞŶƚƐ ?ƚŚĞ “ǁĂǇdĞĂŵ ?ŵĞŵďĞƌƐǁĞƌĞ
encouraged to share the learning with their colleagues back in their sites and at the LLE.  For the 
purpose of the evaluation the site staff ǁĞƌĞƚĞƌŵĞĚ “,ŽŵĞdĞĂŵƐ ? ? Further detail of the NLE and 
LLE is provided in the methods section.    
The SPSP-PPC Evaluation Team 
The SPSP-PPC Evaluation Team comprised of members drawn from NHS Education for Scotland and 
the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS):   
Professor Marion Bennie, Professor of Pharmacy Practice, University of Strathclyde 
Dr Rosemary Newham, Research Fellow, University of Strathclyde 
Mrs Emma Dunlop Corcoran, Research Assistant, University of Strathclyde  
Prof  Anne Watson, Postgraduate Pharmacy Dean, NHS Education for Scotland 
Dr Paul Bowie, Programme Director for Safety & Improvement, Associate Advisor, NHS 
Education for Scotland 
Ms Natalie McFadyen Weir, PhD candidate, University of Strathclyde  
 
The team was supported by an Evaluation Steering Group which met approximately 4-6 monthly. This 
group comprised the aforementioned individuals and also representatives for NHS Healthcare 
Improvement Scotland (HIS): 
 
Dr Neil Houston, National Clinical Lead Patient Safety in Primary Care, NHS Health 
Improvement Scotland (HIS) 
Ms Jill Gillies, Improvement Advisor, NHS HIS  
Ms Andrea Smith, National Clinical Lead SPSP-PPC, NHS HIS  
Ms Wendy Forbes, Project Officer, NHS HIS (Administrative Support) 
 
 
i. Scope of Evaluation   
The SPSP-PPC collaborative theory is presented in Figure 7 as a Logic Model.  The logic model highlights 
the potential to link selected intervention activities and their anticipated outcomes.  The theory driven 
perspective is based upon the assumption that the long-term outcomes will only be achieved if the 
short and interim outcomes (within the logic model) are delivered as anticipated. This fact, the 
timeframe of the study and the funding made available for the evaluation has resulted in this 
evaluation focusing on short-term and interim outcomes and the alignment of these to the activities 
delivered.  Consequently, the overall aim of the evaluation is to ascertain if medication care process 
reliability and patient safety knowledge, skills, attitudes and behaviours can be improved by: 
 
x Using an Improvement Collaborative Programme, including the Model for Improvement 
(MI)/PDSA cycles, to drive improvements in communication and closer working relationships 
between pharmacy teams and GP practices. 
x Using a care bundle approach to enhance the appropriate prescribing, dispensing and 
monitoring of high risk medications  
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x Improving the reconciliation of high risk medications when a patient is discharged from 
hospital  
x Encouraging the use of the SafeQuest-CP questionnaires in pharmacy in primary care teams 
so increasing the awareness of, and learning focus on, the organisational and professional 
ĨĂĐƚŽƌƐĐŽŶƚƌŝďƵƚŝŶŐƚŽĂƐƚƌŽŶŐ ‘ƐĂĨĞƚǇĐƵůƚƵƌĞ ? 
x Building relevant topic expertise in a range of settings and stakeholder groups (e.g. primary 
care (PC) pharmacy leaders, academics, educators and improvement advisers in territorial and 
special health boards).  
 
The evaluation has been designed to explore both: the delivery of the collaborative approach in 
support of the change packages (and factors which went well and not so well); and how the 
pharmacy/dispensing practice sites are utilising the change packages.  Within this context the 
Evaluation Team pose four evaluation questions:   
 
(1) To what extent was the overall programme a success? What were the barriers/successes 
to engagement at community pharmacy/dispensing practice and NHS Board level? 
(2) How did the intervention programmes improve the practice of high risk medicines (HRM) 
handling?  
(3) How did the intervention programme improve the process of Medicines Reconciliation  W 
specifically changes in communication between multi-professional team (MPT)? 
(4) How did the intervention programme improve awareness and perception of safety 
climate? Did this change communication between MPT? 
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ii. Ethics 
 
Ethical approval was not deemed necessary because: the project was considered as a service 
development; patients were not involved in data collection or the wider study; and participant 
recruitment was invitational and any data would be irreversibly anonymised to protect identities. 
Participants gave their written and verbal consent to take part in any research activities through the 
completion of questionnaires and/or consent forms or recorded verbal confirmation of consent, and 
could not be identified by ĚŝƌĞĐƚƋƵŽƚĂƚŝŽŶƵƐĞĚ ?&ƵƌƚŚĞƌŵŽƌĞ ?ƚŚĞhŶŝǀĞƌƐŝƚǇŽĨ^ƚƌĂƚŚĐůǇĚĞ ?ƐŽĚĞŽĨ
Practice on Investigations Involving Human Beings does not apply to work that is part of routine 
practices in professional contexts, a service evaluation or an audit of an existing service. Consequently, 
University of Strathclyde ethical approval was not required for this piece of work. All participants 
received a full explanation of any research activities and assurances about confidentiality and 
anonymity were given 
 
Theoretical Frameworks   
The analysis has been guided by two theory driven analytical frameworks: firstly, a learning evaluation 
theory (the Kirkpatrick Model) to investigate the process and impact of education and training 
delivered through the collaborative; secondly, Implementation Science Theory (Proctor et alƐ ?
Taxonomy of Outcomes and Schouten eƚĂů ?ƐĂŶĚƵĐŬĞƌĞƚĂů ?Ɛ Quality Improvement Collaborative 
Success Factors) to examine how the program had been implemented and gain understanding of the 
factors which may affect the implementation process on moving to rollout across NHS Scotland.  
 
i. Learning Evaluation Theory  
The reason for evaluating any learning or training programme is often cited as establishing the 
effectiveness of the intervention (26). There are a vast array of learning evaluation models available 
through which to evaluate training/learning interventions, many of which enable multi-level analysis 
applied at a range of organisational scales. As the SPSP-PPC collaborative was multi-dimensional, it 
was important to choose  a model which would assist the assessment of QI methodology learning in a 
way that provided measurement of real-world observable changes in staff working practices, aligned 
to patient safety; the Kirkpatrick  Model was selected for this study.   
 
The Kirkpatrick Model was first published in 1959 by Dr Don Kirkpatrick as a framework for evaluating 
the effectiveness of training intervention (27, 28). This theoretical model was devised into an 
applicable Business Model and Consultancy Service in 2008, and was again remodelled in 2010 (29). 
The model spans time before, during and after training in order to provide a comprehensive view of 
training impact.  
 
The Kirkpatrick model stipulates a number of founding principles important to its application which 
were considered to have been met in the context of the SPSP-PPC collaborative: firstly, successful 
training begins where it ends, that is, training designers must consider the desired measurable 
outcomes or results before designing a training intervention to influence those results  W the pre-
specified SPSP change packages;  secondly, an appropriate needs assessment is required when 
designing, delivering and evaluating a training - the program was shaped by a pre-existing and pre-
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measured need to improve patient safety; thirdly, successful business partnership  W a shared vision  
and co-creation of change packages to improve patient safety across the collaborative was 
ĞƐƚĂďůŝƐŚĞĚ ?ĨŽƵƌƚŚůǇ ? “learning professionals͟ in any given training environment must also invest 
themselves at the first three stages of the model  W the Away Teams receiving the training had 
responsibilities for dissemination and application within the practice sites;  fifthly, the Kirkpatrick 
model proposes to provide a reliable chain of evidence which will illustrate the true value and impact 
of a training intervention, if the model attributes are incorporated and considered at the time of 
training delivery and evaluation design  W model incorporated into the SPSP-PPC program design and 
evaluation process.  
 
The model also provides suggestions as to how best to evaluate each level (Figure 8), in order to gain 
accurate and reliable measures of success and these have been incorporated into the SPSP-PPC 
evaluation plan.   
 
 
LEVEL EVALUATION DESCRIPTION EXAMPLES OF TOOLS 
Level 1: 
Reaction 
The degree to which participants find 
the training favourable, engaging and 
relevant to their jobs 
Feedback forms. 
 
Verbal reaction, post-training surveys 
or questionnaires. 
Level 2: 
Learning 
The degree to which participants 
acquire the intended knowledge, 
skills, attitude, confidence 
and commitment based on their 
participation in the training 
Assessments or tests before and after 
the training. 
 
Interview or observation  
Level 3: 
Behaviour 
The degree to which participants 
apply what they learned during 
training when they are back on the 
job 
Observation and interview over time 
Level 4: 
Results 
The degree to which targeted 
outcomes occur as a result of the 
training and the support 
and accountability package 
Measures are already in place via 
normal management systems and 
reporting 
Figure 8: Suggested Evaluation Tools For Each Level of the Kirkpatrick Model 
 
i. Implementation Science Theory 
/ŵƉůĞŵĞŶƚĂƚŝŽŶ^ĐŝĞŶĐĞĐĂŶďĞĚĞĨŝŶĞĚĂƐƚŚĞ “study of theories, process, models and methods of 
implementing evidence-based practice ? (30). Its application throughout the evaluation of the SPSP-
PPC was crucial to offer theoretical underpinning to the programme design and inform the next phases 
of implementation. The theoretical basis of implementation science is operationalized through 
frameworks or theories which can guide or offer understanding to various aspects of implementation 
(31).  
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Nilsen identified that Implementation frameworks can have one of three aims (31). Figure 9 outlines 
the three framework types, and the specific framework selected for application to the SPSP-PPC 
evaluation. As many Implementation Frameworks focus only on a single aspect applicable to 
implementation, using multiple to guide an implementation process and evaluation can have merit 
(32, 33). 
 
 
Different aims of Implementation 
Frameworks 
Implementation Framework or Theory 
applied to the SPSP-PPC Evaluation 
Those which offer guidance on 
implementation evaluation 
Proctor et alƐ ?dĂǆŽŶŽŵǇŽĨKƵƚĐŽŵĞƐ(34). 
Those offering understanding or 
explanation on the factors which can 
affect the implementation process  
Schouten eƚĂů ?ƐĂŶĚƵĐŬĞƌĞƚĂů ?Ɛ success 
factors within Quality Improvement 
Collaborative (35, 36).   
Those which describe or offer guidance 
on the implementation process  
The Institute of Healthcare Improvements 
 ?/,/ ?ĨƌĂŵĞǁŽƌŬ ‘'ŽŝŶŐƚŽ&Ƶůů^ĐĂůĞ ? (37). 
Figure 9: Implementation Frameworks Applied Within the SPSP-PPC Evaluation 
NB. Definitions adapted by Nilsen.  
 
Proctor et alƐ ?dĂǆŽŶŽŵǇŽĨKƵƚĐŽŵĞƐ 
Procter and colleagues describe three facets of outcome: implementation outcome, service outcome 
and clinical outcome, depicted in Figure 10. The merit of looking at each allows for an understanding 
of not just the benefits of the SPSP-PPC elements (service and patient outcome), but also the 
pragmatism surrounding implementation (implementation outcome) (38, 39). It is theorised that 
implementation outcomes, such as feasibility, will impact on service and patient outcomes. 
 
Implementation Outcomes Service Outcomes Client Outcomes 
Acceptability Efficiency Satisfaction 
Adoption Safety Function 
Appropriateness Effectiveness Symptomology 
Cost Equity  
Feasibility Patient-Centeredness  
Fidelity Timeliness  
Penetration   
Sustainability   
Figure 10: Proctor et al's Taxonomy of Outcomes 
 
For the purpose of this study the Evaluation Team have used the Implementation outcome domains 
(definitions outlined in Figure 11 (34)) as the main framework to analyse the early deployment of the 
SPSP-WWĐŚĂŶŐĞƉĂĐŬĂŐĞƐ ?dŚĞƐĞĐĂŶďĞƵƐĞĚƚŽ “ŵŽĚĞůŝŵƉůĞŵĞŶƚĂƚŝŽŶƐƵĐĐĞƐƐ ? ?ĂŶĚĂůůŽǁĨƵƌƚŚĞƌ
implementation efforts to be designed to facilitate different aspects  W for example improving the 
ŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶĂůƐ ?ĂĐĐĞƉƚĂŶĐĞƵƐŝŶŐĂŶĂƉƉƌŽƉƌŝĂƚĞĐŽŵŵƵŶŝĐĂƚŝŽŶƐƚƌĂƚĞŐǇ ?dŚĞĞǀĂůƵĂƚŝŽŶ
results also present some early findings of service/client outcomes, where appropriate.  Many of 
Proctor ĞƚĂů ?Ɛtaxonomy constructs are heavily ŝŶĨůƵĞŶĐĞĚďǇǀĞƌĞƚƚZŽŐĞƌƐ ‘ŝĨĨƵƐŝŽŶŽĨ/ŶŶŽǀĂƚŝŽŶ ? 
(40).    
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The definitions of the Implementation outcomes can be found in Figure 11 (34): 
 
FACTOR DEFINITION 
Acceptability The perception among implementation stakeholders that a given treatment, service, 
practice, or innovation is agreeable, palatable, or satisfactory.  
Adoption The intention, initial decision, or action to try or employ an innovation or evidence-based 
ƉƌĂĐƚŝĐĞ ?ĚŽƉƚŝŽŶĂůƐŽŵĂǇďĞƌĞĨĞƌƌĞĚƚŽĂƐ “ƵƉƚĂŬĞ ? ?
Appropriateness The perceived fit, relevance, or compatibility of the innovation or evidence based practice 
for a given practice setting, provider, or consumer; and/or perceived fit of the innovation 
to address a particular issue or problem. 
Feasibility The extent to which a new treatment, or an innovation, can be successfully used or carried 
out within a given agency or setting.  
Fidelity The degree to which an intervention was implemented as it was prescribed in the original 
protocol or as it was intended by the program developers.  
Cost The cost impact of an implementation effort. 
Penetration The integration of a practice within a service setting and its subsystems. 
Sustainability The extent to which a newly implemented treatment is maintained or institutionalized 
ǁŝƚŚŝŶĂƐĞƌǀŝĐĞƐĞƚƚŝŶŐ ?ƐŽŶŐŽŝŶŐ ?ƐƚĂďůĞŽƉĞƌĂƚŝŽŶƐ ? 
Figure 11: Definitions of Proctor et al's Implementation Outcomes 
 
Shouten and Duckers Quality Improvement Collaborative Success Factors 
 
Work by both Schouten et al and Duckers et al has focused on the development of psychometrically 
validated instruments to measure Quality Improvement Collaborative (QIC) Success Factors (35, 36). 
Both instruments focus on crucial elements to success within QICs, with overlapping constructs. For 
the purpose of this study the Evaluation Team conducted a content analysis to develop a single 
questionnaire contextualised to the SPSP-PPC setting (see Methods for detail) which focused on the 
following determinants of collaborative success: Expert Leads Support, Teamwork, Collaborative 
Process and Organisation Support.  
 
 
METHODOLOGY 
The SPSP-PPC collaborative activities have been delivered over a two year time period commencing in 
November 2014 with a national event and completing in October 2016 with a celebratory event.  
During this timeframe the Evaluation Team have worked closely with the programme participants to 
gather evidence to describe and understand how the collaborative has been working, the successes 
and challenges with implementing the three change packages and identifying any early quantifiable 
outcomes and impact of the program on patient care.   
 
A mixed methods approach to the evaluation has been developed to achieve both breadth and depth 
of coverage. This has allowed triangulation of data to verify findings from different sources and 
methods. Figure 12 provides a timeline of SPSP-PPC collaborative events and Evaluation activities.   
Table 1 details all the tools applied to support the evaluation programme incorporating for each tool 
a synopsis of the respondents, tool purpose and the data collected. This is followed by some 
explanatory text to provide context in which the tools were applied and summary of how participant 
recruitment was conducted. Where appropriate participants where provided with an information 
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sheet and participant and practice site demographics were collected. Appendix 4 presents the detailed 
tool development, review and testing undertaken and the recruitment process each time the tool was 
applied, where appropriate.  
 
In addition to the tools outlined in Table 1 a number of items of documentation were circulated by 
the Steering Group throughout the lifespan of the SPSP-PPC collaborative, and provide usual 
documentary evidence in order to inform process and impact. A total of 12 Steering Group meetings 
occurred during the lifespan of the project (2014-2016). SBAR (Situation, Background, Assessment, 
and Recommendation) Reports providing activity data were produced by each Health Board and were 
presented at each Steering Group meeting. The content within these reports has been used to inform 
parts of this report 
 Figure 12 provides a timeline of SPSP-PPC collaborative events and Evaluation activities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Timeline of SPSP-PPC Collaborative events and Evaluation Activities 
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Table 1: Tools Applied To Support the Evaluation Programme 
 
TOOL WHEN TOTAL 
RESPONDENTS 
DATA COLLECTED TOOL PURPOSE 
Questionnaire 
1 (QA1) 
National 
Learning 
Event (NLE1) 
Nov 2014 
x Away Team & 
other delegates 
(n=64)   
Practice site  knowledge of QI methods and tools; Model for Improvement 
approach; Possible future issues; Support needed 
Focused on the learning and ďĞŚĂǀŝŽƵƌĞůĞŵĞŶƚƐĨƌŽŵ<ŝƌŬƉĂƚƌŝĐŬ ?Ɛ ?ŵŽĚĞů 
(27).  
To measure baseline knowledge of QI methods and tools and 
the Model for Improvement approach 
Paired Health 
Board Lead 
Interviews 
February 
2015 
x All Health Board 
Clinical Leads & 
Facilitators 
(n=8) 
Health Board leads account of the  site recruitment process, Health Board 
engagement and sponsorship and early progress with  implementation of 
the HRM Care Bundle  
To gain an understanding of the Health Board collaborative 
setup processes and early progress within sites.   
Questionnaire 
2 (QA2)   
Local 
Learning 
Event (LLE1) 
Mar/Apr 
2015 
x LLE1 attendees 
(Away & Home 
Team) (n=50) 
 
Modified QA1 plus: Knowledge of HRM; Multidisciplinary working; Point of 
contact; Workload; Pharmacy support; Improvements in safe use of 
medicine (27, 34). 
FŽĐƵƐŽŶƚŚĞůĞĂƌŶŝŶŐĂŶĚďĞŚĂǀŝŽƵƌĞůĞŵĞŶƚƐĨƌŽŵ<ŝƌŬƉĂƚƌŝĐŬ ?Ɛ ?ŵŽĚĞů. 
To measure knowledge of QI methods/tools and progress with 
HRM Care Bundle implementation   
HRM Focus 
Groups  
Apr-
May2015  
x Away & Home 
Team- 2 Boards 
(n=8) 
How the HRM care bundle was being implemented in the sites drawing out 
any levers and challenges within practice.    
Thematic analysis applied 
dŽĞǆƉůŽƌĞŚŽǁƚŚĞ,ZDŝŶƚĞƌǀĞŶƚŝŽŶǁĂƐůĂŶĚŝŶŐĂƚƚŚĞ “ĐŽĂů-
ĨĂĐĞ ? ?
SafeQuest-CP April 2015 x Participating 
sites (n= 24)  
 
Number of participating sites per NHS Board plus average Likert scores for 
each factor (leadership, teamwork, safety systems, communication, working 
conditions)  by: NHS Board; National; Management vs non-management; 
Clinical vs non-clinical; Dispensing practices vs CPs (Health Board 4) using a 
previously validated tool (20). 
The provide sites with a snapshot of their perception and 
emphasis on safety in context of other study sites.    
 
HRM 
Community 
Pharmacy 
Case Studies 
April  W Nov 
2015 
x N=8 community 
pharmacies 
x N=19 interview 
participants 
Pharmacy staff simulation of warfarin/NSAID prescription dispensing and 
relevant materials photographed. Staff member engagement internally 
within the site and with the public and multidisciplinary team. Success 
factors and barriers to the implementation of HRM  
To create a process map detailing the steps involved in 
delivering the NSAID/Warfarin Care Bundle intervention 
process in the pharmacy.  
Questionnaire 
3 (QA3) 
National 
Learning 
Event (NLE2) 
Nov 2015 
x Away Team & 
other delegates 
(n=56) 
See QA1 To examine any change in knowledge of QI methods and tools 
over time 
Questionnaire 
4 (QA4) 
NLE2 (Nov 
2015) 
x Away Team 
(n=48) 
Likert scale rating of factors known to predict success within QI 
collaboratives: Expert lead support; Team work; Collaborative process; 
Organisational support 
dŽĐŽůůĂƚĞƉĂƌƚŝĐŝƉĂŶƚƐ ?ǀŝĞǁƐŽŶĂƌĂŶŐĞŽĨŬŶŽǁŶY/
collaborative predictors of success in the context of the SPSP-
PPC collaborative. 
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Adapted from Schouten ĞƚĂů ?Ɛ& Duckers ĞƚĂů ?ƐQI Collaborative Success 
Factors (35, 36). 
SafeQuest-CP 
Short 
interviews  
NLE2 (Nov 
2015) 
x Away Team 
(n=19) 
Access and completion of the survey; had the results been fed back; discussion 
and actions from the results; concerns with use.   
To gain an understanding of how the SafeQuest-CP 
questionnaire had  “ůĂŶĚĞĚ ?ǁŝƚŚŝŶƐŝƚĞƐ.  
SafeQuest-CP 
Summary 
May 2016 x Participating 
pharmacies 
(n=18)  
 
Number of participating sites per NHS Board plus average Likert scores for 
each factor (leadership, teamwork, safety systems, communication, working 
conditions)  by: NHS Board; National; Management vs non-management; 
Clinical vs non-clinical; Dispensing practices vs CPs (Health Board 4) using a 
previously validated tool (20).  
To provide sites with data of their perception and emphasis on 
safety 12 months after first completion and in context of other 
study sites.    
Questionnaire 
5a (QA5a):  
Celebratory 
Event (CE) 
(Oct 2016) 
x Away Team 
(n=29) 
See QA1 
See QA4 
In addition site staff perceived benefits arising from the change package 
activities (service and patient outcome) and potential for routine integration 
into practice (34-36).  
 
To examine any change in knowledge of QI methods and tools 
over time 
dŽ ĐŽůůĂƚĞ ƉĂƌƚŝĐŝƉĂŶƚƐ ? ǀŝĞǁƐ ŽŶ Ă ƌĂŶŐĞ ŽĨ ŬŶŽǁŶ Y/
collaborative predictors of success in the context of the SPSP-
PPC collaborative 
To capture staff perceived success of the SPSP-PPC.  
Questionnaire 
5b (QA5b):  
CE (Oct 2016) x Home Team 
(n=46) 
See QA1  To measure Home Team knowledge of QI methods and tools at 
the end of the SPSP-PPC collaborative 
Patient 
impact  
Short 
interviews 
CE (Oct 2016) x Away Team 
(n=12) 
Patient  impact stories  To capture examples of patient impact stories arising from being 
involved in the programme.   
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National Learning Event 1 (NLE1) 
The National Learning Event took place in November 2014 and was the first collective meeting of all 
participating pharmacies / dispensing practices and members of the Project Steering Group. The event 
focused on an introduction to the concept of patient safety, safety culture and core Quality 
Improvement methods with a focus of the HRM Care Bundle.  
Questionnaire 1 (QA1) Baseline Knowledge of QI & Collaborative Process 
The baseline questionnaire ascertained initial knowledge and understanding of the health board 
collaborative members and included: knowledge of QI methods and tools; Model for Improvement 
approach; possible future problems; and support needed. The questionnaire was distributed to all 
delegates 2 weeks in advance of the NLE1 event.   Delegates were asked to return completed 
questionnaires at registration or completed these on arrival at the event. The final questionnaire is 
included in Appendix 5.  
Paired Health Board Lead Interviews 
Interviews were conducted in February 2015 in each of the four Health Boards with the Health Board 
Leads. A semi-structured interview schedule (Appendix 6) with a focus on three main areas; 
experience, recruitment of sites and engagement was conducted via conference call. The paired 
interview allowed a better understanding of the Health Board collaborative setup processes and the 
progress within Health Boards thus far.  
Local Learning Event 1 (LLE1) 
The first Local Learning Events took place in March - April 2015. These were smaller board-specific 
meetings involving those staff participating in the SPSP-PPC collaborative from community pharmacies 
/ dispensing practices. The aim of the event was for participants to share their experiences and 
activities thus far in the programme.  
Questionnaire 2 (QA2) Knowledge of QI and Collaborative Process (Modified QA1) & HRM 
Implementation) 
The first part of QA2 was based on a modified QA1, with the addition of questions on the HRM element 
of the SPSP-PPC being tested at this time point in the study sites. The final questionnaire is included 
in Appendix 7. 
The questionnaire was sent to all registered LLE attendees 1 week before the event.  Delegates were 
asked to return completed questionnaires at registration or completed these on arrival at the event. 
Within Health Board 4 the LLE was run remotely and participants were asked to return by email. Non-
returning staff were reminded once to maximise returns. 
HRM Focus Groups with Pharmacy Staff 
Focus groups were run with Away and Home Team members in two Health Boards  April - May 2015 
(one testing each of the NSAIDs and Warfarin Care Bundle) to explore how the HRM intervention was 
ůĂŶĚŝŶŐĂƚƚŚĞ “ĐŽĂů-ĨĂĐĞ ? ?ZĞĐƌƵŝƚŵĞŶƚŽĨƉĂƌƚŝĐŝƉĂŶƚƐǁĂƐƚŚƌŽƵŐŚƚŚĞ>> ?ĂŶĚďǇĞŵĂŝůƚŽĂůůƐƚƵĚǇ
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sites in each Health Board with remuneration of £100 being offered for attendance. The focus groups 
lasted approximately 1 hour and took place in the evening. The interview schedule was based on 
common themes derived from review of the QA2 open-ended questions.  The focus group schedule is 
included in Appendix 8.  
SafeQuest-CP Safety Climate Survey 2015 
The SafeQuest Safety Climate Survey was first administered in April 2015 (Appendix 2). The aim of the 
survey was to provide sites with a snapshot of their perception and emphasis on safety, and to provide 
them means to improve safety culture in a blameless and supportive manner. Within each site, the 
manager or a nominated lead was to encourage staff to complete the online survey. Post-completion, 
site managers were instructed to run off the results and disseminate and discuss them with the team, 
making appropriate changes to practice where needed.  
All staff who worked in sites participating in the SPSP-PPC collaborative were asked to complete it, 
regardless of whether they attended any of the learning events or not. Participants were provided a 
guide by which to complete the survey and utilise the results within their practice, as they would be 
provided feedback on how they scored against the national average.  
Safety Climate Survey Summary Results 
The Evaluation Team were provided with a summary of results at Board and national level of the 
SafeQuest-CP tool by SPSP programme national leads.   
HRM Community Pharmacy Case Studies  
Case studies were conducted in eight community pharmacies between June and November 2015 (four 
pharmacies in June/July, and four pharmacies October/November). Pharmacy staff simulated the 
process undertaken when a warfarin/NSAID prescription was presented at the pharmacy. This was 
audio recorded and any relevant resource materials (e.g. education posters, alert stickers, etc.) 
photographed. This was used to create a process map detailing the steps involved in delivering the 
care bundle intervention which was emailed to the community pharmacist for validation. The 
information from the process maps were collated, commonalities were identified and were used to 
create an overarching process map for NSAIDs and warfarin (Appendix 9). Subsequently, the generic 
process maps were shared for review at the NLE2 and also tested in a further four community 
pharmacies for applicability within their system.    
National Learning Event 2 (NLE2) 
The second National learning Event (NLE2) took place over 2 days in November 2015 and was attended 
by all SPSP-PPC participating pharmacy / dispensing practice representatives and members of the 
Project Steering Group. The aim of the event was to share progress to date, introduce the importance 
of leadership in patient safety and design the Medicines Reconciliation Care Bundle.  
Questionnaire 3 (QA3) Knowledge of QI and Collaborative Process (Modified QA1)  
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QA3 was a repeat of the Modified QA1, 12 months following the NLE1 to examine any change in 
knowledge base of participants over time.  The questionnaire is included in Appendix 10.  
All registered delegates were invited to complete the questionnaire. The questionnaires were 
distributed via email two weeks prior to the event, and a reminder was sent approximately 1 week 
later. Delegates were asked to return completed questionnaires at registration or completed these on 
arrival at the event. Staff unable to attend were encouraged to return the questionnaire by post.  
Questionnaire 4 (QA4) Schouten ĞƚĂů ?Ɛ& Duckers ĞƚĂů ?Ɛ Success Factors 
In order to explore the QI collaborative predictors of success within sites, two psychometrically 
previously validated questionnaires (35, 36) were adapted for use within the SPSP programme 
(community pharmacy and dispensing practice versions).  Following a development process QA4 
focused on four factors suggested to predict success within QI collaborative: expert lead support; team 
work; collaborative process; and organisational support.  The questionnaires are included in Appendix 
11.  
All registered delegates were invited to complete the questionnaire in a similar process as for QA3.  
Short Safety Climate Interviews 
In order to gain an understanding of how the SafeQuest-CP questionnaire ŚĂĚ “ůĂŶĚĞĚ ?ǁŝƚŚŝŶƐŝƚĞƐ ?
a short interview schedule was designed to capture early response to the tool and how the results had 
been used in the sites. Researchers approached Away team delegates opportunistically at the NLE2 
who were invited to participate in a brief 5-10 min interview. The schedule is included in Appendix 12.        
SafeQuest-CP Safety Climate Survey 2016 
The SafeQuest Safety-CP Climate Survey was repeated in June 2016 (Appendix 2).  
Safety Climate Survey Summary Results 
The Evaluation Team were provided with a summary of results of the SafeQuest-CP tool by SPSP 
programme national leads. 
Local Learning Event 2 (LLE2) 
A second Local Learning (LLE2) event occurred in June  W July 2016 with a view to allow participating 
pharmacy / dispensing practice staff to share their learning to date with the Medicines Reconciliation 
Care Bundle.  
Celebratory Event (CE)  
The Celebratory Event (CE) took place in October 2016 and provided the opportunity to reflect the 
successes of the SPSP-PPC collaborative, share learning, and discuss potential areas for roll-out 
nationally. 
Questionnaire 5a (QA5a): Impact - Knowledge of QI and Collaborative Approach (modified 
QA1); modified QA4; and Perceived Outcomes  
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The final summative evaluation of the SPSP-PPC collaborative took the form of an impact 
questionnaire comprised of three sections:  
- examination of staff knowledge and behaviour (modified QA1) 
- organisation context and success factors (modified QA4);  
- New section to gain an understanding of the perceived benefits arising from the change package 
activities (service and patient outcome) and potential for routine integration into practice.  
The full questionnaire is included in Appendix 13. All Away Team delegates attending the CE were 
invited to complete the questionnaire. The questionnaires were mailed to each participating site 1 
week prior the CE.  Away Team members were asked to bring any completed questionnaires to the 
CE.  In the event of possible non-attendance, all sites were asked to post these to the evaluation team. 
Sites received reminder telephone calls 10-14 days post the CE.   
Questionnaire 5b (QA5b): Knowledge of QI and Collaborative Approach (modified QA1)  
QA5b was aimed at Home Team members and was a duplicate of modified QA1. The questionnaire is 
included in Appendix 14.  
Copies of the questionnaires (based on estimated staff numbers) were posted to each study site 1 
week prior the SPSP-PPC CE. The site manager was asked to distribute to all Home Team members 
and for all completed forms to be sealed by staff in an envelope to assure anonymity per to collation 
by the manager. Away Team members were asked to bring any completed questionnaires to the CE.  
In the event of possible non-attendance, all sites were asked to post these to the evaluation team. 
Sites received reminder telephone calls 10-14 days post the CE.   
Short Patient Impact interviews   
In order to capture how each element of the SPSP-PPC collaborative (High Risk Medicines, Medicines 
Reconciliation and Safety Climate Survey) impacted on patients a short interview schedule was 
designed to provide the opportunity to describe examples of patient impact stories arising from being 
involved the programme.  The schedule is included in Appendix 15.  Away team delegates where 
approached opportunistically at the CE and invited to participate in a brief 5-10 min interview.      
Additional Supplementary Data  
ĚĚŝƚŝŽŶĂůƌĞĐŽƌĚŝŶŐƐ ? “ĂƵĚŝŽŶŽƚĞƐ ? ?ǁĞƌĞŵĂĚĞĚƵƌŝŶŐƚŚe CE. Participants on the day were asked 
to write their opinions on the event on post-it notes and display them. Photographs of these notes 
were taken by the Evaluation Team. Steering Group minutes and associated SBAR (situation, 
background, assessment, report) reports were also collated.  
 
DATA ANALYSIS  
The data analysis methods for each data element are presented in Figure 13.  
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DATA 
SOURCE 
FORMAL ANALYSIS METHOD RESEARCH 
QUESTION 
QA1 ʹ QA5b All data entered into Microsoft Excel, with 20% of the data entry validated by a 
second researcher to ensure validity.  
Questionnaire Statement Likert Scale responses were coded as follows, depending on 
the statement type: 
1 = Not at all / Strongly Disagree 
2 = To a very limited extent / Disagree 
3 = To a limited extent / Slightly Disagree 
4 = To a moderate extent / Neutral 
5 = To a considerable extent / Slightly Agree 
6 = To a great extent / Agree 
7 = To a very great extent / Strongly Agree 
Descriptive statistics (Modes and Medians) were calculated in order to describe 
responses  
1-4 
HRM Focus 
Groups 
The HRM Focus Groups were transcribed using an intelligent verbatim approach and 
coded thematically using the software package NVivo.  
 
1-2 
NLE2 Safety 
Climate 
Short 
Interviews 
The NLE2 Short Interview data was transcribed using an intelligent verbatim approach 
and coded thematically using the software package NVivo. 
4 
CE Short 
Patient 
Impact 
Interviews 
The CE Short Interviews were transcribed using an intelligent verbatim approach. The 
data underwent a deductive analysis using the domains from Proctor et al ?ƐƚĂǆŽŶŽŵǇ 
(34).  Interviews were deductively mapped to the taxonomy concepts independently 
by two researchers who then met and compared their categorisation. Any 
disagreements were resolved by negotiation. The ordered dataset then was 
thematically analysed within each category.  
2-4 
Case Study 
HRM 
Simulations 
Simulations of HRM prescribing and dispensing were audio recorded but not 
transcribed. This data was compiled with photograph evidence of associated tools and 
a process map was developed (see Methods section). No other formal analysis of the 
data was conducted.  
1-2 
Other Data Supplementary data such as WebEx notes, Steering Group Minutes, SBARs etc. have 
been used to supplement information and learning from the analysis of the data 
collected through the formal evaluation activities and has undergone no formal data 
analysis.  
1-4 
Figure 13: Data Analysis Methods 
 
RESULTS 
 
Study Sites and Participants 
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Table 2 displays the demographics of all participants for all methods applied throughout the 
evaluation programme. This extends beyond the Home and Away Team members to Health Board 
Leads and Steering Group members. It is estimated that a total of 187 unique individuals participated 
in the evaluation at some point.  However we are unable to establish whether Home Team members 
who completed questionnaires did or did not participate in earlier Focus Groups or Case Studies.  
30 
 
Table 2: Study Sites and Participants 
 
 
 QA1 BASELINE 
(n=64)Ώ 
QA2 
(n=50) 
HRM CASE 
STUDIES (n=30) 
QA3 
(n=56) 
HRM FOCUS 
'ZKhW^Ώ;ŶсϲͿ 
PAIRED HEALTH 
BOARD LEAD 
INTERVIEWS (n=8) 
QA4 
(n=48) 
NLE 2 Short Safety 
Climate Interviews 
(n=19) 
CE Short Patient 
Impact Interviews  
(n=13) 
QA5a 
(n=29) 
QA5b HOME 
TEAM (n=46) 
No. SITES /TEAMS 26 CPs/ 2 DPs 26 CPs */ 
1 DP 
8 CPs 25 CPs* / 
2 DPs 
4 CPs * 4 26 CPs / 2 
DPs 
16 CP / 1 DP 10 CP* / 1 DP 19 CPs / 2 
DPs 
15 CPs / 1 DP 
GENDER 
 Male 11 12 8 10 1 2 10 6 3 9 5 
Female 53 38 23 43* 3 6 34 13 10 20 40 
ROLE IN COLLABORATIVE 
 Board Clinical 
Lead 
5 - - 3 1 4 1 1 1 - - 
 Board Facilitator 4 - - 5 - 4 1 1 1 - - 
Staff from CP / DP 50 49 - 37 - - 36 16 10 29 46 
Other / Unknown 5 1 - 6 - - 5 - 1 - - 
JOB ROLE 
 Pharmacist 
Owner 
6 7 2 5 1 - 5 1 2 2 - 
Pharmacist 
Branch Manager 
14 15 6 13 2 - 13 6 4 11 2 
Second 
Pharmacist 
2 3 3 2 1 - 2 2 2 2 1 
Accredited 
Checking 
Technician 
6 4 2 2 - - 2 1 1 3 1 
Locum 
Pharmacist 
- - 1 - - - - - - - 2 
Technician 7 7 - 4 - - 4 1 1 2 7 
Relief pharmacist 1 - - - - - - - - - - 
Dispensing Staff 6 6 12 5 - - 3 3 1 4 20 
Pre-Reg 1 3 2 4 - - 4 1 - - 1 
Counter Assistant - - 4 - - - - - - - 10 
Other / Unknown 3 3 - 5 - - 5 3 1 1 - 
YEARS IN JOB ROLE 
 <1 8 9 2 13 1 - 13 5 1 - 3 
1 ? 5 17 19 7 10 1 - 10 4 1 12 19 
6-10 13 14 9 5 - - 5 4 4 8 14 
11-15 1 2 4 3 1 - 2 - 2 3 5 
16-20 3 2 2 4 1 - 4 2 1 3 2 
>20 5 3 4 6 - - 6 3 2 3 3 
 ?KŶĞƉŚĂƌŵĂĐǇǁŝƚŚĚƌĞǁĨƌŽŵƚŚĞĞǀĂůƵĂƚŝŽŶĂŶĚƚŚĞƌĞĨŽƌĞƚŚĞŝƌĚĂƚĂŝƐŶŽƚŝŶĐůƵĚĞĚ 
Number of * indicates some no responses / unknown data  
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In total, 60 Away Team participants and a minimum of 46 Home Team participants took part. 
Participants other than Home or Away team members (n=24) also contributed throughout the 
programme, as well as Health Board Leads (n=8). Figure 14 displays how many Away Team members 
had been involved in the collaborative from the beginning, for 1-2 years and for less than 1 year (tested 
in QA5a at the Celebratory Event in 2016): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 shows the total number of questionnaires Away Team members completed, with the 
maximum being 5. As shown, most Away Team members completed 4 out of the 5 questionnaires, 
with QA2 being most completed (n=47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12, 20%
13, 22%
4, 7%
17, 29%
13, 22%
How Many Questionnaires Away Team Members Completed 
(n=60)
1 Questionnaire
2 Questionnaires
3 Questionnaires
4 Questionnaires
5 Questionnaires
72%
14%
14%
Length of Time Away Team Members Have Been Involved in Collaborative 
(n=29)
From the beginning
1-2 years
less than 1 year
(n=4) 
(n=4) 
(n=21) 
Figure 14: Away Team Duration of Participation in Collaborative 
Figure 15: Number of Questionnaires Completed by Away Team 
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a. EVALUATION QUESTION 1:  To what extent was the overall programme a 
success? What were the barriers/successes to engagement at community 
pharmacy / dispensing practice and health board level? 
 
i. KNOWLEDGE & BEHAVIOUR 
 
 
 
 
 
 
 
The evaluation has been designed to explore both: the delivery of the collaborative approach in 
support of the change packages; and how the pharmacy/dispensing practice sites are utilising the 
change packages.  This section of the results will be reported under <ŝƌŬƉĂƚƌŝĐŬ ?Ɛ>ĞĂƌŶŝŶŐǀĂůƵĂƚŝŽŶ
model in order to understand the effectiveness of the overall SPSP-PPC collaborative (27).  This will 
allow theories to be developed about mechanisms (for example the tools used or changes skills and 
behaviours) and contexts (for example health board or type of pharmacy) underpinning the measures 
of success such as the quantitative reliability data.  
 
Level 1: Reaction 
 
 
 
 
 
As the concept of patient safety may have been unfamiliar to some community pharmacy staff, it was 
important to ascertain the thoughts of Away Team members around the relevance of patient safety 
as an SPSP-PPC collaborative element. Figure 16 shows the responses from Away Team members at 
three points between baseline (2014 at NLE1) and the Celebratory Event in 2016. There was no change 
ŝŶ ŵĞĚŝĂŶ ƌĞƐƉŽŶƐĞ ƚŽ  “WĂƚŝĞŶƚ ƐĂĨĞƚǇ ŝƐ ƉƌŝŵĂƌŝůǇ Ă ŚŽƐƉŝƚĂů ŝƐƐƵĞ ? ĂĐƌŽƐƐ Ăůů ƚŚƌĞĞ ƚŝŵĞ ƉŽŝŶƚƐ ?
showing that throughout programme participation, most felt that patient safety was not primarily a 
hospital issue, and was relevant in the context of community pharmacy. 
 
 
 
 
 
 
 
 
 
 
 
Data Used in Analysis 
x Select data from QA1, QA2, QA3, QA4 and QA5a 
x Community Pharmacy HRM Case Studies 
x HRM Focus Groups 
Reaction: The degree to which participants find the training favourable, engaging and relevant to 
their jobs.  
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Furthermore, there is a sharp increase in the understanding of both the concepts of Quality 
Improvement and Patient Safety within community pharmacy between the baseline (2014) and NLE2 
event 1 year later, which is maintained / slightly decreased at testing over the following year, showing 
that the programme elements were engaging to staff to an extent to increase and sustain awareness.  
 
Figure 17 shows further median responses from Away Team members at the end of the SPSP-PPC 
collaborative (CE, Oct 2016) regarding their thoughts on the relevance of and their engagement with 
the three change packages: High Risk Medicines; Medicines Reconciliation; and Safety Culture: 
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5 = To a considerable extent 
6 = To a great extent 
7 = To a very great extent 
Figure 16: Away Team Responses to Relevance of Patient Safety Element 
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All three elements elicited median responses ranging mostly between Agree and Strongly Agree, 
however there is a trend that High Risk Medicines and Medicines Reconciliation were considered as 
more relevant and influential to the role of the community pharmacy/dispensing practices and 
professionally had a more positive impact on job performance. The most contrasts can be seen 
between High Risk Medicines and Safety Culture in the statements  “Participation in this programme 
ĞůĞŵĞŶƚĂůŝŐŶƐƚŽƚŚĞǀŝƐŝŽŶŽĨƉŚĂƌŵĂĐĞƵƚŝĐĂůĐĂƌĞ ?ĂŶĚ “/ŚĂǀĞŐŽŽĚĂǁĂƌĞŶĞƐƐŽĨƚŚŝƐƉƌŽŐƌĂŵme 
ĞůĞŵĞŶƚ ?which may suggest that Away Team members see a more direct link between HRM and 
pharmaceutical care in general than with the Safety Culture element, perhaps due to the direct patient 
involvement.  
 
Finally at baseline, Away Team members were asked to provide any thoughts they had on what they 
thought the main benefits or successes to involvement in the SPSP-PPC collaborative would be. Table 
3 displays a range of the responses provided, categorised by theme. Of the 45 Away Team QA1 (2014) 
responders, 32 provided an answer. 
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Figure 17: Away Team Response to Relevant of and Engagement with Collaborative Elements 
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Table 3: Away Team Perceived Benefits & Successes of Participation 
 
Improve Own Knowledge & Confidence 
 “Improve my personal knowledge of QI & networking within a wider NHS & organisational ƐƚƌƵĐƚƵƌĞ ? ?
 “I hope to learn more about SPSP ? ?
 “Building my own confidence ? ?
Improve Patient Care 
 “/ƚŚŝŶŬŝƚǁŝůůŝŵƉƌŽǀĞŵǇĂďŝůŝƚǇƚŽƉƌŽǀŝĚĞƐĂĨĞĐĂƌĞĨŽƌƉĂƚŝĞŶƚƐ QƚŽƚĂŬĞƉĂƚŝĞŶƚƐĂĨĞƚǇƚŽƚŚĞŶĞǆƚůĞǀĞů ?
More reliable medicine ƌĞĐŽŶĐŝůŝĂƚŝŽŶ QǁŝƚŚƚŚĞƉĂƚŝĞŶƚďĞŝŶŐƚŚĞĐĞŶƚƌĞŽĨƚŚĞƉƌŽĐĞƐƐŝŶǀŽůǀŝŶŐƚŚĞŵ ? 
Improved Patient Safety 
'ƌĞĂƚĞƌŬŶŽǁůĞĚŐĞĂŶĚƵŶĚĞƌƐƚĂŶĚŝŶŐ QůĞĂĚŝŶŐƚŽŝŶĐƌĞĂƐĞĚƉĂƚŝĞŶƚƐĂĨĞƚǇŝŶƚŚĞƉŚĂƌŵĂĐǇ ? ?
 “Improved Patient Safety, improved Safety Culture in team ? ?
Improve Processes 
 “Improve processes for high risk meds and meds rec in community pharmacies. ?  
 “Learning how [Models for Improvement] can be implemented so that they become part of routine practice 
in every pharmacy. ? 
 “Improved records/statistics for future planning ? ?
Maximise Role of Community Pharmacy  
 “Identifying a clearer role for community pharmacy in both reducing risk of high risk medicines and improving 
ŵĞĚŝĐŝŶĞƐƌĞĐŽŶĐŝůŝĂƚŝŽŶ ? ?
 “Identification of a greater and more involved role of Community Pharmacy in Patient Safety. ?  
 “Reducing professional isolation for pharmacists ? ?
 Improved Networking, Sharing & Communication 
 “Better communication between all care providers. ? 
 “More confidence in contacting other primary care professionals ? ?
 “Networking with other pharmacists ? ?
Involve the Whole Pharmacy Team 
 “Improvement of the safety climate within community pharmacy, from all members of staff whatever their 
role. ?  
 “Involving the whole pharmacy team in a project ? ?
 
During the Community Pharmacy HRM Case studies, various members of the pharmacy team were 
interviewed and asked about their experiences of the programme. The HRM Case studies occurred 
between June and November 2015. Participants mainly spoke of how they were implementing the 
HRM element of the programme, but also provided insight into the successes and challenges of 
participation. The main overall challenge reported was time, but this mainly related to the practical 
delivery of the care bundles as opposed to participation in the learning events. Very few comments 
were made about the frequency of training events and the pressures this posed.  Some comments 
were made about aspects of the QI methods being demanding: 
 
 “dŚĞĚŝĨĨŝĐƵůƚƚŚŝŶŐĂŶĚƚŚĞƚŝŵĞĐŽŶƐƵŵŝŶŐďŝƚŝƐƚŚŝƐďŝƚ ?ƚŚĞW^ĐǇĐůĞďĞĐĂƵƐĞ/ ?ŵ
not used to doing something like this.  So I think this is taking me quite a while to 
work out how to do it.  Like I'm never sure for example where to start in the cyclĞ ? ?
(Branch Manager, Health Board 4) 
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For this participant, there was a lack of clarity on what point in the PDSA cycle they were to start and 
that completing and submitting the cycles was onerous. However, several participants could not 
provide examples of any challenges to participation when prompted, one participant commenting: 
 
 “/ƚ ?ƐƋƵŝƚĞĂŶŝŵƉŽƌƚĂŶƚƌŽůĞƚŽďĞƋƵŝƚĞŚŽŶĞƐƚďĞĐĂƵƐĞŝƚ ?ƐƐŽŵĞƚŚŝŶŐƚŚĂƚĂůŽƚŽĨ
patients deal with and to have them understand better and us have better 
ƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞƉĂƚŝĞŶƚƐ QŝƚǁŽƌŬƐǁŝƚŚƚŚĞƉŚĂƌŵĂĐǇǁĞůů ? ? 
(Accredited Checking technician, Health Board 1) 
 
Additional qualitative data was gathered at the HRM focus groups (April  W May 2015), with some 
ƉĂƌƚŝĐŝƉĂŶƚ ?ƐĚŝƐĐƵƐƐŝŶŐŚŽǁƌĞůĞǀĂŶƚthey thought the HRM implementation was to their work and to 
community pharmacy as a whole. Comments were generally very positive, with participants agreeing 
that the HRM element of the programme fits well within the culture of change in community 
pharmacy: 
 
 “dŚŝŶŐƐĂƌĞĐŚĂŶŐŝŶŐǁŝƚŚ ?ƉŚĂƌŵĂĐǇ ?ĂŶǇǁĂǇ ?/ŵĞĂŶŝĚĞĂůůǇǁĞ ?ůůďĞƉƌĞƐĐƌŝďŝŶŐ
ǁŝƚŚŝŶƚŚĞŶĞǆƚƚĞŶǇĞĂƌƐ QƐŽǇŽƵ ?ƌĞĚŽŝŶŐŵŽƌĞĐůŝŶŝĐĂůƚŚŝŶŐƐ ?ƚŚĞƉĂǇŵĞŶƚ ?ƐĐŚĂŶŐĞĚ ?
ǇŽƵ ?ǀĞŐŽƚƚŽĚŽŵŽƌĞƉĂƚŝĞŶƚĐĂƌĞƌĞĐŽƌĚƐĂŶĚƐƚƵĨĨůŝŬĞƚŚĂƚ ? ?
(Pharmacy Manager, Health Board 2) 
 
In terms of the training received, staff reported that it was a motivating factor at the beginning, and 
contributed towards them feeling encouraged and engaged. However, there was a recognition that it 
was difficult to get those staff who had not received any training to feel as passionately about SPSP-
PPC: 
 
 “/ŵĞĂŶŝƚ ?ƐĨŝŶĞŶŽǁďƵƚ/ƚŚŝŶŬďack then at the start it was quite hard to get [the other 
ƐƚĂĨĨ ?ĞŶƚŚƵƐŝĂƐƚŝĐĂďŽƵƚŝƚďĞĐĂƵƐĞƚŚĞǇŚĂĚŶ ?ƚďĞĞŶƚŽƚŚĞƚƌĂŝŶŝŶŐĂŶĚǁĞǁĞƌĞĂůůĨŝƌĞĚ
ƵƉĂŶĚƌĞĂĚǇƚŽŐŽ ? ? 
(Pharmacy Manager, Health Board 2) 
 
Another participant in this focus group went on to say that they felt that this lack of involvement in 
any direct training for Home Team members made it difficult to have them completing tasks 
associated with the programme: 
 
 “/ƚŚŝŶŬƐƚĂĨĨƐŽŵĞƚŝŵĞƐƐĞĞŝƚĂƐũƵƐƚƐŽŵĞƚŚŝŶŐĞůƐĞƚŚĞǇ ?ǀĞŐŽƚƚŽĚŽ Q/ĚŽŶ ?ƚƋƵŝƚĞ
know how to portray it any different, because I am asking them-ŝƚŝƐŵŽƌĞƚŚŝŶŐƐǇŽƵ ?ǀĞ
ƚŽĚŽŝŶǇŽƵƌĚĂǇĂŶĚŝƚ ?Ɛ-ŝƚ ?ƐĚŝĨĨŝĐƵůƚ ? ? 
(Pharmacist, Health Board 2) 
 
AlthoƵŐŚƚŚĞƚƌĂŝŶŝŶŐǁĂƐĂŵŽƚŝǀĂƚŝŶŐĨĂĐƚŽƌĨŽƌƐŽŵĞ ?ŽŶĞƉĂƌƚŝĐŝƉĂŶƚĚŝĚƐĂǇƚŚĂƚƚŚĞŝŶŝƚŝĂů “ŚŝŐŚ ?
ĂĨƚĞƌƚŚĞƚƌĂŝŶŝŶŐĚŝƐƐŝƉĂƚĞĚƋƵŝĐŬůǇ ?ůĞĂǀŝŶŐƚŚĞŵĨĞĞůŝŶŐůĞƐƐ “ĨŝƌĞĚ-ƵƉ ?ŽŶĐĞƚŚĞǇŚĂĚƌĞƚƵƌŶĞĚƚŽ
day-to-day activity. 
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As well as comments specific to the training, staff did express their views on the associated resources 
they were provided. Stories around spreadsheets with inaccurate data and patient lists that were out 
of date were shared in the focus groups. In reference to the original QI training materials, the original 
 “ďĂƐŝĐ ?ŵĂƚĞƌŝĂůƐǁĞƌĞǀĂůƵĞĚ ?ǇĞƚƐŽŵĞŽĨƚŚĞŵŽƌĞůĞŶŐƚŚǇĂĚĚŝƚŝŽŶĂůŵĂƚĞƌŝĂůƐǁĞƌĞŶ ?ƚƵƐĞĚĚƵĞƚŽ
a number of reasons, mainly a lack of practicality: 
 
 “dŚĞY/ƚŽŽůƐƚŚĂƚǁĞ ?ǀĞŚĂĚ/ƚŚŝŶŬĂƌĞŵŽƌĞƚŚĞŽƌĞƚŝĐĂůƚŚĂŶƉƌĂĐƚŝĐĂů ?/ĚŽŶ ?t have 
ƐĞǀĞƌĂůŚŽƵƌƐ QƚŚĞŽŶĞ/ ?ŵƚŚŝŶŬŝŶŐŽĨŝƐƚŚĞĨŝƐŚĚŝĂŐƌĂŵƚŚĂƚǁŽƵůĚƚĂŬĞƐŽůŽŶŐƚŽ
ĐŽŵƉůĞƚĞƌĞĂůůǇƚŽĂƐƵďƐƚĂŶƚŝĂůůĞǀĞůŽĨŝƚƐƉƵƌƉŽƐĞƐ ?ŝƚ ?ƐũƵƐƚŶŽƚƌĞĂůůǇĨĞĂƐŝďůĞ ? ?
(Trainee Technician, Health Board 1) 
 
This participant also highlighted that now they are in the depths of participation, continually updating 
their PDSA cycles and small tests of change was proving challenging. They found that changes were 
made and were successful, but that finding additional tweaks to make was difficult and were time 
consuming to generate when no real sizable benefit was realised. Therefore, although the tools were 
beneficial, the constant expectation of engagement with the tools was often time consuming and 
work-generating, and was thus viewed less favourably has the programme progressed.  
 
 
 
 
Level 2: Learning 
 
 
 
 
 
 
Away Team participants were provided training on the variety of tools that were to be used for each 
of the elements in this QI collaborative. Various questions contained within the range of 
questionnaires applied were designed to assess participant learning throughout the programme. 
Figures 18-20 shows the level of agreement to statements around understanding, knowledge and 
confidence of the QI tools at various points in time:  
 
 
 
 
 
Conclusions: From the data we can suggest that Away Team members had a positive reaction to 
their engagement with the SPSP-PPC collaborative, with some of their aspirations for 
involvement being around an increase in knowledge and an application of that knowledge to 
improve processes, care, safety, and collaboration. The training was viewed positively and 
provided some Away Team members with a high level of motivation at the start. Utilising the 
training materials however was not always feasible in the participating sites due to work 
pressures. 
Learning: The degree to which participants acquire the intended knowledge, skills, attitude, 
confidence and commitment based on their participation in the training.   
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From the QI tool-related questions, it appears that there was a general overall increase in knowledge 
and understanding of the tools between 2014 and March 2015, with a slight dip in overall agreement 
between Nov 2015 and the CE in 2016 regarding Run Charts specifically, however this may be 
attributable to the lower response rate to this questionnaire.  
 
Figure 19 shows the overall agreement with statements around understanding of and confidence in 
using the Model for Improvement.  
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Figure 18: Away Team Response to Acceptability of HRM Tools 
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Once again, a sharp increase in understanding and confidence in use of the model is observed between 
NLE1 (2014) and LLE1/NLE2 (2015) with the overall effect then sustained to the end of 2016.  Figure 
20 displays the level of general understanding at specific times through the programme for each of 
the change packages.  
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Figure 19: Away Team Response to Knowledge & Confidence of MI 
Figure 20: Away Team Response to Understanding of Collaborative Elements 
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There is an overall upward trend in Away Team understanding of the various change packages, with 
positive differences in median response rates between scores taken at Baseline (2014) and NLE2 
(2015), which is mostly sustained for the following year.   
 
Interestingly, Figure 21 shows the difference between Away Team and Home Team responses to 
questions around the knowledge and confidence in use of SPSP-PPC collaborative tools at the 
Celebratory Event (QA5a&b). What can be observed is a stark contrast between Away and Home Team 
understanding of the tools and elements.  The most divisive statements were around understanding 
Run Charts and their use, understanding Driver Diagrams and understanding how PDSA cycles can be 
used.  
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Figure 21: Away vs Home Team Response to Understanding of & Confidence in Element Tools 
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Level 3: Behaviour 
 
 
 
 
 
To assess any changes in behaviour as a result of learning, questions were included in QA5a and QA5b 
to measure the uptake and use of the tools at the end of the study programme (October 2016) (Figure 
22):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: Understanding and knowledge of SPSP-PPC tools and programme elements was low 
at NLE1 for Away Team members, yet a sharp and sustained increase over the following 2 years 
is observed in knowledge, understanding and confidence in the use and application of these tools 
and change packages. This indicates that the training involved at NLE1 was sufficient in 
facilitating participant learning. What is lacking however is the dissemination of this learning to 
the Home Team members.   
Behaviour: The degree to which participants apply what they have learned during training when 
they are back on the job.   
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Figure 22: Away vs Home Team Response to Use of SPSP-PPC Tools 
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Amongst Away Team participants, median responses were highest for use of care bundles, with Run 
Charts eliciting the lowest level of use. Interestingly, all elements elicited a far lower rate from Home 
Team participants, with Run Charts and Driver Diagram use showing the lowest level of agreement 
(i.e. Slightly Disagree and Neutral respectively ? ?/ŶĨĂĐƚŶŽŶĞŽĨƚŚĞƚŽŽůƐŽƌĞůĞŵĞŶƚƐĞůŝĐŝƚĞĚ “positive ?
statements from Home Team members. This indicates that the learning provided to Away Team 
members increased knowledge and awareness of programme elements and tools, however this 
learning was perhaps not disseminated to Home Team members and as a result did not influence any 
change in working behaviour of Home Team staff and/or how they would describe any change in the 
context of the QI approach and tools.  
 
There was a consensus amongst HRM Focus Group participants that it was generally the Pharmacist 
who was responsible for implementing the SPSP-PPC Program, primarily due to the Pharmacist being 
one of the two who attended the National Learning events. Some pharmacists seemed reluctant to 
involve other staff; there was a belief that other staff members (for example technicians and support 
workers) would not be equipped or confident enough to provide the intervention: 
 
 “W ? PďƵƚĂůƐŽƚŚĞƌĞ ?ƐĚŝĨĨĞƌĞŶƚƉĂƚŝĞŶƚƐ ? Q Q with this are they on a PPI or is it because 
ƚŚĞǇ ?ƌĞŐĞƚƚŝŶŐƐŝĚĞĞĨĨĞĐƚƐŽƌŝƐŝƚďĞĐĂƵƐĞƚŚĞǇ ?ƌĞŽŶƚƌŝƉůĞǁŚĂŵŵǇƐŽƚŚĞƌĞǁĂƐ
ĚŝĨĨĞƌĞŶƚĐŽŶǀĞƌƐĂƚŝŽŶƐ Q 
W ? PǇŽƵŬŶŽǁƉƌŽďĂďůǇƚŚĞƐƚĂĨĨĂƌĞŶ ?ƚĂƐĐŽŶĨŝĚĞŶƚŝƚŚĂƚƐŽƚŚĞǇ ?ƌĞƚŚŝŶŬŝŶŐ 
W ? P ‘ĐĂƵƐĞƚŚĞǇǁŽƵůĚŶ ?ƚĂůůŬŶŽǁǁŚĂƚĂŶĂĐĞŝŶŚŝďŝtor is 
W ? PŽƌƚŚĞǇ ?ůůŬŶŽǁĂĨĞǁŽĨƚŚĞŶŽŶ-steroidals but maybe not all of them 
W ? PĞǆĂĐƚůǇ ?
(P1: Pharmacy Manager, P3: Pharmacist, P4: Pharmacist, Health Board 2) 
 
 
In these situations some staff groups were therefore only involved (if at all) in the early stages of the 
process, when alerting the pharmacist that an eligible patient has presented a prescription in the 
pharmacy. Some participants considered the programme and delivering the intervention was akin to 
aspects of the role of the pharmacist. Therefore, delivering the programme was seen by many as just 
part of the job as a pharmacist and not the wider team. This may support the reason as to why 
pharmacists tended to be the one driving the delivery of the programme.  
 
This lack of wider site staff involvement in the collaborative resonated in the Community Pharmacy 
HRM Case Study interviews (June - November 2015). Comments were made by a number of 
ƉĂƌƚŝĐŝƉĂŶƚƐĂƌŽƵŶĚ “ŵŽƌĞĞǆƉĞƌŝĞŶĐĞĚƐƚĂĨĨ ? ?ŽƌĂůĂĐŬƚŚĞƌĞŽĨ ?ĞǆƉůĂŝŶŝŶŐƚŚĞŝƌƌĞĂƐŽŶƐďĞŚŝŶĚŽŶůǇ 
having the SPSP-PPC Away Team members actively involved in delivering HRM Care Bundles. Some 
staff reported having a low-ůĞǀĞůĂǁĂƌĞŶĞƐƐŽĨƚŚĞŝƌƉŚĂƌŵĂĐǇ ?ƐƉĂƌƚŝĐŝƉĂƚŝŽŶ P 
 
 “dŚĞǇ ?ƌĞĂǁĂƌĞďƵƚƚŚĞǇ ?ƌĞŶŽƚƌĞĂůůǇŝŶǀŽůǀĞd. Up until the summer I had a Pre-Reg so 
ƐŚĞĚŝĚĂůŽƚŽĨƚŚĞĂƐƐĞƐƐŵĞŶƚƐǁŚŝĐŚǁĂƐŐƌĞĂƚĨŽƌŚĞƌĂŶĚĨŽƌŵĞ QzĞĂŚƚŚĞƐƚĂĨĨĂƌĞ
ĂǁĂƌĞŽĨŝƚĂŶĚƚŚĞǇŬŶŽǁǁŚĂƚƚŚĞƐƚŝĐŬĞƌŵĞĂŶƐďƵƚƚŚĞǇĚŽŶ ?ƚĚŽƚŚĞĂƐƐĞƐƐŵĞŶƚƐ ? ?
(Branch Manager, Health Board 1) 
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In total 12 Home Team participants from a total of 31 Away and Home Team members involved in the 
case studies stated that they were not involved in the SPSP-PPC collaborative when asked, despite 
their pharmacy being involved.  
 
 
Level 4: Results 
 
 
 
 
Due to the evaluation period being limited to the SPSP-PPC project timeline, it has not been possible 
to ascertain whether the target outcomes were realised as a result of the training.  Any outcomes 
captured are reported under the appropriate activity:  HRM Care Bundles (Evaluation Question 2); 
Medicines Reconciliation (Evaluation Question 3); and Safety Culture (Evaluation Question 4)  
 
 
ii. ORGANISATIONAL & CONTEXT FACTORS 
 
 
 
 
 
 
 
 
During the early Health Board Leads interviews (February 2015), perceived challenges and success 
factors were discussed. The time involved for the Health Board Leads was raised as an issue by two of 
the four Board teams  W predominantly due to the distances between sites in these health boards. In 
addition, issues raised included the ability to deliver the SPSP QI approach within the community 
pharmacy setting and also the engagement of General Practices in the programme.  On being asked 
generally what factors may influence success, teams felt that engagement with the site staff would 
underpin the success of the programme  W through building relationships with the site staff, 
encouraging enthusiasm from the site manager ĂŶĚƚŚĂƚƚŚĞƐƚĂĨĨ ?ƐŚĂƌĚǁŽƌŬbe recognised through 
appropriate remuneration.  
 
More quantitative evaluation of success factors was measured through QA4 (NLE2, November 2015) 
and QA5a (CE, October 2016) which examined four factors thought to predict success within a QI 
collaborative: expert lead support; team work; collaborative process; and organisational support. All 
33 Away Team participants at NLE1 completed the questionnaire and 26 Away Team participants at 
Conclusions:  The data shows that although Away Team members reported a level of 
agreement to statements relating to the use of the SPSP-PPC tools, use reported by Home Team 
members was far lower, mimicking the lower levels of understanding also. This suggests that 
wider team involvement with the SPSP-PPC was not happening within sites and is corroborated 
by Community Pharmacy Case Study and HRM Focus Group data.  
Results: The degree to which targeted outcomes occur as a result of the training and the support 
and accountability package.   
Data Used in Analysis 
x Select data from QA1, QA2, QA3, QA4 and QA5a 
x HRM Community Pharmacy Case Studies 
x Local Learning Event (LLE) Focus Groups 
x Paired Health Board Leads Interviews 
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NLE2, comprising 41 unique individuals, 20 of whom completed both questionnaires. The summary 
result are presented in Figures 23-26 below.  
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Figure 23: Away Team Response to QI Collaborative Processes 
Figure 24: Away Team Response to Teamwork 
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We can see that median responses tended to remain the same across all time points.   
 
Figure 27 shows the median scores for the four factors examined in QA4 and QA5a by all 4 Health 
Boards. Statements that were worded negatively were reverse scored. Overall agreement was 
moderate  W to - high and generally remained so regarding expert lead support, team work, 
organisational support and collaborative processes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: Health Board Leads agreed that team support and engagement would be critical 
factors to the success of the programme. This was corroborated by the Away Teams through the 
quantitative evaluation which reported Collaborative Processes, Expert Lead Support and 
Organisation Support as positive.  
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Figure 27: Overall Away Team Response to QI Collaborative Questions 
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b. EVALUATION QUESTION 2:  How did the intervention programme improve 
the practice of high risk medicines (HRM) handling?  
 
This section of the results will be reported under the Framework of Proctor et al ?Ɛ ƚĂǆŽŶŽŵǇ ŽĨ
Implementation outcomes. The results will examine the acceptability, adoption, perceived 
appropriateness, feasibility, fidelity to, penetration and sustainability of the HRM change package 
within the SPSP-PPC collaborative by Away and Home Teams. The implementation cost element will 
not be examined as this project was funded and participating sites received remuneration for their 
participation.  
 
 
Implementation Outcomes 
  
Acceptability 
 
 
 
 
 
 
Data Used in Analysis 
x Select data from Away Team responses to QA1, QA2, QA3 and QA5a 
x HRM Community Pharmacy Case Studies 
x HRM Focus Groups 
x Celebratory Event Short Patient Impact Interviews 
 
 
Acceptability of HRM Element 
 
The HRM element of the programme is dependent on staff having an understanding of the 
underpinning QI tools.  Figure 18 illustrates the understanding of care bundles, run charts and PDSA 
cycles over team for Away Team participants. Over the course of the programme, it is clear that there 
is an increase in understanding of these key HRM programme elements and concepts, with less 
progress observed between the NLE1 (Nov 2014) and CE (Oct 2016). This perhaps represents a ceiling 
effect which is retained and sustained throughout year 2.   
 
The CE Short Patient Impact interviews (Oct 2016) also provided insight into how the acceptability of 
the HRM intervention was approaching the end of the programme. Participants were generally 
positive about this programme element and all reported that they were still implementing it in their 
sites and were seeing the change in the perception of their role, reinforcing the notion that it was 
accepted as important by participants and by patients:  
 
Acceptability: The perception among implementation stakeholders that a given treatment, 
service, practice, or innovation is agreeable, palatable, or satisfactory. 
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 “ŐĂŝŶďƵŝůĚŝŶŐƚŚĂƚƌĞůĂƚŝŽŶƐŚŝƉŶŽƚũƵƐƚďĞƚǁĞĞŶƚŚĞƉŚĂƌŵĂĐŝƐƚďƵƚƚŚĞƉŚĂƌŵĂĐŝƐƚ
ĂŶĚƚŚĞƐƚĂĨĨĂƐǁĞůů ? ?^ƚĂĨĨ ?ƵƐĞĚƚŽŐĞƚĂƐŬĞĚƋƵĞƐƚŝŽŶ ? “ĂŶ/ƐƉĞĂŬƚŽƚŚĞ
ƉŚĂƌŵĂĐŝƐƚ ? ?ĂŶĚŝƚǁĂƐƐŽŵĞƚŚŝŶŐĂŶŽƚŚĞƌŵĞŵďĞƌŽĨƐƚĂĨĨĐŽƵůĚŚĂǀĞĚĞĂůƚǁŝƚŚůŝŬĞ
ordering a repeat, whereas now because the staff are giving out that information in the 
ĐĂƌĞďƵŶĚůĞ QŝƚŵĞĂŶƐƚŚĞĐƵƐƚŽŵĞƌƐĂŶĚƚŚĞƉĂƚŝĞŶƚƐĂƌĞŵƵĐŚŵŽƌĞůŝŬĞůǇƚŽĂƐŬƚŚĞŵ
ƋƵĞƐƚŝŽŶƐ Q/ƚŚŝŶŬŝƚ ?ƐŵĂĚĞŝƚůŽŽŬůŝŬĞĂƉŚĂƌŵĂĐǇƚĞĂŵƌĂƚŚĞƌƚŚĂŶƚŚĞƉŚĂƌŵĂĐŝƐƚ
being ƚŚĞŽŶůǇƉĞƌƐŽŶƚŚĂƚŬŶŽǁƐĂďŽƵƚŵĞĚŝĐŝŶĞƐ ? ? 
(Pharmacist, Health Board 4) 
 
The QA5a questionnaire (Oct 2016) identified a high level of agreement with the statements: HRM 
was important within community pharmacy/dispensing practice; HRM element of the SPSP-PPC 
ĐŽůůĂďŽƌĂƚŝǀĞĂůŝŐŶĞĚƚŽƉĂƌƚŝĐŝƉĂŶƚƐ ?ǀŝĞǁƐŽĨŽŵŵƵŶŝƚǇWŚĂƌŵĂĐǇ/dispensing practice; and aligned 
with the overall vision of Pharmaceutical Care (Prescription for Excellence).  
 
During the HRM Focus Groups (LLE1, Apr-May2015), participants were asked about the 
implementation of the HRM care bundles thus far. Participants provided details of how they were 
implementing the element and who was primarily involved. Participants discussed the process by 
which they identified eligible patients, which spanned a number of methods. Most were provided the 
intervention opportunistically as they entered the practice, and staff were alerted that they were 
potentially eligible for the intervention based on the prescription they presented. Most participants 
said ƚŚĂƚĂƚƐŽŵĞƉŽŝŶƚŝŶƚŚĞƉƌŽĐĞƐƐŽĨŝĚĞŶƚŝĨǇŝŶŐĂŶĚƌĞĐƌƵŝƚŝŶŐƉĂƚŝĞŶƚƐ ?ƚŚĞǇĐŚĞĐŬĞĚƉĂƚŝĞŶƚƐ ?
names off of a list derived from their own patient records, yet a list of patients generated and provided 
by the SPSP-PPC leads was also discussed. However, the list supplied to the pharmacies by the project 
was deemed to be out-of-date and was not a fully comprehensive list of all patients who may be 
eligible for the intervention, and was thus not accepted by staff: 
 
 “W ? P,ĂůĨƚŚĞƉĂƚŝĞŶƚƐŚĂĚŶ ?ƚďĞĞŶƚŽŽƵƌpharmacy for six months or- 
W ? PƚŚĞǇ ?ĚĐŽŵĞǁŝƚŚŝƚŽŶĐĞ 
P1: Yes 
P3: and they lived elsewhere 
W ? P/ƚ ?ƐĂůŝƚƚůĞďŝƚŽƵƚŽĨĚĂƚĞĂƐǁĞůůǁŚĞŶ/ůŽŽŬĞĚĂƚŝƚ/ƚŚŝŶŬ 
P1: I think they recognised that though after they sent the list out that it was maybe 
not bĞƚŚĞďĞƐƚŝĚĞĂ ? ?
(P1: Pharmacy Manager, P2: Pharmacy Manager, P3: Pharmacist, Health Board 2) 
 
Some patients were proactively contacted to participate in the intervention. These participants 
tended to be house-bound, or had a patient representative normally attend the pharmacy for them, 
and were contacted via telephone. This recruitment method was accepted well by staff who saw it 
appropriate for this hard-to-reach patient cohort: 
 
 “W ? PdŚĞŚĂƌĚĞƐƚŽŶĞƐĂƌĞůŝŬĞƚŚĞĚĞůŝǀĞƌŝĞƐ ?ƚŚĞƉĞŽ ůĞǁŚŽŶĞǀĞƌĐŽŵĞŝŶƚŽ
ƚŚĞƉŚĂƌŵĂĐǇ QƚŚĞŽŶůǇŝŶƚĞƌĂĐƚŝŽŶƚŚĞǇŚĂǀĞŝƐƉƌŽďĂďůǇǁŝƚŚƚŚĞĚĞůŝǀĞƌǇ
ĚƌŝǀĞƌ QƚŚĞĚĞůŝǀĞƌǇĚƌŝǀĞƌ ?ŚĞ ?ƐŽŶďŽĂƌĚƐŽŚĞ ?ƐŬŝŶĚĂƚĞůůŝŶŐƚŚĞŵĂďŝƚĂďŽƵƚ
ǁŚĂƚǁĞ ?ƌĞĚŽŝŶŐĂŶĚƚŚen asking if they can phone into the 
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ƉŚĂƌŵĂĐǇ QƚŚĂƚ ?ƐǁŽƌŬĞĚƋƵŝƚĞǁĞůů ? ? 
(Pharmacist, Health Board 1) 
 
Beyond identifying patients from the (inaccurate) list, the most prominent issue was in simply 
identifying enough patients to submit data for every month. Some participants felt that the criteria 
were so specific that it made it very difficult to identify enough patients to interact with:  
 
 “W ? P/ƚ ?ƐƋƵŝƚĞĂĐŽŵƉůŝĐĂƚĞĚ QƚŚĞƉĂƚŝĞŶƚĐŽŚŽƌƚ ?ǇŽƵ ?ǀĞŐŽƚƚŽ ƌƵŶ ƚŚƌŽƵŐŚ ?ŝƐŝƚĂ
triple whammy medication? Are they getting non-steroidal anti-inflammatory? 
,ŽǁŽůĚĂƌĞƚŚĞǇ ?ŶĚǇŽƵ ?ǀĞŐŽƚƚŽƌƵŶƚŚƌŽƵŐŚƚŚŝƐďĞĨŽƌĞǇŽƵĐĂŶŝĚĞŶƚŝĨǇ
whether or not they fall into the specific cohort. I think with [another health 
ďŽĂƌĚ ? ?ƚŚĞǇ ?ƌĞĚŽŝŶŐĂǁĂƌĨĂƌŝŶĂŶĚŶŽŶ-steroidal which is easy to flag up. So one 
ĐŽŵƉůĂŝŶƚ/ ?ǀĞŐŽƚĨŽƌ ?ƚŚŝƐŚĞĂůƚŚďŽĂƌĚ ?ŝƐŝƚ ?ƐŵŽƌĞĐŽŵƉůŝĐĂƚĞĚƚŚĂŶŝƚƌĞĂůůǇ
ŶĞĞĚƐƚŽďĞƚŽďĞŚŽŶĞƐƚ QǁŚĞŶǇŽƵůŽŽŬĂƚƚŚĞƉĂƉĞƌǁŽƌŬǇŽƵ ?ǀĞďĞĞŶĞŵĂŝůĞĚ
out about how to identify the patient, what the patient cohort is, ŝƚ ?ƐůŝŬĞĨůĂŵŝŶŐ
ĨůŽǁĚŝĂŐƌĂŵ QĂŶĚŝƚ ?ƐŚĂƌĚ ?ǇŽƵĐĂŶ ?ƚƌĞĂůůǇĂƐŬƐƚĂĨĨŽĚŽŝƚďĞĐĂƵƐĞƚŚĞǇ ?ƌĞŶŽƚ
ƐƵƌĞ ? ? 
(Pharmacy Manager, Health Board 2) 
 
Acceptability of HRM Resources  
 
HRM Focus Group participants explained that beyond the basic requirements of implementing the 
HRM Care Bundles, they used a number of resources, namely stickers which were to be applied to the 
ƌĞůĞǀĂŶƚƉĂƚŝĞŶƚƐ ?ƉƌĞƐĐƌŝƉƚŝŽŶƐ ?ƉƌĞƐĐƌŝƉƚŝŽŶďĂŐƐƚŽŚŝŐŚůŝŐŚƚƚŚĞŵĂƐƉĂƌƚŽĨƚŚĞĐŽŚŽƌƚ P 
 
 “W ? PdŚĞŐŝƌůƐŽŶƚŚĞĐŽƵŶƚĞƌǁŚĞŶƚŚĞǇƐĞĞthe sticker they know that they need to 
ĂƐŬďƵƚŝƚ ?ƐũƵƐƚĂďŽƵƚŐĞƚƚŝŶŐƚŚĂƚƐƚŝĐŬĞƌŽŶƚŚĞƉƌĞƐĐƌŝƉƚŝŽŶ ?^ŽƚŚĞŶĞǁƐƚŝĐŬĞƌƐ
ĐĂŵĞŽƵƚĂŶĚ/ ?ǀĞƉůĂĐĞĚƚŚĞŵƌŝŐŚƚďĞƐŝĚĞĞĂĐŚŽĨƚŚĞĐŽŵƉƵƚĞƌƐ QƚŚĞǇƌĞĂůůǇĐĂŶ ?ƚ
ŵŝƐƐƚŚĞŵ ‘ĐĂƵƐĞƚŚĞǇ ?ƌĞƌĞĂůůǇďŝŐ ? ? 
(Pharmacy Manager, Health Board 1) 
 
The use of stickers was well-accepted however the posters that had been provided to them by 
management were not as they felt that they had no room within their pharmacy to display them.  
 
Participation in the programme was also challenging beliefs around what the role of the Pharmacist 
was for other staff (see Evaluation Question 1: Level 3 Behaviour). Participants also explained their 
interactions with nurses and nursing home staff in relation to their involvement in the programme. 
The overall response was that staff relationships with nursing staff were supported by the SPSP-PPC 
collaborative, as some of the sites involved serviced care homes. Furthermore, where patients could 
not attend the practice in person (i.e. care home residents), staff had delivered the interventions to 
ĐĂƌĞŚŽŵĞƐƚĂĨĨĂƐŝƚǁĂƐƚŚĞǇǁŚŽǁŽƵůĚďĞƌĞƐƉŽŶƐŝďůĞĨŽƌƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƐ P 
 
 “W ? PzĞĂŚĐĂƵƐĞǇŽƵŬŶŽǁ ?ƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ǁĞŶƚƌŽƵŶĚƚŚĞƚǁŽĐĂƌĞŚŽŵĞƐĂŶĚ
he took the bundle questionnaires and basically went through them with the Head 
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Nurses at both care homes and they basically answered them for each patient so 
ǇĞĂŚƚĞĐŚŶŝĐĂůůǇƚŚĂƚŝƐũƵƐƚƚŝĐŬŝŶŐƚŚĞŵŽĨĨ Q 
 
W ? PzĞĂŚ/ǁŽƵůĚƐĂǇƚŚĂƚ ?ƐĚŽŶĞĨŽƌƚŚĞŵƚŚŽƵŐŚďĞĐĂƵƐĞŝĨŝƚǁĂƐƐŽŵĞǁŚĞƌĞŝŶ
a house and it was the wife for example a wife looking after a husband and the 
ŚƵƐďĂŶĚǁĂƐŶ ?ƚĐĂƉĂďůĞƚŽŐŽƚŚƌŽƵŐŚƚŚĞƋƵĞƐƚŝŽŶƐǇŽƵǁŽƵůĚŐŽƚŚƌŽƵŐŚŝƚǁŝƚŚ
ƚŚĞǁŝĨĞĂŶĚǇŽƵǁŽƵůĚƚŝĐŬƚŚĞŵŽĨĨďĞĐĂƵƐĞŝƚ ?ƐĚŽŶĞĨŽƌƚŚĂƚƉĞƌƐŽŶ ?/ƚŚŝŶŬ
ǁŚŽĞǀĞƌ ?ƐŝŶƉƌŝŵĂƌǇĐĂƌĞŽĨƚŚĞŝƌŵĞĚŝĐŝŶĞ ? ? 
(P3: Pharmacist, P2: Trainee Technician, Health Board 1) 
 
The acceptability of the element can also be seen in more tangible detail through the HRM community 
pharmacy case studies (June  W Nov 2015). One participant did express that the appropriateness of the 
care bundle did hinge on factors such as the length of the intervention and how acceptable that would 
be to the patient, and that this could depend on the individual patient: 
 
 “ĐƚƵĂlly [the]  consultation itself can be quite lightweight but in some cases can actually 
ďĞƋƵŝƚĞůĞŶŐƚŚǇ QƐŽ ?ŝƚ ?ƐƚƌǇŝŶŐƚŽĨŝŶĚĂďĂůĂŶĐĞďĞƚǁĞĞŶǁŚĂƚǁŽƌŬƐĂŶĚǁŚĂƚ ?ƐŐŽŶŶĂ
ďĞďĞŶĞĨŝĐŝĂů ? ? 
(2nd Pharmacist, Health Board 1) 
 
 
 
 
Adoption 
 
 
 
 
 
Data Used in Analysis 
x Select data from QA1-QA3 and QA5a & b 
x HRM Community Pharmacy Case Studies 
x HRM Focus Groups 
x CE Short Patient Impact Interviews 
 
In theory, a number of factors could inhibit adoption of the intervention, therefore it was pertinent to 
examine to what extent (and what aspects of) the implementation were adopted by participants, how, 
and why.  
 
Conclusions: At the beginning of the SPSP-PPC collaborative, staff acceptability of the HRM 
intervention was lower due to a lack of understanding. However, progressing through the 
programme staff understanding and acceptance of the HRM care bundle was developed and 
maintained in part through local contextualised solutions to implementation.  
Adoption: The intention, initial decision, or action to try or employ an innovation or evidence-based 
ƉƌĂĐƚŝĐĞ ?ĚŽƉƚŝŽŶĂůƐŽŵĂǇďĞƌĞĨĞƌƌĞĚƚŽĂƐ “ƵƉƚĂŬĞ ? ?
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In QA5a and QA5b (CE, Oct 2016) a number of items specifically focused on action i.e. where 
participating sites completing the activities and using and adopting the tools and practices. Figures X 
(Evaluation Question 1: Level 3 Behaviour) illustrates the Away and Home Team responses to 
statements on the use of care bundles, Run Charts and PDSA cycles.  The results were more positive 
for Away team than Home Team participants. There was a higher median level of agreement that care 
bundles were being used by the Away Team. This would seem reasonable as the care bundle 
Implementation was one of the more established elements of the programme.  Use of Run charts was 
less frequent for both teams than any other tool.  Earlier in QA2 (LLE1, March-April 2015), participants 
were asked to detail if they had completed at least 1 PDSA cycle at that point in the programme. Of 
ƚŚĞ ? ?ǁĂǇdĞĂŵƌĞƐƉŽŶĚĞŶƚƐ ? ? ?ƐĂŝĚƚŚĞǇŚĂĚĐŽŵƉůĞƚĞĚĂƚůĞĂƐƚ ?W^ĐǇĐůĞ ? ? ?ƌĞƉŽƌƚĞĚ “EŽ ?
and 7 were either unsure or did not respond) which potentially affirms an issue with potentially 
integrating these tools into routine practice.   
 
WheŶƌĞƐƉŽŶĚŝŶŐƚŽƚŚĞƐƚĂƚĞŵĞŶƚ “te are doing all we can with HRM ? in QA5a & b (CE, Oct 2016) 
the levels of agreement between Away Team and Home Teams were similar (median = 5 and median 
= 4.5 respectively.  Away Team median responses over time are displayed in Figure 28:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: Sites had adopted Care Bundles with confidence, and PDSA cycles and Run Charts to a 
lesser degree as part of the HRM element of SPSP-PPC collaborative.  
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Questionnaire Statement
Away Team Median Responses to Adoption of HRM (QA1, Nov 2014, 
QA3, Nov 2015 & QA5a, Oct 2016)
QA1 (Nov 2014)
QA3 (Nov 2015)
QA5a (Oct 2016)
1 = Not at all 
2 = To a very limited extent 
3 = To a limited extent 
4 = To a moderate extent 
5 = To a considerable extent 
6 = To a great extent 
7 = To a very great extent 
Figure 28: Away Team Response to Adoption of HRM 
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Appropriateness 
 
 
 
 
 
Data Used in Analysis 
x Select data from Away Team responses to QA2  
x HRM Community Pharmacy Case Studies (Home and Away) 
x HRM focus group data (Home and Away) 
 
From QA2 (LLE, Mar-Apr 2015) we see that participants had a median score of  “dŽĂ'ƌĞĂƚ EǆƚĞŶƚ ? ?ŝŶ
ƌĞƐƉŽŶƐĞƚŽƚŚĞƐƚĂƚĞŵĞŶƚ “/ƚŚŝŶŬƚŚĂƚƚŚĞƚŽŽůƐǁĞĂƌĞƵƐŝŶŐǁŝůůŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?ƐĂĨĞƵƐĞŽĨƚŚĞ
ŚŝŐŚƌŝƐŬŵĞĚŝĐŝŶĞ ? ?dŚŝƐƐŚŽǁƐĂŐŽŽĚůĞǀĞůŽĨĂŐƌĞĞŵĞŶƚƚŚĂƚparticipants felt the tools were fit for 
purpose and appropriate.  
 
During the HRM Focus Groups (April-May2015), participants discussed the process by which they 
identified eligible patients. Some participants expressed that the list of patients eligible for the NSAIDs 
intervention, supplied to the pharmacies by the Health Board Leads, was deemed to be out-of-date 
and was not a fully comprehensive and was thus disregarded (see HRM: Acceptability).   
 
 
Some HRM Focus Group participants mentioned that the SPSP-PPC collaborative had reinforced the 
image of the pharmacist as being someone who does more than just dispense medicines. Engaging 
with patients about their medicines challenged them to consider the pharmacist role as more evolved: 
 
 “W ? P/ƚŚŝŶŬŝƚ ?ƐƐƚŝůůƚŚĞǇƚŚŝŶŬ ?ƚŚĂƚ ?ƐƚŚĞƉƌĞƐĐƌŝƉƚŝŽŶǁƌŝƚƚĞŶ ?ƚŚĂƚ ?ƐŵǇŵĞĚŝĐŝŶĞƐ ?
just give me it and go or what 
W ? PǇĞĂŚǇŽƵƌƌŽůĞ ?ƐŶŽƚƚŽƚĂůŬĂďŽƵƚŝƚ ?ŝƚ ?ƐũƵƐƚƐƚŝĐŬŝƚŝŶĂďĂŐĂŶĚŐŝǀĞŝƚŽƵƚƚŽ
ŵĞ Q 
W ? PǇŽƵƌũŽďŝƐƚŽƉƌŽĚƵĐĞĂůĂďĞůĂŶĚƐƚŝĐŬŝƚŽŶĂŶĚƐŝŐŶŝƚ ?ůĂƵŐŚƐ ? ? ?
(P3: Pharmacist, P2: Pharmacy Manager, P1: Pharmacy Manager, Health Board 1) 
 
One participant did feel that taking part in the programme aligned well with how community 
pharmacy is changing over the course of the next few years, mainly due to the Prescription for 
Excellence Action Plan. Having a more active role in patient medicines seemed natural in this context.  
 
Several of the participants detailed that their pharmacy delivered a multitude of other high-risk or 
disease-specific interventions for patients that were not dissimilar to that of the SPSP-PPC including 
the Chronic Medication Service (CMS) and Gluten Intolerance Service. It was suggested that the 
current warfarin and NSAIDs Care Bundles could be delivered as part of other services:  
Appropriateness: The perceived fit, relevance, or compatibility of the innovation or evidence 
based practice for a given practice setting, provider, or consumer; and/or perceived fit of the 
innovation to address a particular issue or problem. 
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 “W ? PzŽƵĐŽƵůĚƉƌŽďĂďůǇƋƵŝƚĞĞĂƐŝůǇŝŵƉůĞŵĞŶƚŝƚŝŶƚŽƉĂƌƚŽĨƚŚĞƉĂƚŝĞŶƚĐĂƌĞ
ƌĞĐŽƌĚƐ ‘ĐĂƵƐĞƚŚĞǇ ?ǀĞĚŽŶĞƚŚĂƚǁŝƚŚƚŚĞŶĞǁƐĞƌǀŝĐĞƚŚĂƚ ?ƐŶĂƚŝŽŶǁŝĚĞ ?ŝƚ ?ƐƚŚĞ
gluten-ĨƌĞĞƐĞƌǀŝĐĞ ?ƐŽƚŚĂƚ ?Ɛ now got its own bit on the patient care records that 
ǇŽƵĐĂŶĨŝůůŝŶǁŚĞŶǇŽƵ ?ƌĞŚĂǀŝŶŐĂĐŽŶƐƵůƚĂƚŝŽŶ ?ƐŽǇĞĂŚƚŚĞǇĐŽƵůĚĂĚĚƚŚĂƚŽŶ
ƋƵŝƚĞĞĂƐŝůǇ/ƐƵƉƉŽƐĞ Q 
P1: ǇŽƵ ?ƌĞĂůŵŽƐƚĚƵƉůŝĐĂƚŝŶŐǁŽƌŬƚŚĞŶĂƌĞŶ ?ƚǇŽƵďĞĐĂƵƐĞǁĞ ?ƌĞĨŝůůŝŶŐŽƵƚƚŚĞ
form to send in ƚŽ ?ƚŚĞ>ĞĂĚ ? ?ĂŶĚƚŚĞŶǇŽƵ ?ƌĞĚŽŝŶŐŝƚŽŶƚŚĞWZ 
W ? P ‘ĂƵƐĞǁĞ-ǁĞ ?ǀĞŐŽƚƐŽŵĂŶǇƉĞŽƉůĞƚŚĂƚǁĂŶƚƵƐƚŽĚŽƚŚŝŶŐƐ QǇŽƵ ?ǀĞŐŽƚ
lots of different people wanting different things but if you can slot them in to all of 
them then you can kill two birds with onĞƐƚŽŶĞ ?Ƶƚ/ƐƵƉƉŽƐĞƚŚĞƌĞ ?ƐƚŚĞŶƚŚĞƌĞ ?Ɛ
ŽǀĞƌůĂƉŝŶǁŚĂƚĂůůƚŚĞƉĞŽƉůĞĂƌĞĂƐŬŝŶŐǇŽƵƚŽĚŽ ? ?
(P1: Pharmacy Manager, P4: 2nd pharmacist, Health Board 2) 
As the quote suggests integration within other national services which would minimise the amount of 
reporting or logging of patient details could be helpful moving forward. Although the HRM element 
fits well with the ethos of community pharmacy, there was perhaps discord relating to the suitability 
relating to the staff on-site who could potentially deliver the intervention, versus those who were 
actually involved (see Evaluation Question 1: Level 3 Behaviour section).  
 
At the Celebratory Event (QA5a, 2016), Away Team members were asked to score their agreement on 
the appropriateness of the HRM element in relation to a number of different statements (Figure 29).  
Strong agreement was observed across the range of statements covering health policy, working 
practices and patient care.   
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Questionnaire Statements
Away Team Median Responses to Appropriateness of HRM Care Bundle Element (QA5a, 
Oct 2016)
1 = Not at all 2 = To a very limited extent 3 = To a limited extent 4 = To a moderate extent 5 = To a considerable extent 6 = To a great extent 7 = To 
a very great extent 
Figure 29: Away Team Response to Appropriateness of HRM 
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Feasibility 
 
 
 
 
 
Data Used in Analysis 
x Select Away Team data from QA2 & QA5a 
x HRM Community Pharmacy Case Studies 
x CE Short Patient Impact Interviews 
x Additional Supplementary Data from CE 
 
Participants were asked about the time and resource participating in the programme consumed 
through the variety of questionnaires over the evaluation period. Figure 30 shows the change in 
opinion from NLE1 (QA1, Nov 2014) to NLE2 (QA3, Nov 15) for statements relating to data collection 
and the pressure of attending SPSP-PPC meetings: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: The HRM element of the programme was seen as appropriate in the context of the 
role of the practice sites, especially community pharmacy, and the provision of safe and reliable 
patient care.  Better alignment with other national services was proposed in moving forward.  
Feasibility: The extent to which a new treatment, or an innovation, can be successfully used or 
carried out within a given agency or setting 
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Data Collection (QA1, Nov 2014 & QA3, Nov 2015)
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3 = To a limited extent 
4 = To a moderate extent 
5 = To a considerable extent 
6 = To a great extent 
7 = To a very great extent 
Figure 30: Away Team Response to Concerns of Time 
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Participants were not concerned about the burden of data collection at baseline, however scores did 
increase 1 year later to a median of Slightly Agree, perhaps due to having more experience of data 
collection.  This was also reported in the HRM Community Pharmacy Case Studies (June-November 
2015) with one participant indicating that the HRM Care Bundle format and associated data reporting 
documents were not useful: 
 
 “/ĨŽƵŶĚƚŚĞŵŽƐƚĚŝĨĨŝĐƵůƚƉĂƌƚǁĂƐƌĞĂĚŝŶŐƚŚĞƉĂƉĞƌǁŽƌŬ ?/ŚĂĚƚŽĂĐƚƵĂůůǇǁƌŝƚĞŝƚŽƵƚ
ŵǇƐĞůĨƚŽƵŶĚĞƌƐƚĂŶĚǁŚĂƚǁĞǁĞƌĞƚƌǇŝŶŐƚŽĂƵĚŝƚ Q/ƚǁĂƐŶ ?ƚŐŽŝŶŐŝŶƚŽŵĞ ?ƐŽ/ŚĂĚƚŽ
put it down differently, and it made it easier for my student to do his audiƚ ? ? 
(Second Pharmacist, Health Board 2) 
 
Other staff reported their own solutions in developing localised data recording tools to aid the process.  
Many case study participants also reflected that time pressures challenged the feasibility of 
participating in the HRM change package. These included time pressures of general pharmacy work, 
of patient consultations (which vary), of data reporting, and of other services being provided: 
 
 “/ƚũƵƐƚůŝŬĞŝƚƐĞĞŵƐůŝŬĞƚŚĞƌĞ ?ƐƐŽŵĂŶǇĚŝĨĨĞƌĞŶƚůŽĐĂůĞŶŚĂŶĐĞĚƐĞƌǀŝĐes going on that 
ŝƚ ?ƐƌĞĂůůǇŚĂƌĚƚŽŬĞĞƉƵƉ QŝƚƐĞĞŵƐůŝŬĞŝƚŝƐĂŐŽŽĚŝĚĞĂŝĨƚŚĞƐĞƚŚŝŶŐƐĂƌĞĐĂƵƐŝŶŐ
ƉƌŽďůĞŵƐďƵƚŝƚ ?ƐũƵƐƚƚŚĞǀŽůƵŵĞŽĨƚŚĞƐĞƐĞƌǀŝĐĞƐ QƉůƵƐŚĂǀŝŶŐƚŽĚŽĞǀĞƌǇƚŚŝŶŐĞůƐĞĂƐ
well, it seems really difficult. Quite daunting in some ways. ? 
(Pre-Registration Pharmacist, Health Board 2) 
 
Furthermore, some participants reported it was not deemed feasible for all pharmacy staff to fully 
participate in the HRM Care Bundle; as mentioned previously, the responsibility tended to realistically 
fall on the Pharmacist  
 
 “ƚƚŚĞŵŽŵĞŶƚďĞĐĂƵƐĞǁĞ ?ƌĞƐŚŽƌƚ-ƐƚĂĨĨĞĚ ?ǁĞ ?ǀĞŐŽƚŽŶĞŽĨŽƵƌŵŽƌĞĞǆƉĞƌŝĞŶĐĞĚ
members off long-ƚĞƌŵƐŝĐŬƐŽƚŚŝŶŐƐŚĂǀĞŬŝŶĚĂďĞĞŶĂďŝƚŚĂŝƌǇ QƐŽ ?ƚŚĞŽƚŚĞƌƐƚĂĨĨ ?ĂƌĞ
ĂǁĂƌĞƚŚĂƚǁĞ ?ƌĞĚŽŝŶŐ ?ƚŚĞƉƌŽŐƌĂŵŵĞ ?ďƵƚƚŚĞǇ ?ƌĞŶŽƚĂƐŝŶǀŽlved as I would have 
ŚŽƉĞĚĨŽƌŽƌƚŚĞǇǁĞƌĞƉƌĞǀŝŽƵƐůǇ ? ? 
(Pharmacist and Branch Manager, Health Board 3) 
 
However, these challenges were alleviated somewhat within some pharmacies who took a pragmatic 
approach:   
 
 “/ĨǁĞĐĂŶĚŽŝƚ ?ǁĞǁŝůůĚŽŝƚ ?/ĨǁĞĐĂŶ ?ƚĚŽŝƚ ?ǁĞĐĂŶ ?ƚĚŽŝƚĂŶĚǁĞ ?ůůĐĂƚĐŚƚŚĞŵŝŶƚŚĞ
ŶĞǆƚƚŝŵĞ ?^Ž ?ǁĞǁŽŶ ?ƚůĞƚĂŶǇ ?ĂŶǇŽƚŚĞƌĐƵƐƚŽŵĞƌƐƵĨĨĞƌďĞĐĂƵƐĞǁĞ ?ƌĞƐƉĞĂŬŝŶŐƚŽŽŶĞ
ƉĞƌƐŽŶ Q^Ž ?ŝƚ ?ƐŶŽƚďĞĞŶĚŝƐƌƵƉƚŝǀĞďĞĐĂƵƐĞǁĞ ?ǀĞĂůǁĂǇƐƉŝĐŬĞĚƵƉƚŝŵĞwhere we can 
ŐŝǀĞƚŚĞŵŽƵƌƚŝŵĞ ? ? 
(Pharmacist and Branch Manager, Health Board 1) 
 
Participants also commented on challenges around the feasibility of accessing the patient cohort, as 
participants tended to see a lot of the same patients repeatedly for some aspects of the care bundles 
(see HRM: Acceptability section). ĚĚŝƚŝŽŶĂůůǇ ?ƚŚĞƌĞǁĂƐĂŶ ŝƐƐƵĞĂƌŽƵŶĚ “ŚĂƌĚ-to-ƌĞĂĐŚƉĂƚŝĞŶƚƐ ? ?
whereby carers or patient representatives collected their prescriptions from the pharmacies:  
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 “^Ž ?ǁĞũƵƐƚŚĂǀĞƚŽƉŚŽŶĞƚhem if we can get, you know, if we are able to talk to them 
ŽŶƚŚĞƉŚŽŶĞ ?ǁŚŝĐŚŝƐƋƵŝƚĞĚŝĨĨŝĐƵůƚ Q ?ĂŶĚ ?ŝĨŝƚ ?ƐƐŽŵĞďŽĚǇĞůƐĞƚŚĂƚĐŽŵĞƐŝŶĨŽƌƚŚĞŵ
ǇŽƵŬŶŽǁ Q ?ŝƚ ?ŚĂƉƉĞŶƐƋƵŝƚĞĂůŽƚ ? ? 
(Accredited Checking Technician, Health Board 1) 
 
Away Team participants reported that participation in the HRM programme element was not too 
onerous, Case Study Pharmacy participants did report that the element was more involved than 
anticipated, although these comments again focused more around the data collection and reporting 
as opposed to delivery of the care bundle. It was deemed that entering and reporting data can be 
disruptive to the natural flow of work, whereas counselling patients was seen as part of the role of 
community pharmacy already.   
 
However, 1 year post-HRM Case Studies, Away Team members at the Celebratory Event (QA5a, Oct 
2016) were asked about the sufficiency of time and resource in delivering the HRM intervention and 
agreed overall that they had sufficient time and resource to a great extent (Figure 31): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the Celebratory Event Short Patient Impact Interviews, one participant commented that although 
they had stopped collecting and reporting data back to their health board, delivering the HRM Care 
Bundles was feasible due to it fitting in well with current community pharmacy practice: 
 
 “/ƚŚŝŶŬŝƚ ?ƐŶŽǁũƵƐƚƐĞĐŽŶĚŶĂƚƵƌĞĨŽƌƚŚĞƐƚĂĨĨ QŝƚĚŽĞƐŶ ?ƚƚĂŬĞůŽŶŐ ?ũƵƐƚĂƋƵŝĐŬ
ĐŽŶǀĞƌƐĂƚŝŽŶ QǇŽƵĚŽƐƚŝůůĨŝŶĚƚŚĞŽĚĚƉĂƚŝĞŶƚƚŚĂƚ ?ƐůŝŬĞ ‘ŽŚ/ ?ŵŶŽƚďŽƚŚĞƌĞĚďǇƚŚĂƚ ? I 
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Figure 31: Away Team Response to Feasibility of HRM 
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ĚŽŶ ?ƚƌĞĂůůǇƚĂŬĞ ?ŵǇE^/Ɛ ?ĂĨƚĞƌĨŽŽĚĂŶĚƚŚĂƚ ?ƐǁŚĞŶƚŚĞŶŝƚŚŝŐŚůŝŐŚƚƐƚŚĂƚĂĐƚƵĂůůǇǁĞ
ĚŽŶĞĞĚƚŽŚĂǀĞƚŚŝƐĐŽŶǀĞƌƐĂƚŝŽŶ ? 
(Job role unknown, Health Board 2) 
 
 
Fidelity 
 
 
 
 
Data Used in Analysis 
x Select data from QA1  
x HRM Focus Groups 
x HRM Community Pharmacy Case Studies 
 
From previous data presented Away Team participants had a good understanding of the HRM 
elements (care bundles, PDSA cycles and run charts), and this level of understanding was maintained 
over the course of the programme, although less so for the Home Team. During the HRM Focus 
Groups, participants were asked how they were identifying eligible patients. The methods for patient 
identification was found to be variable (see Adoption and Fidelity sections) with sites often solving for 
this locally, particularly for the NSAID Care Bundle. Furthermore, participants had issues around the 
strict patient cohort criteria (especially for NSAIDs) and were therefore targeting patients who tended 
to either be outside of the recommended age bracket for intervention, or were not on a triple 
whammy but as per the ƉŚĂƌŵĂĐŝƐƚ ?ƐũƵĚŐĞŵĞŶƚƐƚŝůůƌĞƋƵŝƌĞĚĂŶŝŶƚĞƌǀĞŶƚŝŽŶ ?DŽƐƚƉĂƌƚŝĐŝƉĂŶƚƐĚŝĚ
seem to adhere to using some of the additional tools to aid the implementation of the HRM Care 
Bundle, including the stickers for prescription bags: 
 
 “W ? PdŚĞŐŝƌůƐŽŶƚŚĞĐŽƵŶƚĞƌǁŚĞŶƚŚĞǇƐĞĞƚŚĞƐƚŝĐŬĞƌƚŚĞǇŬŶŽǁƚŚĂƚƚŚĞǇŶĞĞĚƚŽĂƐŬ
ďƵƚŝƚ ?ƐũƵƐƚĂďŽƵƚŐĞƚƚŝŶŐƚŚĂƚƐƚŝĐŬĞƌŽŶƚŚĞƉƌĞƐĐƌŝƉƚŝŽŶ ?^ŽƚŚĞŶĞǁƐƚŝĐŬĞƌƐĐĂŵĞŽƵƚ
ĂŶĚ/ ?ǀĞƉůĂĐĞĚƚŚĞŵƌŝŐŚƚďĞƐŝĚĞĞĂĐŚŽĨƚŚĞĐŽŵƉƵƚĞƌƐ QƚŚĞǇƌĞĂůůǇĐĂŶ ?ƚŵŝƐs them 
 ‘ĐĂƵƐĞƚŚĞǇ ?ƌĞƌĞĂůůǇďŝŐ ? ? 
(Pharmacy Manager, Health Board 1) 
 
The HRM Community Pharmacy case studies (April - November 2015) highlighted that there was 
variable engagement of the Home Teams in delivery of the care bundles; the intention had been to 
achieve broad Home Team participation in programme delivery to support sustainability.  However, 
in reality the responsibility of participating in the programme was often held by the pharmacist and 
sometimes the other Away Team members, and often other staff members were not actively 
encouraged to be involved: 
Conclusions: Although participation in the SPSP-PPC collaborative at this pilot phase could be 
moderately onerous for some, delivering the HRM care bundles was seen as feasible for 
participants.  
Fidelity: The degree to which an intervention was implemented as it was prescribed in the original 
protocol or as it was intended by the program developers. 
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 “/ƚŚŝŶŬĂƚƚŚĞŵŽŵĞŶƚďĞĐĂƵƐĞŝƚŝƐũƵƐƚŵǇƐĞůĨƚĂŬŝŶŐŽŶƚŚĞǁŚŽůĞƉƌŽĐĞƐƐ ?ŝĨ/ ?ŵŶŽƚ
ƚŚĞƌĞĐĂƵƐĞ/ ?ǀĞŚĂĚĂĚĂǇŽĨĨ QƚŚĞĚĂƚĂ ?ƐŶŽƚŐĞƚƚŝŶŐĐŽůůĞĐƚĞĚ QdŚĞǇ ?ƌĞŵĂǇďĞŶŽƚ
ĨŽůůŽǁŝŶŐƵƉ QŝĚĞĂůůǇǁĞ ?ĚŚĂǀĞŝƚƐŽƚŚĂƚƐƚĂĨĨǁŽƵůĚďĞĂďůĞƚŽŚĞůƉǁŝƚŚĂŶǇŬŝŶĚŽĨ-like 
ƚŚĞǇĐŽƵůĚĨŝůůŝŶŝĨ/ǁĂƐŶ ?ƚƚŚĞƌĞ ?ƐŽƚŚĂƚ ?ƐŬŝŶĚŽĨƚŚĂƚ ?ƐƚŚĞŵĂŝŶƚŚŝŶŐũƵƐƚŶŽǁ ? ?
(Branch Manager, Health Board 3) 
 
 
 
 
 
 
 
Penetration 
 
 
 
 
Data Used in Analysis 
x Select data from QA2, QA5a & b 
x HRM Community Pharmacy Case Studies 
x HRM  Focus Groups 
x CE Short Patient Impact Interviews 
 
In QA2 (LLE1, March  W April 2015) participants were asked if their wider pharmacy team was involved 
in the HRM Care Bundle (Figure 32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Penetration: The integration of a practice within a service setting and its subsystems. 
Conclusions: The practicalities of patient identification was found to be challenging, particularly 
for the NSAID Care Bundle.   Once identified the care bundle was seen as the responsibility of the 
pharmacist and not involving the wider pharmacy team in a number of practice sites. Sites 
utilised some of the central resources but also developed local tools to support integration into 
established systems and procedures.  
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Participants felt that the wider pharmacy team was both involved in and supportive of their 
participation in the HRM element to a considerable extent (median = 5). When asked in QA5a (CE, Oct 
2016) if they would like to continue with the HRM element of the programme, the Away Team elicited 
a median response of 7 ( “Strongly Agree ?) that the process had penetrated into their working practices 
and were favourable to continuing their involvement.  
 
As discussed previously in the Fidelity analysis, it was reported that some Away Team members were 
assuming responsibility for the delivery of the HRM change package providing a clear measure of a 
lack of penetration across the practice team. However, this was not always the case with some 
examples of wider team involvement being described through the CE short interviews:   
 
 “gain building that relationship not just between the pharmacist but the pharmacist 
ĂŶĚƚŚĞƐƚĂĨĨĂƐǁĞůů ?dŚĞǇƵƐĞĚƚŽŐĞƚĂƐŬĞĚƋƵĞƐƚŝŽŶ ? “ĐĂŶ/ƐƉĞĂŬƚŽƚŚĞ
ƉŚĂƌŵĂĐŝƐƚ ? ?ĂŶĚŝƚǁĂƐƐŽŵĞƚŚŝŶŐĂŶŽƚŚĞƌŵĞŵďĞƌŽĨƐƚĂĨĨĐŽƵůĚŚĂǀĞĚĞĂůƚ
ǁŝƚŚ QǁŚĞƌĞĂƐŶŽǁďĞĐĂƵse the staff are giving out that information in the care 
ďƵŶĚůĞĂďŽƵƚǁĂƌĨĂƌŝŶ QŝƚŵĞĂŶƐƚŚĞĐƵƐƚŽŵĞƌƐĂŶĚƚŚĞƉĂƚŝĞŶƚƐĂƌĞŵƵĐŚŵŽƌĞůŝŬĞůǇ
ƚŽĂƐŬƚŚĞŵƋƵĞƐƚŝŽŶƐĂƐǁĞůůĂŶĚŶŽƚĂůǁĂǇƐƚŚĞƉŚĂƌŵĂĐŝƐƚ ?^Ž/ƚŚŝŶŬŝƚ ?ƐŵĂĚĞŝƚ
look like a pharmacy team rather than the pharmacist being the only person that 
ŬŶŽǁƐĂďŽƵƚŵĞĚŝĐŝŶĞƐ ? ? 
(Pharmacist, Health Board 4) 
 
Furthermore, examples were given where the multidisciplinary team were being involved in the HRM  
Care Bundle element, therefore helping to provide a more holistic and effective pharmaceutical care 
experience for these high-risk patients: 
 
 “/ĚŝĚŶ ?ƚĨƵůůǇƵŶĚĞƌƐƚĂŶĚƚŚĞ/EZĐůŝŶŝĐĂŶĚǇŽƵŬŶŽǁ ŚĂƚƚŚĞǇĚŝĚƚŚĞƌĞ Q^Ž/ǁĞŶƚ
to the nurses at our local hospital and asked if I could sit in one of the clinics and they 
were very, very happy to let me do that, and to show me you know their processes 
and I shared you know what we did and what we were hoping to do whilst doing the 
warfarin work, and it highlighted a lot of things. You know I explained to them that 
we really needed these certain pages in the book filling in and sometimes they were 
missing and how best did they want me to help and its really simple but I just 
highlighted the bits in the book so that next time when the patient went in to the INR 
clinŝĐƚŚĞŶƵƌƐĞǁŽƵůĚŽƉĞŶŝƚƵƉĂŶĚ “ŽŚƌŝŐŚƚǁĞĚŝĚŶ ?ƚĨŝůůƚŚĂƚďŝƚŝŶ ?ĂŶĚŝƚǁŽƵůĚ
ŐĞƚĨŝůůĞĚŝŶ ? ?
(Registered Technician, Health Board 3) 
 
 
 
 
 
 
Conclusions: Penetration of awareness and understanding of the HRM care bundle was variable, 
much stronger for Away Team participants, and this impacted on whom in the practice team was 
delivering the care bundle to patients. However, some Away Team participants could provide 
examples where the Home Team were involved in the delivery of the HRM bundles, and also 
involvement of the wider MPT.  
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Sustainability 
 
 
 
 
Data Used in Analysis 
x Select data from QA5a 
x HRM Focus Groups 
x CE Short Patient Impact Interviews 
 
During the HRM focus groups, participants mentioned a number of barriers which were limiting their 
participation; in the main these were time and information technology (IT) issues. Although delivering 
ƚŚĞĐĂƌĞďƵŶĚůĞŝƚƐĞůĨǁĂƐƐĞĞŶĂƐ “ďƵƐŝŶĞƐƐĂƐƵƐƵĂů ? ?ƚŚĞĚĂƚĂƌĞĐŽƌĚŝŶŐĂŶĚƵƐĞŽĨW^ĐǇĐůĞƐǁĂƐ
seen as time-consuming (the former may not be part of sustained delivery of the HRM change 
package). IT was an issue again when reporting data back to Health Board Leads. Participants were 
also asked if they had any issues with any of the resources or materials associated with the SPSP-PPC 
collaborative. Comments were generally positive about the associated materials, and where there 
were issues, they were frequently resolved: 
 
 “W ? P/ƚŚŝŶŬǁŚĂƚĞǀĞƌǁĞ ?ǀĞĂƐŬĞĚŽĨƚŚĞŵƚŚĞǇ ?ǀĞŐĞŶĞƌĂůůǇƚƌŝĞĚƚŽĨŝǆĂŶĚĐŽŵĞ
up with ĚŝĨĨĞƌĞŶƚƚŚŝŶŐƐ QtĞƌĞƉŽƌƚĞĚďĂĐŬĂďŽƵƚƐƚŝĐŬĞƌƐ QƚŚĞƐƚŝĐŬĞƌƐǁĞƵƐĞ
ǁĞƌĞŶ ?ƚƌĞĂůůǇƚŚĂƚƵƐĞĨƵůďĞĐĂƵƐĞŽĨƚŚĞŝƌĐŽůŽƵƌand their size and stuff so [the 
leads] went away and re-designed that. We asked for posters to put up and they 
ǁĞŶƚĂǁĂǇĂŶĚĚŽŶĞƚŚĂƚĂŶĚŐŽƚǀĂƌŝŽƵƐƌĞĐŽƌĚŝŶŐƚŽŽůƐƚŚĂƚƚŚĞǇ ?ǀĞƌĞĂůůǇƚƌŝĞĚƚŽ
make as easy as possible on us, tried to kind of auto input as many fields as possible 
ĂŶĚƐƚƵĨĨƐŽƚŚĞǇ ?ǀĞƚƌŝĞĚƚŽŵĂŬĞŝƚĂƐůĂďŽƵƌ-ĨƌĞĞĂƐƉŽƐƐŝďůĞ/ǁŽƵůĚƐĂǇ ? ?
(Trainee Technician, Health Board 1) 
 
One participant remarked on the warfarin yellow book and how, due to some patients now receiving 
print-outs of their levels, the books were not being kept up-to-date and patients were not bringing 
them in to the practice with them.  This lack of use was affecting the implementation of the Warfarin 
Care Bundle.  Developments were reported to be ongoing in regard of the yellow book completion to 
facilitate a more sustainable care bundle moving forward.  
 
In QA5a (CE, Oct 2016), participants were asked if they would like to continue with the HRM Care 
Bundle element of the programme post-pilot stage. Clearly motivation to continue would be a 
contributory factor to the sustainability of any programme element beyond pilot. The median 
response of 7 (strongly agree) to the statement  “/ ǁŽƵůĚ ůŝŬĞ ŽƵr site to continue to use the 
programme tools/procedure of the HRM element after the SPSP-PPC collaboratŝǀĞĐŽŵĞƐƚŽĂŶĞŶĚ ? ?
indicates a high level of willingness to continue with the HRM Care Bundles.  
 
During the CE Short Patient Impact Interviews, staff were asked about their current activity regarding 
the HRM Care Bundles, and as discussed previously (section x) some provided insight into how the 
practice had been integrated into their day-to-day work, suggesting sustainability would be possible. 
Sustainability: The extent to which a newly implemented treatment is maintained or 
ŝŶƐƚŝƚƵƚŝŽŶĂůŝǌĞĚǁŝƚŚŝŶĂƐĞƌǀŝĐĞƐĞƚƚŝŶŐ ?ƐŽŶŐŽŝŶŐ ?ƐƚĂďůĞŽƉĞƌĂƚŝŽŶƐ ? 
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Furthermore, one staff member had since left their post and had begun working in a hospital setting. 
Having seen the benefits of the HRM Care Bundles in the primary care setting, this staff member had 
endeavoured to carry on with the HRM Care Bundle as a way of sustaining the service beyond the 
initial intended environment: 
 
 “/ ?ĚĚĞĨŝŶŝƚĞůǇƐĂǇƚŚĞďƵŶĚůĞ/ ?ǀĞƚĂŬĞŶŝŶƚŽ ?ŵǇŶĞǁƌŽůĞ ?ǁŝƚŚŵĞŶŽǁ Q/ĐĂŶƵƐĞŝƚ
 ?ƚŚĞƌĞ ?ǁŚĞŶ/ ?ŵƚƌĂŝŶŝŶŐƉĂƚŝĞŶƚƐĂƐǁĞůůƐŽ/ĚĞĨŝŶŝƚĞůǇƚŚŝŶŬŝƚ ?ƐƌĂŝƐĞĚŵǇĂǁĂƌĞŶĞƐƐŽĨ
ŝƚĂŶĚŚŽƉĞĨƵůůǇƐŽŵĞŽĨŝƚ/ ?ůůďĞĂďůĞƚŽƚĂŬĞĂĐƌŽƐƐǁŝƚŚŵĞĂŶĚŚŽƉŝŶŐƚŽ develop some 
ŬŝŶĚŽĨ ?,ZD ?ŝŶŝƚŝĂƚŝŽŶƉƌŽƚŽĐŽů QƚŚĞƌĞ ?ƐĂůŽƚŽĨƵŶĐĞƌƚĂŝŶ ǇĂďŽƵƚǁŚŽ ?ƐƌĞƐƉŽŶƐŝďŝůŝƚǇ
ŝƚŝƐƚŽŵĂŬĞƐƵƌĞƚŚĞƉĂƚŝĞŶƚ ?Ɛ/EZŝƐĐŚĞĐŬĞĚǁŚĞŶƚŚĞǇ ?ƌĞĚŝƐĐŚĂƌŐĞĚ Q/ ?ĚƐĂǇĚĞĨŝŶŝƚĞůǇ
is given me the starting blocks to take the work forward with ŵĞ ? ? 
(Second Pharmacist, Health Board 3) 
 
 
 
 
 
 
i. Client Outcomes 
 
Proctor et al ?Ɛ ƚĂǆŽŶŽŵǇ ĂůƐŽ ĐŽŵƉƌŝƐĞƐůŝĞŶƚ ŽƵƚĐŽŵĞƐ ?ĞŶĐŽŵƉĂƐƐŝŶŐ ƐĂƚŝƐĨĂĐƚŝon, function and 
symptomatology (34). It is not possible at this point in time to ascertain the extent to which 
implementation of the HRM element of the SPSP-PPC collaborative has impacted on patient function 
or symptomatology, yet details on patient satisfaction can be reported on.  When discussing the 
ĞǀŝĚĞŶĐĞƚŽƐƵƉƉŽƌƚƚŚĞƌĞĂůŝƐĂƚŝŽŶŽĨĐůŝĞŶƚŽƵƚĐŽŵĞƐ ?ƚŚĞ  “ĐůŝĞŶƚ ? ŝŶƚŚŝƐĐŽŶƚĞǆƚǁŝůůƌĞĨĞƌƚŽƚŚĞ
patient / carer.  
 
Patient Satisfaction 
 
Data Used in Analysis 
x Select data from QA5a 
x Community Pharmacy HRM Case Studies 
x CE Short Patient Impact Interviews 
 
No direct patient testing was conducted on satisfaction before, during or after HRM element 
implementation. Patient satisfaction was gauged via reports from the Away Team members. Early in 
the programme during the HRM Community Pharmacy Case Studies (June  W Nov 2015), some staff felt 
that patients were not always willing to receive the intervention: 
 
 “DŽƐƚƉĞŽƉůĞ Q ?ǇŽƵ ?ĂƐŬƚŚĞŵĂŶŽƚŚĞƌƋƵĞƐƚŝŽŶĂďŽƵƚƚŚĞŝƌŝďƵƉƌŽĨĞŶĂŶĚƚŚĞǇ ?ƌĞĂ
bit like,  ‘&ŽƌŐŽŽĚŶĞƐƐ ?ƐĂŬĞ W another thing  W / ?ǀĞũƵƐƚŐŽƚĂƐŽƌĞŚĞĂĚ ? ? ? 
(Health Care Assistant, Health Board 4) 
 
Conclusions: The HRM element of the SPSP-PPC collaborative was seen as fitting well with pre-
existing activities within the sites. Aside from data collection and reporting, the HRM change 
package was ongoing in the practice sites now for almost 2 years.   There was a strong 
willingness from staff to continue with the HRM Care Bundle.  
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Staff noted that some patients were too busy at times, whereas others highlighted it was an issue to 
understand if the patient was actually listening to what they were saying. In one account the yellow 
card (warfarin care bundle) was useful in case the patient was not receptive to being spoken to: 
 
 “^ŽŵĞƚŝŵĞƐǁŚĞŶǇŽƵ ?ƌĞƚƌǇŝŶŐƚŽĞǆƉůĂŝŶ ?ŝƚ ?ƐƋƵŝƚĞĚŝĨĨŝĐƵůƚƚŽĂĐƚƵĂůůǇŐĞƚƚŚĞŵƚŽ
ůŝƐƚĞŶ Q ?ƚŚĞǇ ?ŵŽƐƚŽĨƚŚĞƚŝŵĞƚŚĞŬŝŶĚŽĨŵĂǇďĞĚŝƐŵŝƐƐǁŚĂƚǇŽƵ ?ƌĞƐĂǇŝŶŐŽƌĚŽŶ ?ƚ
ƌĞĂůůǇůŝƐƚĞŶ ?ĂƌĞŶŽƚƌĞĂůůǇŝŶƚĞƌĞƐƚĞĚ QƚŚĞǇ ?ƌĞŵĂǇďĞũƵƐƚŝŶĂŚƵƌƌǇ QƚŚĂƚ ?ƐǁŚǇǇŽƵ
ŐŝǀĞƚŚĞŵƚŚĞĐĂƌĚ ?/ƐƵƉƉŽƐĞ ?ƐŽƚŚĞǇĐĂŶĂůǁĂǇƐƌĞĂĚƚŚĂƚŝŶƚŚĞŝƌŽǁŶƚŝŵĞ ? ? 
(Dispenser, Health Board 4) 
 
However, there was a perception that patients were becoming more aware of their medicines and the 
different things they had to do in order to take them safely e.g. with food, etc. 
 
In QA5a (CE, Oct 2016) Away Team members were asked about patient awareness and value of the 
HRM care bundle; it was not a pre-requisite of programme participation to inform patients specifically 
about practice involvement with the SPSP-PPC. As Figure 33 shows the median Likert Scale responses 
of Away Team indicate agreement that patients were both aware of the HRM element and that felt 
that it was valued:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The topic of patient satisfaction was also explored somewhat during the Celebratory Event Short 
Patient Impact Interviews. WĂƌƚŝĐŝƉĂŶƚƐǁĞƌĞĂƐŬĞĚƚŽƐŚĂƌĞƉĂƚŝĞŶƚ “ŝŵƉĂĐƚƐƚŽƌŝĞƐ ?ĂƌŽƵŶĚƚŚĞ,ZD
change package, and were asked how they felt the care bundle process was perceived by patients. 
Although some said that patients did highlight that they had already been told the information before, 
the response to receiving the bundle was generally positive: 
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Figure 33: Away Team Response to Patient Awareness & Value of HRM 
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 “/ƚƐĞĞŵƐƚŽďĞǀĞƌǇŐŽŽĚ ?ǇĞĂŚ ? “ŽŶ ?ƚŐŝǀĞŵĞŽŶĞŽĨƚŚ ƐĞĐĂƌĚƐ ?/ ?ǀĞŐŽƚŽŶĞ ?
 ?ůĂƵŐŚƐ ? Q 
 
/ P'ŽŽĚƐŽƉĞŽƉůĞĂƌĞĂĐƚƵĂůůǇƐĂǇŝŶŐƚŽǇŽƵ “EŽ ?/ŬŶŽǁƚŚŝƐ ? ? ? ? ?^ŽƚŚĞǇ ?ǀĞƌĞƚĂŝŶĞĚƚŚĞ
information? 
 
P: Yeah which is good ? 
(Dispenser, Health Board 4) 
 
Furthermore, the care bundle had value for patients on a more general level, in that patients 
appreciated that the practice staff were taking time to speak to them almost regardless of the fact 
that it was about their high risk medicines: 
 
 “tĞůůǁĞŵĂĚĞĂŶŽĨĨŝĐŝĂůĂƉƉŽŝŶƚŵĞŶƚǁŝƚŚ ?ƚŚĞƉĂƚŝĞŶƚ ?ǁŚŝĐŚǁĞĨŽƵŶĚǁas really 
helpful and he came and we gave him all the information, and he was asking lots of 
ƋƵĞƐƚŝŽŶƐ ‘ĐĂƵƐĞŚĞƐĂǇƐƚŚĂƚŚĞĨĞĞůƐůŝŬĞƐŽŵĞƚŝŵĞƐƉĞŽƉůĞĚŽŶ ?ƚŚĂǀĞƚŝŵĞ ?^ŽŚĞ
ĂƐŬĞĚůŽƚƐŽĨƋƵĞƐƚŝŽŶƐĂŶĚ/ƚŚŝŶŬŶŽǁǁĞůůŚĞ ?ƐĂůǁĂǇƐĐŽŵŝŶŐŝŶĂƐŬŝŶŐƵƐ
quĞƐƚŝŽŶƐ Qŝƚ ?ƐƋƵŝƚĞŐŽŽĚ ? ? 
(Accredited Checking Technician, Health Board 3) 
 
Therefore implementing the HRM Care Bundle with patients opened the door to communication 
between the practice team and the patient which in turn was perceived positively and as an accessible 
communication avenue by patients through which to enquire about any other health concerns.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: Although receiving the full extent of the HRM Care Bundle on a regular basis was 
perceived as laborious for some patients, 1 year post-intervention patients appreciated the 
communication channel the HRM element offered and also appeared to be retaining the 
information about their high risk medicines which could in turn positively affect patient care.  
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c. EVALUATION QUESTION 3: How did the intervention programme improve 
the process of Medicines Reconciliation?  
 
Data Used in Analysis 
x Select data from QA1-QA3 and QA5a & b 
x CE Short Patient Impact Interviews 
x Steering Group Minutes & SBAR Reports 
 
A single Medicines Reconciliation Care Bundle was agreed across the four Health Boards (see Figure 4 
in SPSP-PPC Change Packages section). This section of the results will be reported under the 
Framework of Proctor et al ?Ɛ ƚĂǆŽŶŽŵǇŽĨ /ŵƉůĞŵĞŶƚĂƚŝŽŶŽutcomes. The results will examine the 
acceptability, adoption, perceived appropriateness, feasibility, fidelity to, and sustainability of the 
Medicines Reconciliation element of the SPSP-PPC collaborative with Away and Home teams. The 
Implementation Cost element will not be examined as this project was funded and participating sites 
received remuneration for their participation. The Implementation Penetration element cannot be 
examined in this section due to a lack of supporting data.  
 
Implementation Outcomes 
  
Acceptability 
 
 
 
 
 
Away Team acceptability of a Medicines Reconciliation element was tested at baseline (2014) and at 
1 year intervals (QA3 in 2015 and QA5a in 2016). Figure 34 displays the median Likert Scale responses: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acceptability: The perception among implementation stakeholders that a given treatment, 
service, practice, or innovation is agreeable, palatable, or satisfactory. 
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Figure 34 shows that understanding of Medicines Reconciliation was moderate at baseline (2014). This 
increased to a considerable extent at one year and was maintained as such at the Celebratory Event 
in 2016, showing that understanding and acceptability of the element improved. In contrast the Home 
Team response at the end of the project lifespan (QA5b, October 2016), was moderate amongst this 
staff group.  Away Team participant awareness and knowledge of this change package element (QA5a, 
Oct 2016) was high at the Celebratory Event (Figure 35): 
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Figure 34: Away Team Response to Acceptability of Medicines Reconciliation 
Figure 35: Away Team Response in Importance, Awareness & Knowledge of Medicines Reconciliation 
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These results were somewhat corroborated qualitatively during the Celebratory Event Short Patient 
Impact Interviews (Oct 2016). Away Team members were asked if they could provide details of their 
experiences with Medicines Reconciliation. Acceptability of Medicines Reconciliation was high, with 
most feeling that it was an important issue to tackle through the element: 
 
 “/ƚ ?ƐĞĂƐŝĞƌ ? ?ŝƚ ?ŵĞĂŶƐƚŚĂƚǇŽƵ ?ƌĞŶŽƚƌĞůǇŝŶŐŽŶŚĂǀŝŶŐƚŽŐĞƚƐĞĐŽŶĚŚĂŶĚŝŶĨŽƌŵĂƚŝŽŶ
over the phone from the receptionist or a patient showing up a week after discharge 
ǁŝƚŚƚŚĞŝƌƚƌĂǇĞǆƉĞĐƚŝŶŐũƵƐƚƚŽŐĞƚĂŶŽƚŚĞƌŽŶĞ Q ?/ ?ƚŚŝŶŬǁĞŶĞĞĚƚŽŬŶŽǁǁŚĞŶ the 
ƉĂƚŝĞŶƚ ?ƐŝŶŚŽƐƉŝƚĂůĂŶĚƚŚĂƚ ?ƐŶŽƚĚŽŶĞ ?/ƚŚŝŶŬǁĞ ?ƌĞƚŽůĚĂƚƚŚĞůĂƐƚŵŝŶƵƚĞǁŚĞŶƚŚĞǇ
ŐĞƚŽƵƚ ? ? 
(Job Role Unknown, Health Board 2) 
 
A small number of participants cited that they struggled to see the importance or impact of the care 
bundle itself due to them having very little opportunity to reconcile medicines: 
 
 “/ƚĚŝĚŶ ?ƚƌĞĂůůǇŝŵƉĂĐƚ ?ǁĞĚŝĚŶ ?ƚŚĂǀĞĂůŽƚŽĨŵĞĚŝĐŝŶĞƌĞĐŽŶĐŝůŝĂƚŝŽŶŝŶŽƵƌƉŚĂƌŵĂĐǇ
ĂƚĂůů ? ? 
(Accredited Checking Technician, Health Board 1) 
 
It appeared that at least in theory, Medicines Reconciliation was viewed as important and impactful, 
yet some sites had more of an opportunity to engage than others.  
 
 
 
 
 
 
Adoption 
 
 
 
 
Medicines Reconciliation was implemented in the second year of the SPSP-PPC collaborative, with 
sites across and within Health Boards starting at different times. Information on the extent to which 
it was adopted, and how, is not equitable across all four Health Boards although it is known that all 
Health Boards were participatory in this change package.  
 
The SBARs presented at the September 2016 Steering Group included the most up-to-date Medicines 
Reconciliation Compliance data for each Health Board. Figures 36-39 present compliance with the 
separate elements of the care bundle by Health Board.   
 
 
 
 
 
Conclusions: Understanding of Medicines Reconciliation improved amongst Away Team 
members over time. In general, Medicines Reconciliation was seen as important and 
acceptable.  
Adoption: The intention, initial decision, or action to try or employ an innovation or evidence-based 
ƉƌĂĐƚŝĐĞ ?ĚŽƉƚŝŽŶĂůƐŽŵĂǇďĞƌĞĨĞƌƌĞĚƚŽĂƐ “ƵƉƚĂŬĞ ? ?
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Figure 36: Health Board 1 Cumulative Data on Medicines Reconciliation Compliance (Jan - Aug 2016) 
Figure 37: Health Board 2 Cumulative Data for Medicines Reconciliation Compliance Jan - July 2016 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Health Board 3 Cumulative Data for Medicines Reconciliation Compliance March - Sept 2016 
Figure 39: Health Board 4 Cumulative Data for Medicines Reconciliation Compliance Dec 2015 - Sept 2016 
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What the compliance data shows is evidence of varying adoption of the care bundle. Most NHS Boards 
show compliance rates of between 60  W 100% over the testing period, whereas Health Board 4 show 
greater variability in compliance to the standard process bundle, ranging between 50-100% for most 
elements delivered in community pharmacy.  
 
Health Board 4 were also active in developing a patient medicines information tool to support the 
Medicines Reconciliation process with the help and insight from their patent representative. dŚĞ “DǇ
ŵĞĚŝĐŝŶĞƐ ? ǁĂůůĞƚ ŝŶ ǁŚŝĐŚ ƉĂƚŝĞŶƚƐ ǁŽƵůĚ ďĞ ĞŶĐŽƵƌĂŐĞĚƚŽ ŬĞĞƉ ƚŚĞŝƌ ŵŽƐƚ ƵƉ-to-date repeat 
medication list plus any other information about medicines taken (e.g. over-the-counter (OTC) 
medicines, copies of medicine sick day rules cards, high risk medicine information etc.) was developed 
and rolled out for testing.  
 
What the data from the SBAR shows is a high level of basic adoption from all participating NHS Boards, 
with some modification and adaption to the care bundles as appropriate. One note of caution when 
considering the compliance data is that not all participating community pharmacies and dispensing 
practices submitted data continuously, therefore the charts may not be reflective of actual adoption 
and compliance of the full study sites   
 
tŚĞŶĐŽŶƐŝĚĞƌŝŶŐƚŚĞǁĂǇdĞĂŵŽƉŝŶŝŽŶŽŶ “tĞĂƌĞĚŽŝŶŐĂůůǁĞĐĂŶ ?ĨŽƌDĞĚŝĐŝŶĞƐZĞĐŽŶĐŝůŝĂƚŝŽŶ ?
ƚŚĞƌĞƐƉŽŶƐĞŵŽǀĞĚĨƌŽŵ “Slightly ŝƐĂŐƌĞĞ ?Ăƚ ƚŚĞƐƚĂƌƚŽĨƚŚĞƉƌŽŐƌĂŵŵĞƚŽ  “^ůŝŐŚƚůǇŐƌĞĞ ?ďǇ
2016, showing improvement with some further work required. (Figure 40). This may reflect the fact 
that sites have been reporting issues with accessing IDLs as well as the fact that less time has been 
spent on the Medicines Reconciliation element compared to, for example, the HRM Care Bundle. 
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Figure 40:Away Team Response to Adoption of Medicines Reconciliation 
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From the Celebratory Event Patient Impact Short Interviews (2016), there was no indication that any 
pharmacy team had not actively adopted the Medicines Reconciliation element. A small number of 
participants cited that they had not had the opportunity to deliver the element itself mainly due to a 
lack of patients requiring Medicines Reconciliation. However, the general consensus was that  
Medicines Reconciliation was already occurring to an extent within pharmacies, and that the 
Medicines Reconciliation element was important, useful and used: 
 
 “dŚĞƌĞ ?ƐďĞĞŶĂŵĂƐƐŝǀĞŝŵƉĂĐƚǁŝƚŚƚŚĞŵĞĚŝĐŝŶĞƐƌĞĐŽŶĐŝůŝĂƚŝŽŶ ?ŝƚ ?ƐďĞĞŶĂůŽƚŽĨǁŽƌŬ
ĂŶĚǇŽƵŬŶŽǁǁĞ ?ǀĞĨŽƵŶĚƐŽŵĂŶǇŝƐƐƵĞƐǁŚĞƌĞǁĞŚĂǀĞďĞĞŶĚŽŝŶŐĂŵĞĚŝĐŝŶĞƐ
reconciliation, almost makes you worry about when wĞǁĞƌĞŶ ?ƚĚŽŝŶŐŝƚ ?ůĂƵŐŚƐ ? ?ŶĞĂƌůǇ
ĞǀĞƌǇŽŶĞǁĞ ?ǀĞĚŽŶĞŚĂƐŚĂĚƐŽŵĞŝŵƉƌŽǀĞŵĞŶƚŶĞĞĚĞĚ ? ? 
(Registered Pharmacy Technician, Health Board 3) 
 
 
 
 
 
 
Appropriateness 
 
 
 
 
In QA5a (2016) Away Team participants were asked to respond to various statements relating to the 
appropriateness, relevance and usefulness of the Medicines Reconciliation programme element. 
Figure 41 displays the median Likert scale responses: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appropriateness: The perceived fit, relevance, or compatibility of the innovation or 
evidence based practice for a given practice setting, provider, or consumer; and/or 
perceived fit of the innovation to address a particular issue or problem. 
Conclusions: It appears from the limited data that Medicines Reconciliation has been adopted to 
an extent within the practice teams.  
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Agreement was high with all statements aligned to appropriateness of the Medicines Reconciliation 
element. Participants felt that the element aligned to their own views of the role of practices, as well 
as to the wider views and vision of pharmaceutical care. It was viewed as having a positive impact on 
job performance, process and professional role, and that it was useful in improving the awareness and 
realisation of safety culture in practices. Finally, it was also viewed as being practical and useful in 
delivering safe and reliable care for patients.  
 
Views on the appropriateness of the Medicines Reconciliation element were also captured with some 
participants during the CE Short Patient Impact Interviews. Some reported that the element was in 
fact very similar to processes and procedures that were already being delivered within the community 
pharmacy, reinforcing that it was appropriate and useful:  
 
 “dŚĞďƵŶĚůĞǁŚĞŶŝƚĐĂŵĞŽƵƚǁĂƐǀĞƌǇƐŝŵŝůĂƌƚŽǁŚĂƚǁĞǁĞƌĞĂĐƚƵĂůůǇĚŽŝŶŐ
ĂŶǇǁĂǇ ?ůůŝƚǁĂƐĂĐĂƐĞŽĨǁĂƐƚƌǇŝŶŐƚŽĚŽĐƵŵĞŶƚŝƚĂŶĚƉƵƚĚŽǁŶƌĞĂƐŽŶƐĨŽƌŝƚ ? ?
(Second Pharmacist, Health Board 1) 
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Figure 41: Away Team Response to Appropriateness if Medicines Reconciliation 
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However, this participant also highlighted that delivering the element as stipulated by the SPSP team 
was not necessarily appropriate for all patients: 
 
 “/ƚŚŝŐŚůŝŐŚƚĞĚƚŚĞŽŶĞŝƐƐƵĞƚŚĂƚǁĞŚĂĚǁĂƐŶŽƚŶĞĐĞƐƐĂƌŝůǇĂůǁĂǇƐƉĂƐƐŝŶŐƚŚĞ
ŝŶĨŽƌŵĂƚŝŽŶƚŽƚŚĞƉĂƚŝĞŶƚŽƌƚŚĞĐĂƌĞƌ QƚŚĞŝƌŝŶĚĞƉĞŶĚĞŶĐĞŽĨŵĞĚŝĐŝŶĞƐǁĂƐĨĂŝrly 
ƌĞŵŽǀĞĚĂŶǇǁĂǇ QĂŶĚĂůŽƚŽĨŽĐĐĂƐŝŽŶƐǁĞŬŶĞǁƚŚĞƉĞƌƐŽŶŽƌƚŚĞĐĂƌĞƌ ?ĞŝƚŚĞƌƚŚĞ
ƉĞƌƐŽŶǁŽƵůĚŶ ?ƚĐŽƉĞǁŝƚŚƚŚĞĂĚĚŝƚŝŽŶĂůŝŶĨŽƌŵĂƚŝŽŶ ?ĚĞůŝǀĞƌĞĚƚŽƚŚĞŵƚŚƌŽƵŐŚƚŚĞ
DĞĚŝĐŝŶĞƐZĞĐŽŶĐŝůŝĂƚŝŽŶƉƌŽĐĞƐƐ ?ŽƌĚŝĚŶ ?ƚĐĂƌĞĂďŽƵƚƚŚĞĂĚĚŝƚŝŽŶĂůŝŶĨŽƌŵĂƚŝŽŶŽƌƚhe 
ĐĂƌĞƌĂĐƚƵĂůůǇĚŝĚŶ ?ƚǁĂŶƚƚŽďĞŝŶǀŽůǀĞĚ QďĞĐĂƵƐĞŽĨƚŚĞďƵŶĚůĞ ?ǁĞĚŝĚƉƵƐŚĨŽƌŝƚ ?ŝƚ
ǁĂƐƚĞĚŽƵƌƚŝŵĞ ? ? 
(Second Pharmacist, Health Board 1) 
 
 
 
 
Feasibility 
 
 
 
 
Information relating to the feasibility of Medicines Reconciliation was reported on my some NHS 
Boards via the SBARs presented at the Steering Group. In April 2016, Health Board 4 reported via SBAR 
reporting that access to Immediate Discharge Letters (IDLs) via SCI store (NHS online patient 
information system, not ordinarily made available to community pharmacies) was in use at two sites 
however IT issues and computer firewalls were reported in SBARs as a major challenge to accessing 
IDLs.  IDLs were also accessed via direct emails /other communication from GP practices and hospitals 
to community pharmacy at the other sites. Therefore, aside from the two sites who had access via SCI 
Store, all access to patient IDL was person-dependent and non-automated. In terms of systems, 
processes for recording the receipt of an IDL to trigger Medicines Reconciliation when the next 
prescription arrived was in place at four sites in April 2016.  Furthermore, community pharmacies in 
Health Board 4 reported that dealing with the volume of IDLs was an onerous task in terms of time 
and resource.  This contrasted with Health Board 3 who over the course of their involvement with 
Medicines Reconciliation only received 37 electronic IDLs (eIDLs) in total, resulting in a lack of 
opportunity to fully explore and develop the care bundle. Dispensing Practice-specific issues were 
ĂƌŽƵŶĚ'WƐŶŽƚƌĞĐŽƌĚŝŶŐƚŚĞŝƌƌĞĂƐŽŶƐĨŽƌŵĂŬŝŶŐĐŚĂŶŐĞƐƚŽƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƐ ?ǁŚŝĐŚŵĂǇƌĞƐƵůƚ
in an unnecessary and time consuming investigations into prescribing behaviours.  
 
In QA5a (Oct 2016), Away Team participants were asked to score their agreement with statements 
regarding the feasibility of the Medicines Reconciliation element in QA5a (2016) (Figure 42): 
 
 
 
 
 
 
Conclusions: The Medicines Reconciliation Care Bundle was seen as appropriate.  
Feasibility: The extent to which a new treatment, or an innovation, can be successfully used or 
carried out within a given agency or setting. 
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WĂƌƚŝĐŝƉĂŶƚ ŵĞĚŝĂŶ ƌĞƐƉŽŶƐĞƐ ǁĞƌĞ  “Slightly Agree ? ?Feasibility of Medicines Reconciliation was 
explored further in the CE Short Patient Impact Interviews (Oct 2016), with the main challenge to 
adoption and delivery being reported as a lack of patients requiring reconciliation by some 
participants. The other main threat to feasibility was gaining access to the IDL or patient discharge 
information, which was critical for the Medicines Reconciliation process: 
 
 “tĞůůŝƚ ?ƐũƵƐƚŽďǀŝŽƵƐůǇƌĞůǇŝŶŐŽŶƚŚĞŚŽƐƉŝƚĂůƐƉƌŽǀŝĚŝŶŐǇŽƵĚŝƐĐŚĂƌŐĞ ?ǁŚŝĐŚĚŽĞƐŶ ?ƚ
happen everǇƐŝŶŐůĞƚŝŵĞ ?tĞ ?ǀĞĂůƐŽŚĂĚĂĨĞǁ/dŝƐƐƵĞƐ ?/ǁŽƌŬĨŽƌŽŶĞŽĨƚŚĞďŝŐŐĞƌ
multiples so IT issues and accessing E,^ŵĂŝůƚŽŐĞƚƚŚĞĚŝƐĐŚĂƌŐĞŚĂƐŶ ?ƚĂůǁĂǇƐďĞĞŶ
ĞĂƐǇ ? ? 
(Pharmacist Branch Manager, Health Board 2) 
 
Feasibility of delivering the element was also dependent on the workload it produced, as one NHS 
Board who had electronic access to the IDL found that they were dealing with a large number of 
medicines discrepancies which would not have been highlighted to them had they not had access to 
the IDL. Therefore, although good access to the IDL resulted in the identification of more errors, the 
workload this produced was something of a challenge. Finally, one participant found that sharing the 
information with the patient on changes to their medicines post-discharge was not always feasible or 
even wanted. The result was that patients/carers were not engaged when discussing their medicines 
ĚƵĞƚŽƚŚĞ “ĂǀĂůĂŶĐŚĞ ?ŽĨŝŶĨŽƌŵĂƚŝŽŶ ?^ƚĂĨĨƌĞƐƉŽŶĚĞĚƚŽƚŚŝƐďǇŚŝŐŚůŝŐŚƚŝŶŐƚŚĂƚŝŶĨŽƌŵĂƚŝŽŶǁĂƐ
available if they chose to access it: 
 
 “/ƚŚŝŐŚůŝŐŚƚĞĚƚŚĞŽŶĞŝƐƐƵĞƚŚĂƚǁĞŚĂĚǁĂƐŶŽƚŶĞĐĞƐƐĂƌŝůǇĂůǁĂǇƐƉĂƐƐŝŶŐƚŚĞ
ŝŶĨŽƌŵĂƚŝŽŶƚŽƚŚĞƉĂƚŝĞŶƚŽƌƚŚĞĐĂƌĞƌ QĞŝƚŚĞƌƚŚĞƉĞƌƐŽŶǁŽƵůĚŶ ?ƚĐŽƉĞǁŝƚŚƚŚĞ
ĂĚĚŝƚŝŽŶĂůŝŶĨŽƌŵĂƚŝŽŶŽƌĚŝĚŶ ?ƚĐĂƌĞ QďĞĐĂƵƐĞŽĨƚŚĞďƵŶĚůĞ ?ǁĞĚŝĚƉƵƐŚ for it, it wasted 
ŽƵƚƚŝŵĞ ?ĐŽŶĨƵƐĞĚƚŚĞŽƚŚĞƌƐŝĚĞ QtĞƚŚĞŶŬŝŶĚŽĨĂĚĂƉƚĞĚŝƚĂŶĚƵƐĞĚŝƚĂƐĂƉƌŽŵƉƚĨŽƌ
information, so opposed to this all-ĞŶĐŽŵƉĂƐƐŝŶŐǁĞŚĂǀĞƚŚŝƐŝŶĨŽƌŵĂƚŝŽŶǁĞ ?ƌĞƚĞůůŝŶŐ
ǇŽƵ ?ǁĞĐŚĂŶŐĞĚ QŝĨǇŽƵǁĂŶƚŝŶĨŽƌŵĂƚŝŽŶŐĞƚŝŶƚŽƵĐŚ QǁĞĨŽƵŶĚƚŚĞƌĞǁĂƐŶ ?ƚŚƵŐĞ
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Figure 42: Away Team Response to Feasibility of Medicines Reconciliation 
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ĞŶŐĂŐĞŵĞŶƚĨƌŽŵŝƚ ?ďƵƚƚŚĂƚŬŝŶĚŽĨŚŝŐŚůŝŐŚƚĞĚƚŽƵƐƚŚĂƚƚŚĞƌĞĂĐƚƵĂůůǇǁĂƐŶ ?ƚĂŶĞĞĚ
ĨŽƌŵĂƐƐŝǀĞĞŶŐĂŐĞŵĞŶƚ ? ? 
(Second Pharmacist, Health Board 1) 
 
The limited timeframe of current testing limits the findings but has identified some of the early 
challenges with delivering this care bundle.  
 
 
 
 
 
Fidelity 
 
 
 
 
As mentioned previously the care bundle questions were consistent across the Health Boards. 
However Health Board 4 chose to add an additional communications-focused care bundle. Therefore, 
although there were modifications made to the delivery of the care bundle, the basic common care 
bundle across the entire project was delivered as agreed by the SPSP Team.  
 
How pharmacies accessed discharge information and which patients were targeted varied across 
Health Boards (i.e. some information was accessed via electronic systems versus email, and some 
ŽĂƌĚƐŽŶůǇƌĞĐŽŶĐŝůĞĚƉĂƚŝĞŶƚƐǁŚŽŚĂĚƚŚĞŝƌŵĞĚŝĐŝŶĞƐƐƵƉƉůŝĞĚƚŚƌŽƵŐŚ “ŽƐĞƚƚĞďŽǆĞƐ ? ? ? 
 
Participants were never directly asked if they delivered the care bundle questions as stipulated by the 
programme team, however as discussed under Feasibility, one pharmacy site adapted how the care 
bundle was delivered to make it acceptable to patients: 
 
 “tĞƚŚĞŶŬŝŶĚŽĨĂĚĂƉƚĞĚ ?ƚŚĞďƵŶĚůĞ ?ĂŶĚƵƐĞĚŝƚĂƐĂƉƌŽŵƉƚĨŽƌŝŶĨŽƌŵĂƚŝŽŶ ?ƐŽ
opposed to this all-ĞŶĐŽŵƉĂƐƐŝŶŐ ?ƚŚŝŶŐ ? QŝƚǁĂƐĂĐŬŶŽǁůĞĚŐŝŶŐƚŚĂƚĂĐŚĂŶŐĞ ?ƚŽƚŚĞŝƌ
ŵĞĚŝĐŝŶĞƐ ?ŚĂĚďĞĞŶŵĂĚĞ ?ďƵƚƉƵƚƚŝŶŐ ?ƚŚĞŽŶƵƐ ?ďĂĐŬŽŶƚŚĞƉĂƚŝĞŶƚŽƌƚŚĞĐĂƌĞƌ Qŝƚ
allŽǁĞĚƚŚĞŵƚŚĞƐŵĂůůŝŶĨŽƌŵĂƚŝŽŶƚŽďĞĂďůĞƚŽǁŽƌŬŽŶ QƚŽŬŝŶĚĂŚĂŶĚŝƚďĂĐŬƚŽƚŚĞ
ƉĂƚŝĞŶƚ QƚŚĞƌĞĐŽŶĐŝůŝĂƚŝŽŶƉƌŽĐĞƐƐŶĞǀĞƌƌĞĂůůǇĐŚĂŶŐĞĚďĞĐĂƵƐĞǁĞǁĞƌĞĚŽŝŶŐƚŚĂƚ
ĂŶǇǁĂǇ ? ? 
(Second Pharmacist, Health Board 1) 
 
 
 
 
 
 
 
 
 
Conclusions: The major challenge to feasibility was access to the IDL, which when resolved 
enabled delivery of the care bundle in practices.   
Fidelity: The degree to which an intervention was implemented as it was prescribed in the original 
protocol or as it was intended by the program developers. 
Conclusions: The Medicines Reconciliation Care Bundle was delivered across all 4 Health Boards 
but the patient cohort to whom it was applied varied. One Health Board did add to the bundle a 
second list of questions relating specifically to communication.  
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Sustainability  
 
 
 
 
As the Medicines Reconciliation element was in its relative infancy in the programme compared to the 
other more established HRM and Safety Culture elements, sustainability of this element could not be 
fully explored. However, in QA5a, when Away Team participants were asked to rate their agreement 
that they would like to continue with the Medicines Reconciliation Care Bundle there was a high level 
of agreement.  
 
As discussed in previous sections it is also arguable that timely and reliable access to patient discharge 
information will affect sustainability of the service over time. Furthermore, ownership of delivering 
the element and the processes this involves within the practice may also have an impact. During the 
CE Short Patient Impact Interviews, one participant discussed how delivery of the care bundle 
appeared to cease at some point due to an interruption in communications: 
 
 
 “dŚĞƌĞǁĂƐůŝŬĞĂŵŽŶƚŚŽƌƚǁŽǁŚĞƌĞǁĞǁĞƌĞŶ ?ƚŐĞƚƚŝŶŐĂŶǇĞŵĂŝůƐĂŶĚ/ĚŽŶ ?ƚŬŶŽǁŝĨ
ŝƚ ?ƐďĞĐĂƵƐĞƚŚĞWƌĞ-Reg finished and no-one else was given the responsibility, but I just 
feel like that was a silly reason to have stopped that service when we knew that there 
was patients in and out of ŚŽƐƉŝƚĂůŚĂǀŝŶŐƚŽŐŽďĂĐŬƚŽƚŚĞǁĂǇƚŚŝŶŐƐǁĞƌĞ ? ? 
(Job Role Unknown, Health Board 2) 
 
When the process is dependent on one individual in the pharmacy, this may affect sustainability of 
service delivery. However, in practices where the Medicines Reconciliation process was already robust 
and established, it is feasible that sustainability of the care bundle is made more possible: 
 
 “KƵƌDĞĚƐZĞĐƉƌŽĐĞƐƐǁĂƐƉƌĞƚƚǇƌŽďƵƐƚŝŶƚŚĞĨŝƌƐƚƉůĂĐĞ ?ǁĞŚĂǀĞŽŶĂǁĞĞŬ-to-week 
basis a dedicated team solely focused on compliance aids. So, that team has always 
taken it upon themselves to deal with any reconciliĂƚŝŽŶ QƐŽĂůƌĞĂĚǇǁĞǁĞƌĞƉƌĞƚƚǇ
focused upon it.  The bundle when it came out was very similar to what we were actually 
ĚŽŝŶŐĂŶǇǁĂǇ ? ? 
(Second Pharmacist, Health Board 1) 
 
One pharmacy had decided to deliver the Medicines Reconciliation Care Bundle in ƉĂƚŝĞŶƚƐ ? ŽǁŶ
homes, as this was seen as a more suitable environment in which to reconcile medicines (i.e. the 
patient in their own setting with their own medicines around them): 
 
 “W PtĞůůǁĞƵƐĞŽƵƌdĞĐŚŶŝĐŝĂŶƚŽĂĐƚƵĂůůǇŐŽŽƵƚĂŶĚǀŝƐŝƚƚŚĞƉĂƚŝĞŶƚƐĂƚŚŽŵĞ ?ďĞĐĂƵƐĞ
ĂůŽƚŽĨƚŚĞŵǇŽƵŬŶŽǁƚŚĞǇ ?ǀĞũƵƐƚĐĂŵĞďĂĐŬĨƌŽŵŚŽƐƉŝƚĂůƐŽƚŚĞǇ ?ƌĞŶŽƚĨŝƚĂŶĚĂďůĞ
ƚŽĐŽŵĞŝŶƚŽƚŚĞƉŚĂƌŵĂĐǇ QǇŽƵ ?ǀĞŐŽƚĂĐĐĞƐƐƚŽƚŚĞŝƌŵĞĚŝĐĂƚŝŽŶ Q ?ĂƉĂƚŝĞŶƚ ?ŚĂd the 
ǁƌŽŶŐŝŶŚĂůĞƌǁŚĞŶƚŚĞǇ ?ĚĐŽŵĞŽƵƚŽĨŚŽƐƉŝƚĂů QŝƚǁĂƐƐŽŵĞŽŶĞĞůƐĞ ?ƐŝŶŚĂůĞƌ QƚŽŚĂǀĞ
ƐŽŵĞŽŶĞĞůƐĞƚŚĂƚ ?ƐŐŽŝŶŐƚŚƌŽƵŐŚ ?ŵĞĚŝĐŝŶĞƐĐŽƵŶƐĞůůŝŶŐ ?ĂŐĂŝŶǁŝƚŚǇŽƵŝŶǇŽƵƌŚŽŵĞ
Sustainability: The extent to which a newly implemented treatment is maintained or 
ŝŶƐƚŝƚƵƚŝŽŶĂůŝǌĞĚǁŝƚŚŝŶĂƐĞƌǀŝĐĞƐĞƚƚŝŶŐ ?ƐŽŶŐŽŝŶŐ ?ƐƚĂďůĞŽƉĞƌĂƚŝŽŶƐ ? 
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and you might ŚĂǀĞŚĂĚƚŝŵĞƚŽƚŚŝŶŬĂďŽƵƚƋƵĞƐƚŝŽŶƐ QƐŽŝƚ ?ƐũƵƐƚĂďŽƵƚĚŽŝŶŐǁhat we 
ĚŽĞǀĞƌǇĚĂǇďƵƚĚŽŝŶŐŝƚŝŶĂǁĞĞďŝƚĚŝĨĨĞƌĞŶƚǁĂǇ ? ? 
(Second Pharmacist, Health Board 3) 
 
Although this was seen as appropriate and successful within that team, such a service may not be 
sustainable beyond the SPSP-PPC collaborative lifespan.  
 
 
 
 
 
 
 
 
Client Outcomes 
 
Proctor et al ?Ɛ ƚĂǆŽŶŽŵǇ ĂůƐŽ ĐŽŵƉƌŝƐĞƐůŝĞŶƚ ŽƵƚĐŽŵĞƐ ?ĞŶĐŽŵƉĂƐƐŝŶŐ ƐĂƚŝƐĨĂĐƚŝon, function and 
symptomatology (34). It is not possible at this point in time to ascertain the extent to which 
implementation of the Medicines Reconciliation element of the SPSP-PPC collaborative has impacted 
on patient function or symptomatology, yet details on patient satisfaction can be reported on.  When 
ĚŝƐĐƵƐƐŝŶŐƚŚĞĞǀŝĚĞŶĐĞƚŽƐƵƉƉŽƌƚƚŚĞƌĞĂůŝƐĂƚŝŽŶŽĨĐůŝĞŶƚŽƵƚĐŽŵĞƐ ?ƚŚĞ “ĐůŝĞŶƚ ?ŝŶƚŚŝƐĐŽŶƚĞǆƚǁŝůů
refer to the patient / carer.  
 
Data Used in Analysis 
x Select data from QA5a 
x CE Short Patient Impact Interviews 
 
 
Patient Satisfaction 
 
No direct patient testing was conducted on satisfaction before, during or after The Medicines 
Reconciliation element implementation. Patient satisfaction was gauged via reports from the Away 
Team members.  
 
Patient experience of Medicines Reconciliation is first discussed in an SBAR report in September 2016. 
NHS GG&C report on a patient story whereby a patent underwent the Medicines Reconciliation bundle 
with their Community Pharmacy, only to have the procedure repeated a short while later by the GP, 
resulting in some unwanted duplication of process. In terms of medicine reconciliation, the patient 
was very supportive of an additional check by the Community Pharmacy yet felt that there was a need 
to improve communication between the Community Pharmacy and the GP in order to avoid 
duplication. The patient was happy to discuss medication issues with the pharmacist but not on a 
repeating basis, as this could come across as patients not being listened to or that their answers are 
not recorded for future reference.  
Conclusions: Medicines Reconciliation itself is sustainable yet depends on a number of factors 
including: timely and reliable access to IDLs; appropriate staff involvement; and delivery of the 
bundle in a realistic and replicable way for all patients requiring reconciliation.  
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In QA5a (Oct 2016), Away Team members were asked to rate their agreement on whether patients 
were aware of the Medicines Reconciliation element, had been impacted positively, and that they 
valued the Medicines Reconciliation Care Bundle element (Figure 43): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was a high median level of agreement that the Medicines Reconciliation element had positively 
impacted patients. The median participant response was Slightly Agree for statements regarding 
patient awareness and value of the programme element. This may be due to the fact that patient 
awareness and value of the element was being assessed by proxy therefore respondents may not have 
been sure what patient opinion actually was.  
 
Away Team members provided some insight into examples of patient satisfaction with service during 
the CE Short Patient Impact Interviews. One participant working in a Dispensing Practice described 
how implementation of the care bundle on the whole was having a positive effect on patients and was 
seen as valuable: 
 
 “W PzĞĂŚ ?ŝƚ ?Ɛ ?ŐŽŽĚĨŽƌƚŚĞƉĂƚŝĞŶƚƐĂƐǁĞůů ?ĂŶĚ/ƚŚŝŶŬƚŚĞƉĂƚŝĞŶƚƐŚĂǀĞďĞĞŶƋƵŝƚĞ
ŚĂƉƉǇ ?ǇŽƵŬŶŽǁƚŽŚĂǀĞƚŚĞĚŽĐƚŽƌƐĐĂůů ? ‘ĐĂƵƐĞŵŽĚĞƌŶĚĂǇĚŽĐƚŽƌƐĂƌĞŶ ?ƚƚŚĞƐĂŵĞĂƐ
ƚŚĞŽůĚĨĂƐŚŝŽŶĞĚŽŶĞƐ ?ůĂƵŐŚƐ ?ƐŽ/ƚŚŝŶŬƐŽŵĞŽĨƚŚĞŵŚĂǀĞďĞĞŶƋƵŝƚĞƚŚĞǇ ?ǀĞŚĂĚĂ
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Figure 43: Away Team Response to Patient Satisfaction of Medicines Reconciliation 
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W PzĞĂŚ ? 
(Dispensing Lead, Health Board 4) 
 
Additionally, another participant highlighted how the care bundle process opened up communication 
channels with patients and the pharmacy team, which was appreciated: 
 
 “ĞƚƚĞƌĐŽŵŵƵŶŝĐĂƚŝŽŶǁŝƚŚƚŚĞƉŚĂƌŵĂĐŝƐƚ ?DŽƌĞƚƌƵƐƚĂŶĚƵŶĚĞƌƐƚĂŶĚŝŶŐĂŶĚ/ƚŚŝŶŬ
ĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?ƐƉŽŝŶƚŽf view the pharmacist is seen as a knowledge of the 
ŵĞĚŝĐŝŶĞƐ QƚŚĞǇ ?ǀĞďĞĞŶŐŝǀĞŶƚŚŝƐŝŶĚŝǀŝĚƵĂůĂƚƚĞŶƚŝŽŶ QŽƚŚĞƌƉĞŽƉůĞĂƌĞĐĂƌŝŶŐĨŽƌƚŚĞŵ
ĐĂƵƐĞ ?ƚŚĞƉŚĂƌŵĂĐǇ ?ĚŽŬŶŽǁǁŚĂƚ ?ƐŚĂƉƉĞŶĞĚǁŚŝůĞƚŚĞǇǁĞƌĞŝŶŚŽƐƉŝƚĂůĂŶĚǁŚĂƚ
the ĐŚĂŶŐĞŚĂƐďĞĞŶ ? ? 
(Pharmacist, Health Board 4) 
 
Furthermore, some participants provided specific examples of scenarios which resulted in a patient 
satisfied with the reconciliation process: 
 
 “tĞŚĂĚĂƉĂƚŝĞŶƚƚŚĂƚǁĂƐĚŝƐĐŚĂƌŐĞĚĂŶĚƐŚĞǁĂƐŚŽƵƐĞďŽƵŶĚĂŶĚŚĂĚŶŽƌĞůĂƚŝǀĞƐ ? ? ?
we had to do a home visit and it was found out that [the hospital] had changed some of 
ŚĞƌŵĞĚŝĐĂƚŝŽŶ QtŚĞŶ/ǁĞŶƚƚŽŚĞƌŚŽŵĞ ?ƐŚĞĚŝĚŶŽƚŚĂǀĞƚŚĞŵĞĚŝĐĂƚŝŽŶ Q ?ƐŚĞŚĂĚ ?Ă
ůŽƚŽĨƚŚĞŵĞĚŝĐĂƚŝŽŶǁŚŝĐŚŚĂĚďĞĞŶƐƚŽƉƉĞĚ ?ƐŽŝĨǁĞŚĂĚŶ ?ƚŐŽŶĞĂŶĚĚŽŶĞƚŚĂƚŚŽƵƐĞ
ǀŝƐŝƚ QŚer changes were so drastic that you know, it needed checking up on, and it turned 
ŽƵƚ QƚŚĂƚƚŚĞůĂĚǇǁĂƐŶ ?ƚĐŽƉŝŶŐǁŝƚŚŚĞƌŵĞĚŝĐĂƚŝŽŶĂŶǇǁĂǇǁŚŝĐŚƉƌŽďĂďůǇůĞĚƚŽŚĞƌ
ending up in [ŚŽƐƉŝƚĂů ? QƐŚĞ ?ƐĂŵƵĐŚŚĂƉƉŝĞƌ ?ŚĞĂůƚŚŝĞƌǁŽŵĂŶ ?ǇŽƵŬŶ ǁĂŶĚƚŚĂƚ ?ƐŽĨĨ
ŽĨƚŚĞďĂĐŬŽĨƚŚĞDĞĚƐZĞĐ ? ? 
(Registered Pharmacy Technician, Health Board 3) 
 
Through the Medicines Reconciliation process, this high risk and hard to reach patient received the 
medicines that were intended for them and had the medicines that were no longer intended for them 
stopped. Furthermore, a general issue of the patient struggling to cope with their medicines was 
realised which in turn was resolved through the care bundle delivery resulting in a more content and 
reassured patient.  
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: Away Team members provided examples of how the Medicines Reconciliation 
process had benefited patients and elicited a positive satisfactory experience for them.  The 
process seemed particularly beneficial for those patients who are hard to reach, and facilitated 
an open communication channel between the patient, the pharmacy and secondary care 
providers.  
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d. EVALUATION QUESTION 4: How did the intervention programme improve 
awareness and perception of safety climate? 
 
This section of the results utilises Proctor et al ?ƐdĂǆŽŶŽŵǇŽĨ/ŵƉůĞŵĞŶƚĂƚŝŽŶKƵƚĐŽŵĞƐ(34) to study 
how the SafeQuest-CP questionnaire was introduced into practice and enable measurement of 
ŝŶĚŝĐĂƚŽƌƐŽĨ ƐƵĐĐĞƐƐĨƵů ŝŵƉůĞŵĞŶƚĂƚŝŽŶ ?  WƌŽĐƚŽƌ ?Ɛ taxonomy details eight concepts: acceptability; 
adoption; appropriateness; feasibility; fidelity; implementation cost; penetration; and sustainability. 
The reported analysis reflects the common themes and subthemes raised within the qualitative data, 
organised by Proctor et al ?Ɛ ƚĂǆŽŶŽŵǇ ?ƐĐŽŵƉŽŶĞŶƚƐ and supported by quantitative measurement 
from the SafeQuest-CP questionnaire, where appropriate  
 
 
Implementation Outcomes 
  
Data Used in Analysis 
x Select data from QA1-QA5a & b 
x Safety Culture Short Interviews (NLE2, 2015) 
x CE Short Patient Impact Interviews (CE, 2016) 
x SafeQuest-CP Summary Data 2015 / 2016 
 
 
Acceptability 
 
 
 
 
 
This dimension was operationalised through mentions of the intervention being agreeable to, or liked 
by, the site staff. Within the tool staff could be identified as management and non-
management/support staff.  Two themes arose  W ƚŚĞ ƐŝƚĞ ƐƚĂĨĨ ?Ɛ ĞŵŽƚŝŽŶĂů ƌĞƐƉŽŶƐĞ ƚŽ ƚŚĞ
ŝŶƚĞƌǀĞŶƚŝŽŶĂŶĚĂůƐŽƉĞƌĐĞƉƚŝŽŶƐŽĨƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐƵƐĞĨƵůŶĞƐƐ ? 
 
Staff Emotional Response 
 
These responses related to the thoughts and feelings around the safety culture tool. There were 
differences between the management and non-management perceptions. Some respondents were 
generally positive about the whole experience, seeming to value the opportunity to use the 
SafeQuest-CP questionnaire: 
 
 “/ůŝŬĞĚŝƚ ?/ƚŚŽƵŐŚƚŝƚwas an excellent way to gain some feedback and I really like 
ĨĞĞĚďĂĐŬ ? ?
(Pharmacist, Health Board 1) 
 
Acceptability: The perception among implementation stakeholders that a given treatment, 
service, practice, or innovation is agreeable, palatable, or satisfactory. 
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 “/think it was good that all the data was anonymised, so people felt free to say 
ǁŚĂƚĞǀĞƌƚŚĞǇǁĂŶƚĞĚ ?ĂŶĚƚŚĞƌĞǁĂƐŶŽƚŚƌĞĂƚŽĨƌĞƉĞƌĐƵƐƐŝŽŶƐĂĨƚĞƌǁĂƌĚƐ ? ?
(Pharmacist, Health Board 4) 
 
,ŽǁĞǀĞƌ ?ƚŚĞƌĞǁĂƐŶĞŐĂƚŝǀŝƚǇƐƵƌƌŽƵŶĚŝŶŐƚŚĞƚŽŽů ?ƐƵƐĞ ?tŝƚŚŝŶŵĂŶĂŐĞŵĞŶƚƐƚĂĨĨƚŚĞƌĞǁĞƌĞŝŶŝƚŝĂů
concerns raised regarding the results and anxiety surrounding the implications of negative results i.e. 
if staff members highlighted issues: 
 
 “/ĨĞůƚĂůŝƚƚůĞďŝƚŶĞƌǀŽƵƐĂďŽƵƚŝƚƚŽďĞŐŝŶǁŝƚŚďĞĐĂƵƐĞ Q/ŚĂĚŶ ?ƚĚŽŶĞŽŶĞďĞĨŽƌĞĂŶĚ/
ǁĂƐŶ ?ƚƐƵƌĞƋƵŝƚĞǁŚĂƚŝƚǁĂƐĂůůĂďŽƵƚ ?ďŝƚŶĞƌǀous about getting some negative 
ĨĞĞĚďĂĐŬĂƐƚŚĞƉŚĂƌŵĂĐǇŵĂŶĂŐĞƌ ?ƐŽ/ ?ĚƐĂǇĂůŝƚƚůĞďŝƚĂŶǆŝŽƵƐ ?ƵƚŚĂǀŝŶŐƚŚĞŶĚŽŶĞ
ŝƚ ?/ĐŽƵůĚƚŚĞŶƐĞĞƚŚĞďĞŶĞĨŝƚƐŽĨŝƚ ? ? 
(Pharmacist, Health Board 4) 
 
It is worth noting that, for the management-level staff interviewed, taking part in the process seemed 
to remove the concerns as the results were predominantly positive. However, there were reports of 
results not being fed back to the team or being discussed ineffectively where issues were raised: 
 
 “ƚŚĞƌĞ ?ƐŶŽƚďĞĞŶĂny like team meeting or anything like that which is really 
ĚŝƐĂƉƉŽŝŶƚŝŶŐďĞĐĂƵƐĞƚŚĞƌĞ ?ƐĂůŽƚŽĨĂƐƉĞĐƚƐƚŚĂƚĐŽƵůĚďĞŝŵƉƌŽǀĞĚƵƉŽŶďƵƚ/ƚŚŝŶŬ
ŝƚƐŵŽƌĞŵĂŶĂŐĞŵĞŶƚŝƐǁŽƌƌŝĞĚĂďŽƵƚĐŽŶĨƌŽŶƚĂƚŝŽŶ QǁŽƌƌŝĞĚĂĐƚƵĂůůǇŚĂǀŝŶŐƚŚĂƚ ?ƐŽ
/ĚŽŶ ?ƚŬŶŽǁŝĨŝƚƐĂďŽƵƚ having some support there for the management about how 
ƚŚĞǇĐĂŶŐŽĂďŽƵƚŝƚŝĨǇŽƵ ?ƌĞŶŽƚƐŽĐŽŶĨŝĚĞŶƚĂďŽƵƚƚŚĂƚŬŝŶĚŽĨƚŚŝŶŐ ? 
(Second Pharmacist, Health Board 3) 
 
For the support staff, negative feelings around the questionnaire predominantly focused on anxiety 
regarding how anonymous their responses were  W perhaps because of the small pharmacy teams: 
 
 “&ƌŽŵƐƉĞĂŬŝŶŐƚŽŽƚŚĞƌŵĞŵďĞƌŽĨƐƚĂĨĨ QƚŚĞǇǁĞƌĞƐƚŝůůŶĞƌǀŽƵƐƚŚĂƚ QƚŚĞǇǁĞƌĞ
ƐŽŵĞŚŽǁĐŽŵŝŶŐƚŽĨŝŶĚŽƵƚǁŚĂƚƚŚĞǇŚĂĚƉƵƚ ? 
(Pharmacist, Health Board 3) 
 
Tool Perceived as Useful 
 
Respondents viewed the tool as being valuable to their practice work. Some respondents felt that the 
process highlighted that patient safety involved the whole team rather than being something which 
only concerns the manager. It also served to highlight what was in place to support patient safety: 
 
 “ǇŽƵŐĞƚƐŽƵƐĞĚƚŽƚŚŝŶŐƐďĞŝŶŐůĂǁƵŶƚŝůǇŽƵĂĐƚƵĂůůǇƌĞ-evaluate and the safety climate 
ƐƵƌǀĞǇ ?/ PŚĂƐĂůůŽǁĞĚǇŽƵũƵƐƚƚŽĚŽƚŚĂƚ ?ĂǇĞŝƚ ?ƐĂůůŽǁĞĚƵƐƚŽŚĂǀĞĂƐĞĐŽŶĚůŽŽŬ ?ŐĞƚ
the opinion of everybody in the shop so not just the pharmacist and the technicians 
ďĞĐĂƵƐĞƚŚĞĐŽƵŶƚĞƌĂƐƐŝƐƚĂŶƚƐŚĂĚƐƵĐŚŐŽŽĚŝĚĞĂƐƚŚĂƚŶŽďŽĚǇŚĂĚƚŚŽƵŐŚƚŽĨĂƐǁĞůů ? ?
(Trainee Checking Technician, Health Board 3) 
 
The results were also viewed as worthwhile and beneficial to the pharmacy as a whole: 
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 “zŽƵĐŽƵůĚƐĞĞǇŽƵǁĞƌĞĚŽŝŶŐǁĞůůŝŶĐĞƌƚĂŝŶĂƌĞĂƐĂŶĚǇŽƵǁĞƌĞƌĞĂůůǇƉƌŽƵĚŽĨŝƚĂŶĚ
ǇŽƵĐŽƵůĚƚĂŬĞĨƌŽŵƚŚĂƚĂŶĚďƵŝůĚŽŶŝƚ ? 
(Registered Technician, Health Board 3) 
 
In QA5a (CE, Oct 2016), there was a high level of agreement that the safety culture element was 
important within the site; that the safety culture element of the SPSP-PPC collaborative aligned to 
ƉĂƌƚŝĐŝƉĂŶƚƐ ? ǀŝĞǁƐ ŽĨ ƚŚĞsite role; and aligned with the overall vision of Pharmaceutical Care 
(Prescription for Excellence). 
 
 
 
 
 
 
 
 
 
Appropriateness 
 
 
 
 
This construct included responses relating to whether the SafeQuest-CP questionnaire was suitable to 
be used within a community pharmacy/dispensing doctor setting in Scotland. It was not focused on 
whether the intervention was viewed positively or not. Thematic analysis drew out three themes W 
existing culture within the practice,   practice features and staff interpretation of questionnaire 
content.  
Existing Culture within the Practice 
tŚĞƌĞƚŚĞĞǆŝƐƚŝŶŐĐƵůƚƵƌĞŵŝŐŚƚďĞĚĞĞŵĞĚ “ŶĞŐĂƚŝǀĞ ?  W for example if staff did not feel that the 
management were approachable or if the management was not open to criticism  W it may be that the 
tool is problematic:   
 “dŚĞƋƵĞƐƚŝŽŶ “ĐĂŶǇŽƵƋƵĞƐƚŝŽŶŵĂŶĂŐĞŵĞŶƚ ? ?ĐĂƵƐĞ ?ŚĞ ?ƐŚĞ ?ŝƐƚŚĞŽŶůǇƉŚĂƌŵĂĐŝƐƚ
ĂŶĚ ?ŚĞ ?ƐŚĞ ?ŝƐƚŚĞŵĂŶĂŐĞƌŽĨƚŚĞƐŚŽƉ QƐŽŵĞŽĨƚŚĞƋƵĞƐƚŝŽŶƐ/ƚŚŽƵŐŚƚƐŚĞĚŝĚƚĂŬĞ
personallǇ ? 
(Technician, Health Board 3) 
Practice Features 
 
It may be that appropriateness of the tool is dependent on the pre-existing environment.  The number 
of staff was raised as an issue with potential for single staff members impacting the results in smaller 
sites:  
 
Conclusions: Throughout the application of the safety culture survey staff acceptability was 
variable some very positive others anxious about level of anonymity, particularly in small 
premises, and how to manage the output of the questionnaire where potential issues raised; 
some responses implying that no feedback was the reaction to such findings.  Further work is 
necessary to support handling of survey output over time. 
Appropriateness: The perceived fit, relevance, or compatibility of the innovation or 
evidence based practice for a given practice setting, provider, or consumer; and/or 
perceived fit of the innovation to address a particular issue or problem. 
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 “tĞũƵƐƚŚĂĚĂƋƵŝĐŬlook at them. The maŝŶƉƌŽďůĞŵŝƐƚŚĞƌĞ ?ƐŽŶůǇĨŽƵƌŽĨƵƐ ?ƐŽŝƚ ?ƐŶŽƚ
ƉĂƌƚŝĐƵůĂƌůǇĂŶŽŶǇŵŽƵƐ ?/ƚ ?ƐǀĞƌǇƐŬĞǁĞĚďǇŽŶĞƉĞƌƐŽŶ ? ? 
(Pharmacist, Health Board 1) 
 
However, smaller sites may not have the capacity and expertise to develop these types of resources 
locally and saw the SPSP-PC as a resource whereas larger sites raised the issue of potentially confusing 
the SafeQuest-CP questionnaire with other questionnaires which are being used/overlap within their 
premises: 
 
 “ƚŚĞďŝŐŐĞƌĐŽŵƉĂŶŝĞƐŵŝŐŚƚŚĂǀĞƐŽŵĞƚŚŝŶŐƐĞƚƵƉŝŶ,ZĨŽƌŵĂƚďƵƚǁĞ ?ƌĞũƵƐƚĂƐŵĂůů
ƉŚĂƌŵĂĐǇ ?ŽŶůǇŝŶĚĞƉĞŶĚĞŶƚ ?ƐŽǁĞ ?ǀĞŶĞǀĞƌƌĞĂůůǇŚĂĚĂĐĐĞƐƐƚŽĂŶǇƚŚŝŶŐůŝŬĞƚŚĞƐĞ
tools before  W I definitely ǁŽƵůĚŶ ?ƚďĞĂďůĞƚŽĚĞƐŝŐŶĂŶǇƚŚŝŶŐůŝŬĞƚŚŝƐŽŶŵǇŽǁŶ W so it 
ǁĂƐĂƌĞĂůůǇƵƐĞĨƵůƚŽŽůƚŽŚĂǀĞ ? ? 
(Pharmacist, Health Board 1) 
 
Staff interpretation of questionnaire content  
A couple of points were raised which related to whether the staff understood the SafeQuest-CP 
questionnaire and the questions which were being asked. This related to there being multiple 
interpretations of the questions, possibly depending on job role and experience: 
 “^ŽŽŶĞŽĨƚŚĞƚŚŝŶŐƐƚŚĂƚǁĞŶŽƚŝĐĞĚǁĂƐŽƵƌĐŽƵŶƚĞƌƐƚĂĨĨŚĂǀĞŐŽƚĂĚŝĨĨĞƌĞŶƚǀŝĞǁŽĨ
what safety means to the clinical staff so the technicians and pharmacists, so if they 
ĂŶƐǁĞƌĞĚƚŚĞƋƵĞƐƚŝŽŶ “ŚŽǁĐĂŶǁĞŝŵƉƌŽǀĞƚŚĞƐĂĨĞƚǇĨŽƌƚŚĞĐƵƐƚŽŵĞƌƐŽƌƚŚĞƉĂƚŝĞŶƚƐ ? ?
ĂŶĚƚŚĞǇĂƵƚŽŵĂƚŝĐĂůůǇƚŚŽƵŐŚƚǁĞůůǁĞŶĞĞĚƚŽŵĂŬĞƐƵƌĞƚŚĞƌĞ ?ƐŶŽďŽǆĞƐůǇŝŶŐŽŶƚŚĞ
ŐƌŽƵŶĚ ?ǁŚĞƌĞǁĞǁŽƵůĚƐĂǇǁĞŶĞĞĚƚŽŵĂŬĞƐƵƌĞƚŚĞƌĞ ?ƐŶŽĞƌƌŽƌƐŝŶƚŚĞŝƌƉƌĞƐĐƌŝƉƚŝŽŶƐ ?
^ŽƚŚĞƌĞǁĂƐĂĐŽƵƉůĞŽĨƚŚŝŶŐƐƚŚĂƚƚŚĞǇ ?ĚŵĂǇďĞƚŚŝŶŬ- we maybe think that patient 
safety is great and we would out a high answer to that, but the customer assistants maybe  
ĂƚƚŚĞĚĞƐŬƚŚĞǇŵĂǇďĞŽŚŶŽƐŽŵĞƚŝŵĞƐǁĞ ?ǀĞŐŽƚďŽǆĞƐůǇŝŶŐĂďŽƵƚƚŚĞĨůŽŽƌƐŽŽƵƌ
patient safety is quite low. So there was a wee bit of trying to figure out- trying to get 
everybody on the same page cause the questions and answers were quite broad, so we 
ŚĂĚĂďƌŽĂĚƌĂŶŐĞŽĨƋƵĞƐƚŝŽŶƐĂŶĚĂŶƐǁĞƌƐƚŽŐŽƚŚƌŽƵŐŚ ? 
(Trainee Checking Technician, Health Board 3) 
 
 
 
 
Adoption  
 
 
 
Conclusions: the appropriateness of the safety culture survey was seen to be impacted upon my 
the environment in which it was to be used;  both number of staff/staff roles completing the 
survey and the underlying culture within the site were seen as factors requiring consideration in 
the future effective use of the tool.  
Adoption: The intention, initial decision, or action to try or employ an innovation or 
evidence-ďĂƐĞĚƉƌĂĐƚŝĐĞ ?ĚŽƉƚŝŽŶĂůƐŽŵĂǇďĞƌĞĨĞƌƌĞĚƚŽĂƐ “ƵƉƚĂŬĞ ? ? 
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This domain relates to the update of the tool across the sites during the study period.  As part of the 
SPSP-CP program all sites where encouraged to access the SafeQuest-CP questionnaire through the 
provided web access, complete, generate a report and discuss this with their staff. In April-May 2015, 
83% (24/29) of sites completed the tool in contrast to only 64% (18/28) of sites one year later.   This 
uptake rate varied across the NHS Boards with update lowest in NHS GG&C and highest in Health 
Board 1 who maintained 100% site participation over the program. Table 4 details the number of sites 
and participants completing the SafeQuest-CP questionnaire at both time points by Health Board.    
Table 4: SafeQuest-CP Questionnaire Completion Rates 2015/2016 
 
VARIABLE Health Board 
2 
Health Board 
3 
Health Board 4 Health Board 1 TOTAL 
Time period 1 
(2015)  
No. of sites  
No. of 
participants  
8 sites 
 
51 
participants 
3 sites 
 
34 
participants 
6 sites 
 
31 participants 
7 sites 
 
54 participants 
24 sites 
 
170 
participants 
Time period 2 
(2016) 
No. of sites  
No. of 
particpants 
3 sites 
 
13 
participants 
5 sites 
 
48 
participants 
3 sites 
 
8 participants 
7 sites 
 
51 participants 
18 sites 
 
120 
participants 
 
During the Celebratory Event Short Patient Impact Interviews, participants were asked how many of 
the Safe Quest-CP questionnaires their site had completed. A total of 8 (61.5%) had completed both, 
while 3 (23.1%) had completed the first in 2015 and 2 (15.4%) had not completed either. Some 
participants cited the reasons for not completing the second survey as time constraints, issues with 
changovers in staff, sickness and maternity leave.   
 
 
 
 
Feasibility  
 
 
This outcome measure was interpreted as whether it was possible to carry out the SafeQuest-CP 
questionnaire within the site settings. There was overlap between the feasibility and appropriateness 
dimensions; however, feasibility was interpreted as the practicalities of the tool (e.g. the mechanics 
of using the questionnaire or issues surrounding implementing the tool fully) rather than site specific 
 
Feasibility: The extent to which a new treatment, or an innovation, can be successfully 
used or carried out within a given agency or setting. 
Conclusions: The uptake of the SafeQuest-CP questionnaire reduced over time and at 
present the reasons are unclear; general messaging around time and resources may in 
part explain this pattern of use.  
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issues. Two themes were raised within this measure: logistics of completing the tool and practice 
features. 
Logistics of Using the Tool 
This included the physical components of the tool and its delivery - for example functioning IT, timing 
for completion, and structure of the questionnaire. Participants were generally positive if these things 
functioned well:   
 “Completing the survey I think was very straight forward as I said as the fact it was 
online and the process was well explained it told the staff what they needed to do that 
ŵĂĚĞŝƚĨĂŝƌůǇƐŝŵƉůĞ ?  
(Pharmacist, Health Board 3) 
 
Where there were issues with accessing the tool for reporting, this had an effect on the 
implementation of the tool: 
 
 “/ŚĂǀĞŶ ?ƚƐĞĞŶƚŚĞƌĞƐƵůƚƐ ?/ĐŽƵůĚŶ ?ƚĂĐĐĞƐƐƚŚĞŵ ?/ĨĞĞů ĂďŝƚĞŵďĂƌƌĂƐƐĞĚĂďŽƵƚƚŚŝƐďƵƚ
/ĐŽƵůĚŶ ?ƚĂĐĐĞƐƐƚŚĞŵ ?/ƚƌŝĞĚĂĐŽƵƉůĞŽĨƚŝŵĞƐĂŶĚ/ĐĂŶ ?ƚƌĞŵĞŵďĞƌŝĨŝƚƐĂŝĚŵǇ
password was wrong or if it.. I seem to think it kept taking me back to login screen and 
ĞǀĞŶƚƵĂůůǇ/ĐŽŶƚĂĐƚĞĚ Q ?ĂŶĚƐŚĞƉƵƚŵĞŝŶƚŽƵĐŚǁŝƚŚƐŽŵĞŽŶĞĞůƐĞ W I think it was 
ƉƌŽďĂďůǇ Q ? ?ŐŽƚďĂĐŬƚŽŵĞǁŝƚŚĂƐƵŐŐĞƐƚŝŽŶŽĨĂĨŝǆ ?ƐŽŵĞďŽĚǇĚŝĚĂŶǇǁĂǇ ?ƐĂŝĚ “tŚǇ
ĚŽŶ ?ƚǇŽƵƚƌǇƚŚŝƐ ? ?ĂŶĚŝƚƐƚŝůůĚŝĚŶ ?ƚǁŽƌŬ ?ŶĚƚŚĞŶŽďĞŚŽŶĞƐƚ/ĨŽrgot all about it until 
ǇĞƐƚĞƌĚĂǇ ? ? 
(Pharmacist, Health Board 1) 
 
Practice Features 
The SafeQuest-CP questionnaire was not just about completing the questionnaire; a follow-up 
meeting to discuss the results was integral to the intervention. This was affected by practice specific 
factors. Some sites reported no issue in having the meeting, aligning it to other routines in the practice 
pharmacy whilst some sites held multiple short feedback sessions on particular sections for the tool:  
 “tĞĐŽŵƉůĞƚĞĂƚĞĂŵ check survey every month as part of our ongoing thing through 
the company anyway so we just sort of carried on from ƚŚĞƌĞ ?ĂŶĚƐŽƌƚŽĨ “ǁŚĂƚĚŝĚǇŽƵ
ƚŚŝŶŬ ? ? “ŚŽǁĐŽƵůĚǇŽƵĚŽƚŚŝƐ ?ĞƚĐ ? ? 
(Pharmacist Branch Manager, Health Board 1) 
 
 ?tĞ ?ĚĂŐƌĞĞĚǁŝƚŚŝŶƚŚĞŚĞĂůƚŚďŽĂƌĚŐƌŽƵƉƚŚĂƚǁĞǁŽƵůĚĚŽƚŚŝƐŝŶƐŽƌƚŽĨƐŶŝƉƉĞƚƐƐŽ
ǁĞǁŽƵůĚƚĂŬĞĞǀĞƌǇƚŽƉŝĐĂŶĚǁĞ ?Ě- you were gonna have a five minute session every 
topic to see what was going on, what we could do better and any opportunities for change 
that we could ŝŵƉůĞŵĞŶƚ ?^ŽǁĞĚŝĚŽŶĞƚŽƉŝĐĂǁĞĞŬŽǀĞƌƐŝǆǁĞĞŬƐ Q QŝƚǁĂƐƌĞĂůůǇŐŽŽĚ
because it was just five minutes at the start of thĞĚĂǇŽƌƌŽƵŶĚĂďŽƵƚƚĞĂďƌĞĂŬ ? ?
(Pharmacist, Health Board 4) 
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Other sites found it more problematic with time, logistics and staffing issues in particular being raised 
as impediments to running all-staff meetings:  
 “/ĨǁĞǁĞƌĞĂƋƵŝĞƚĞƌƉŚĂƌŵĂĐǇ ?ŝĨǁĞŬŶĞǁƚŚĞƌĞǁĂƐĂƋƵŝĞƚĞƌƚŝŵĞŽĨĚĂǇ ?ŽƌǁĞĞŬ ?
then absolutely ǁĞǁŽƵůĚ ?ǀĞŐĞƚĂůůƐƚĂĨĨŵĞŵďĞƌƐŝŶ ?/ǁŽƵůĚ ?ǀĞůŝŬĞƚŽŚĂǀĞŚĂĚƚŚĞ
ŽƉƉŽƌƚƵŶŝƚǇƚŽĨƵůůǇĚŝƐĐƵƐƐŝƚ ?ƐŝƚǁĂƐ ?/ŚĂǀĞŶ ?ƚĚŝƐĐƵƐƐĞĚŝƚǁŝƚŚĞǀĞƌǇŵĞŵďĞƌŽĨƐƚĂĨĨ ?
ƵƚŚĂǀŝŶŐƐĂŝĚƚŚĂƚ ?ĞǀĞƌǇŵĞŵďĞƌŽĨƐƚĂĨĨŚĂƐƐĞĞŶƚŚĞƌĞƐƵůƚƐ ? ? 
(Pharmacist, Health Board 1) 
 “ǁĞ ?ǀĞŐŽƚĂƌĞĂůůǇůĂƌŐĞƚĞĂŵĂŶĚǁĞ ?ƐŽŵĞŽĨǁŚŝĐĂƌĞƉĂƌƚ-ƚŝŵĞ ?ǁĞ ?ƌĞŽƉĞŶƌŝŐŚƚƚŚĞ
ǁĂǇƚŚƌŽƵŐŚƚŚĞĚĂǇ ?ƚŚĞƌĞ ?ƐŶŽƉŽŝŶƚƚŚĂƚǁĞ ?ƌĞĐůŽƐĞĚĂŶĚǁŝƚŚƉĂƌƚƚŝŵĞǁŽƌŬĂŶĚ
ƚŚŝŶŐƐŝƚ ?ƐƌĞĂůůǇŚĂƌĚƚŽŐĞƚŚŽůĚŽĨĞǀĞƌǇŽŶĞ ?/ PzĞĂŚ ?ŶĞĂƌŝŵƉŽƐƐŝďůĞ ?/ P Yeah] when you 
ŽƉĞŶƚŽƚŚĞƉƵďůŝĐƚŚĞĞŶƚŝƌĞƚŝŵĞƚŚĂƚǇŽƵƌŽƉĞŶ Q QĂƐ/ƐĂǇĨƵůůƚĞĂŵŚƵĚĚůĞƐũƵƐƚ
ǁĞƌĞŶ ?ƚƌĞĂůůǇĂŶŽƉƚŝŽŶŽƌŵĂǇďĞƚŚĞǇǁĞƌĞ ?ŝƚ ?ƐũƵ ƚǁĞĐŽƵůĚŶ ?ƚĨŝŶĚĂǁĂǇƚŽŝŵƉůĞŵĞŶƚ
ŝƚ ?   
(Second Pharmacist, Health Board 1) 
 
At the Celebratory Event (QA5a, Oct 2016) when asked about the sufficiency of time and resource in 
delivering the safety culture survey, Away Team participants agreed that they could cope with the 
demands of the Safety Culture element, but only slightly agreed that their pharmacy and they 
themselves had sufficient time / resource to undertake the requirements of the safety culture element 
(Figure 44):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: The tool was considered feasible to deliver where there were no issues with the 
logistics of accessing the tool and the results were either being integrated into current practice 
systems and/or segmented into sections for reflection and discussion.  Where this was not the 
case challenges remained on use of the tool.    
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Figure 44: Away Team Response to Feasibility of Safety Culture 
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Fidelity 
 
 
 
Fidelity was interpreted as the extent to which the parts of the intervention were implemented as 
intended. In this instance, that meant that the questionnaire was completed and also there was 
feedback to the practice staff regarding the results. Preferably this feedback would be given through 
a meeting. The theme which emerged in this construct was results dissemination and the intended 
audience of the results. 
Results dissemination  
Some participants reported the results being fed back in different ways: some provided feedback 
direct to particular staff groupings when staff numbers were potentially too large to run a single group 
meeting; whilst others ran group discussions either covering the full feedback or divided into smaller 
sections over a time period:  
 “tĞŬŝŶĚĂĨĞĚŝŶĨŽƌŵĂƚŝŽŶŽƵƚƚŚĂƚǁĂƐƐƉĞĐŝĨŝĐƚŽƉĞŽƉůĞ ?ƐũŽďƌŽůĞƐ ? ?/ PKŬĂǇ ?ǇƵƉ ?^ŽǁĞ
tailored it to suit and then spoke with them, and through that there was a certainly a drip 
feed scenario [I: Okay] where hopefully the teams for each job role knew what they were 
ĚŽŝŶŐ Q ? ?ďƵƚŝƚŵĞĂŶƚƚŚĂƚǁĞĚŝĚŶ ?ƚŚĂǀĞƚŽŐŽƚŚƌŽƵŐŚĞǀĞƌǇƚŚŝŶŐǁŝƚŚĞǀĞƌǇďŽĚǇ ?/ P
ǀĞƌǇďŽĚǇ ?ďĞĐĂƵƐĞŝƚǁĂƐŶ ?ƚƵƐĞĨƵů ?zĞĂŚĂŶĚĂƐ/ƐĂǇĨƵůůƚĞĂŵŚƵĚĚůĞƐũƵƐƚǁĞƌĞŶ ?ƚƌĞĂůůǇ
ĂŶŽƉƚŝŽŶŽƌŵĂǇďĞƚŚĞǇǁĞƌĞ ?ŝƚ ?ƐũƵƐƚǁĞĐŽƵůĚŶ ?ƚĨŝŶĚĂǁĂǇƚŽŝŵƉůĞŵĞŶƚŝƚ ? 
(Second Pharmacist, Health Board 1) 
 
 “ƚŚĞŽŶůǇƚŚŝŶŐǁĂƐƚŚĞƉŚĂƌŵĂĐǇǁĞŚĂĚ-ƚŚĞƉŚĂƌŵĂĐŝƐƚĂƚƚŚĞƚŝŵĞĚŝĚŶ ?ƚƌĞĂůůǇƐƵƉƉŽƌƚ
it very much so that was one of ƚŚĞƐƚƌƵŐŐůĞƐƚŚĂƚǁĞŚĂĚ ?ƐŽǁĞĚŝĚŶ ?ƚƌĞĂůůǇůĞĂƌŶ
ĂŶǇƚŚŝŶŐĨŽƌŵƚŚĞĨŝƌƐƚƚŝŵĞĞŵĂŶĚǁĞĚŝĚŶ ?ƚĐŚĂŶŐĞĂŶǇƚŚŝŶŐďƵƚƚŚĞƐĞĐŽŶĚƚŝŵĞǁĞĚŝĚ
it this year, we had a different pharmacist and she was a big fan of it so everyone in the 
pharmacy took part in the survey and then we got the results back, everybody got a copy 
of the results and we had a team meeting at night times so everybody volunteered to come 
in cause everybody was as keen on- ŝĨǇŽƵƚĞůůƚŚĞŵŝƚ ?ƐŐŽŶŶĂďĞŶĞĨŝƚƚŚĞŵƚŚĞŶƚŚĞǇ ?ƌĞ
keen to come ŝŶ ? ? 
(Trainee Checking Technician, Health Board 3) 
 
Intended Audience and limited dissemination  
This theme was in relation to staff not getting the results and /or discussing the SafeQuest-CP 
questionnaire. There was a feeling among some respondents who had not received the results that 
the management felt that the results were for them predominantly and therefore feeding back to the 
other staff was not viewed as important:   
 “So the management got the results and were quite pleased with the results so therefore 
ĨĞůƚŝƚĚŝĚŶ ?ƚŶĞĞĚĂĐƚŝŽŶ 
R3- ƐŽǇŽƵĚŝĚŶ ?ƚŚĂǀĞƚĞĂŵŵĞĞƚŝŶŐƐŽƌdiscussions? 
Fidelity: The degree to which an intervention was implemented as it was prescribed in the original 
protocol or as it was intended by the program developers. 
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G3- no team ŵĞĞƚŝŶŐ ? 
(Technician, Health Board 3) 
 
Once the second survey was conducted and comparisons could be made within the pharmacy some 
participants reported that this was challenging when results were not as positive and was leading to 
less engagement: 
 “ƚŚĞĨŝƌƐƚǇĞĂƌǁĂƐƐŽŐŽŽĚ ?ƚŚĂƚŝƚ ?ƐďĞĞŶĨĞůƚƚŚĂ ƚŚĞƐĞĐŽŶĚǇĞĂƌƐďĂĚĂŶĚƚŚĂƚ ?Ɛ
somehow, you know, embarrassing almost to share, actual fact I think it gives us a lot to 
work on, you know. And ƚŚĞƚŽŽů ?ŝƚ ?ƐĨƌƵƐƚƌĂƚŝŶŐŝƚƐŶĂĞďĞĞŶƵƐĞĚĂƐŝƚƐŚŽƵůĚ ?ǁĞĐŽƵůĚ
make a big difference [I: Okay] sharing it out. I also think the first year, people were not 
just sure how confidential it was you know, I think the thought of it their answers could be 
traced back [I: Okay], whereas the second year they were made more aware that it was 
ĂŶŽŶǇŵŽƵƐ ? 
(Registered Technician, Health Board 3) 
 
 
Penetration 
 
 
 
Penetration relates to the extent of integration of a practice within the service setting.  This was 
captured at two time points, the NLE2 (Nov 2015) and CE (Oct 2016).   The corresponding theme 
related to the application of the results. 
Application of Results 
In the early feedback the Safety Climate Survey Results were used in some settings to encourage staff 
to view the pharmacy positively and to improve processes:  
 “^ŽŝƚĂĐƚƵĂůůǇŬŝŶĚŽĨŚĞůƉƐƚŽďƌŝŶŐĂƉŽƐŝƚŝǀĞƐƉŝŶĂŶĚǇŽƵŚĂǀĞĞǀŝĚĞŶĐĞĨŽƌƚŚĂƚ ?^Žŝƚ ?Ɛ
not just a case of ƚŚŝŶŐƐǁŝůůŐĞƚďĞƚƚĞƌŽĨĐŽƵƌƐĞƚŚĞǇǁŝůů ?ŝƚ ?ƐĂĐĂƐĞŽĨ ǁĞĂƌĞƐŚŽƌƚ
ƐƚĂĨĨĞĚĂƚƚŚĞŵŽŵĞŶƚďĞĐĂƵƐĞŽĨǆ ?ǇĂŶĚǌ ?ďƵƚƚŚŝƐĚŽĞƐŶ ?ƚĐĂƌƌǇŽŶďĞĐĂƵƐĞĞǀĞƌǇŽŶĞ
ĂŶƐǁĞƌĞĚƚŚŝƐŚŽŶĞƐƚůǇĂŶĚĞƋƵĂůůǇ ? ? 
Pharmacist, Health Board 1)  
However, it was not universal that the results were acted upon  W some participants reported the 
results making no change to practice processes at both time periods:   
I: So has there been any changes made in light of the results? 
Conclusions: Feedback and discussion of the results was variable ranging from no feedback with 
different rationales given to a range of techniques enabling feedback/discussion with 
groups/subgroups of staff contextualised to the setting.   
Penetration: The integration of a practice within a service setting and its subsystems. 
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P: For results, no we are fine. No, nothing. Because we have everything in place. 
ǀĞƌǇŽŶĞŝƐƋƵŝƚĞŽƉĞŶĂŶĚƚŚĞǇŬŶŽǁƚŚĞǇĐĂŶĂƉƉƌŽĂĐŚŵĞ ?ƚŚĞǇĐĂŶĂƉƉƌŽĂĐŚ Q ?
(Pharmacist, Health Board 2) 
In the later feedback (CE, 2016) some participants described how the results were improving some 
processes/activities including: error and near miss-reporting; a stimulus to look at workflow; and 
supporting more open feedback on systems and procedures by all members of the team:  
 ?MĂǇďĞũƵƐƚĂƌŽƵŶĚƚŚĞ^KWƐĂŶĚƐƚƵĨĨ ?ĞĨŽƌĞ ?ŝƚǁĂƐǀĞƌǇŵƵĐŚ “ŽŚƚŚĞƉŚĂƌŵĂĐŝƐƚ
ĐƌĞĂƚĞƐƚŚĂƚ ? ?ƌĂƚŚĞƌƚŚĂŶŽƚŚĞƌŵĞŵďĞƌƐŽĨƐƚĂĨĨďĞŝŶŐůŝŬĞ “ŽŚǁĞůůĂĐƚƵĂůůǇ ?/ ?ǀĞƌĞĂĚ
ƚŚŝƐ^KWĂŶĚĂĐƚƵĂůůǇƚŚĂƚ ?ƐŶŽƚŚŽǁǁĞĚŽƚŚŝŶŐƐĂŶǇŵŽƌĞ ?ƐŽ ?ƚŚĞƌĞǁĂƐŝŶƉƵƚĨƌŽŵ
ĞǀĞƌǇŵĞŵďĞƌŽĨƐƚĂĨĨ ?ƌĂƚŚĞƌƚŚĂŶũƵƐƚĨƌŽŵƚŽƉĚŽǁŶ ? ? 
(Pharmacist, Health Board 4) 
 
 “KŶĞŽĨƚŚĞƚŚŝŶŐƐƚŚĂƚǁĂƐĐŚĂŶŐĞĚǁĂƐǁŚĞƌĞ/ĐŚĞĐŬ ?/ǁĂƐŝŶƚŚĞǁĂǇǁĂƐĞƐƐĞŶƚŝĂůůǇ
the problem, so my checking bench was beside where our fast moving lines were, so the 
ƐƚĂĨĨǁĞƌĞĐŽŶƚŝŶƵĂůůǇƚƌǇŝŶŐƚŽŐĞƚƌŽƵŶĚŵĞ QƚŚĞŐŝƌůƐŚĂĚƐƵŐŐĞƐƚĞĚĐŚĂŶŐŝŶŐŝƚƐŽ/
ƐĂŝĚ ? “ǁĞůůǇŽƵŵŽǀĞŵĞƚŽǁŚĞƌĞǇŽƵǁĂŶƚŵĞƚŽďĞĂŶĚǁĞ ?ůůƌĞǀŝĞǁŝƚĂŶĚƐĞĞŚŽǁŝƚ
ǁŽƌŬƐ ? ?ĂŶĚƚŚĞǇŵŽǀĞĚŵĞĂŶĚĂůůŵǇŬŝƚĂŶĚĐĂďŽŽĚůĞĨŽƌĐŚĞĐŬŝŶŐƚŽĂŶŽƚŚĞƌ bit of the 
ĚŝƐƉĞŶƐĂƌǇĂŶĚŝƚ ?ƐƐƚŝůůƚŚĞƌĞƚŽƚŚŝƐĚĂǇ QŝƚĂďƐŽůƵƚĞůǇǁĂƐƚŚĞƌŝŐŚƚƚŚŝŶŐƚŽĚŽ ? ?
(Pharmacist, Health Board 4) 
 “tĞĚĞĨŝŶŝƚĞůǇŐŝǀĞĂůŽƚŵŽƌĞĨĞĞĚďĂĐŬŶŽǁ Q/ƚŚŝŶŬĞǀĞƌǇŽŶĞĨĞĞůƐůŝŬĞƚŚĞǇĐĂŶƐĂǇ
things now about it and they know I want feedback if they think things are going wrong 
ƌĂƚŚĞƌƚŚĂŶƚŚĞŵũƵƐƚƐŽƌƚŽĨƉůŽĚĚŝŶŐŽŶƚŚŝŶŬŝŶŐ Q^ Žŝƚ ?ƐĚĞĨŝŶŝƚĞůǇďĞƚƚĞƌŝŶƚŚĂƚƐĞŶƐĞ
[and ǁĞ ?ƌĞĂůůŬŝŶĚĂŵŽƌĞĂǁĂƌĞŽĨƚŚĂƚŶŽǁ ? ? 
(Pharmacist Owner, Health Board 1) 
 
At the CE (QA5a, 2016), Away Team participant were asked to score to what extent they agreed that 
ƚŚĞ^ĂĨĞƚǇƵůƚƵƌĞƚŽŽůŚĂĚŝŵƉƌŽǀĞĚƚŚĞŝƌƉŚĂƌŵĂĐǇ ?ƐƐǇƐƚĞŵƐĂŶĚƉƌŽĐĞĚƵƌĞƐ ?dŚĞmedian Likert 
scale response was  ? ? “^ůŝŐŚƚůǇŐƌĞĞ ? ?, showing some agreement that the tool had penetrated their 
working practices and was facilitating the realisation of improved safety culture.  
 
 
 
 
 
Sustainability 
 
 
 
Conclusions: There are some examples evolving of how the tool is starting to generate 
changes in practice within the individual sites but there may be useful learning to be 
shared more broadly to support wider institutionalisation.   
Sustainability: The extent to which a newly implemented treatment is maintained or 
ŝŶƐƚŝƚƵƚŝŽŶĂůŝǌĞĚǁŝƚŚŝŶĂƐĞƌǀŝĐĞƐĞƚƚŝŶŐ ?ƐŽŶŐŽŝŶŐ ?stable operations. 
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Sustainability is concerned with the maintenance of the intervention over time. Although the use of 
the questionnaire is in its relative infancy, two themes emerged relating to the early engagement with 
the activity and shaping of routine systems development over time.    
Emotional Appraisal of Tool 
The tool being perceived as useful seemed to be linked to an intention to reuse the tool.  Equally 
however, having completed the tool once seems to have increased confidence in the process, perhaps 
due to allaying any negative perceptions of the tool (highlighted under Acceptability): 
 “tĞǁŝůůŽďǀŝŽƵƐůǇĐŽŶƚŝŶƵĞĂŶĚďĞƉĂƌƚŝĐŝƉĂŶƚƐƚŚŝƐǇĞĂƌďĞĐĂƵƐĞǁŚĂƚǇŽƵĚŽŶ ?ƚǁĂŶƚ
ƚŽĨŝŶĚŝƐƚŚĂƚǇŽƵƐůŝƉ ? ? 
(Pharmacist Branch Manager, Health Board 2) 
 
 “zĞƐ ?ƐŽǁĞũƵƐƚŚĞĂƌĚĂďŽƵƚ ?ŶĂŵĞ ?ĚŽŝŶŐŚĞƌƐĂĨĞƚǇŚƵĚĚůĞƐ ?ŵŵ ?/ƚŚŝŶŬ ?ƉƌŽďĂďůǇ ?/
think we did it very quickly and kind of almost like a tick box exercise. I think probably the 
next time we should try and treat it a bit more respect, maybe be a bit more pro-active 
and not just see it as something we have to do. But actually it is going to be, you know, 
ƌĞĂůůǇƵƐĞĨƵů ? ? 
(Pharmacist, Health Board 4) 
 
Fit With Routine/Evolving Practice   
From the Celebratory Event some participants described how they were starting to use the data more 
routinely within their practice and driving potential sustainable improvements:  one practice had 
improved their error reporting approach and had ambition to move to an electronic system; another 
was integrating the output from the survey into their regular safer care meetings with wider team 
contribution:       
 ?tĞůů/ƚŚŝŶŬŝŶƚĞƌŵƐŽĨƚŚĞǁĂǇǁĞƌĞĐŽƌĚĞƌƌŽƌƐŶŽǁŝƐĂůŽƚďĞƚƚĞƌĂŶĚǁĞǁĞƌĞŶ ?ƚĚŽŝŶŐ
ƚŚĂƚƐŽǁĞůůďĞĨŽƌĞƐŽƚŚĂƚ ?ƐƉƌŽďĂďůǇďĞĞŶƚŚĞďŝŐĐŚĂŶŐĞ Q Q ? ?ǁĞ ?ƌĞŚŽƉŝŶŐƚŽŐŽ
ĞůĞĐƚƌŽŶŝĐĂĐƚƵĂůůǇĂƐǁĞůůďƵƚĂƚƚŚĞŵŝŶƵƚĞƚŚĞƌĞ ?ƐũƵƐƚůŝŬĞĂƐŚĞĞƚƵŶĚĞƌƚŚĞĨƌŝĚŐĞĂŶĚ
ĞǀĞƌǇŽŶĞũƵƐƚŬŝŶĚŽĨǁƌŝƚĞƐƚŚĞŝƌŵŝƐƚĂŬĞŽŶƚŚĞƌĞ Q ?KŶĐĞĂŵŽŶƚŚǁĞũƵƐƚŬŝŶĚŽĨƚƌǇƚŽ
look at that and see if we can you know find any common themes or any things that people 
ĐĂŶĨŝŶĚ ? 
(Pharmacy Owner, Health Board 1) 
 “tĞĚŽĂƐƉĂƌƚŽĨŽƵƌŚĞĂĚŽĨĨŝĐĞŬŝŶĚŽĨ^KWƐǁĞĚŽĂƐĂĨĞĐĂƌĞĐŚĞĐŬůŝƐƚĞǀĞƌǇǁĞĞŬĂŶĚ
we have a safer care meeting at least once a month. And I think the health care assistant 
ƚŚŽƵŐŚƚŝƚǁĂƐŶ ?ƚƉĂƌƚŽĨƚŚĞŝƌ ?ďƵƚĂĨƚĞƌǁĞŚĂĚƚŚĞĚŝƐĐƵƐƐŝŽŶĂďŽƵƚƚŚĞƐĂĨĞƌĐĂƌĞĂŶĚƚŚĞ
survey and we tied it all in with our branches safer care meetings they realised it was part 
ŽĨ ?ƚŚĞǇǁĞƌĞƉĂƌƚŽĨŝƚƚŽŽ ? ? 
(Pharmacist Branch Manager, Health Board) 
 
The data generated from all participating sites, presented by factor (working conditions, 
communication, leadership, teamwork, safety systems and learning) over the two time periods is 
presented in Figure 45. There is an observed small reduction in the median level of agreement for all 
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factors except safety systems and learning that is slightly increased. The application of the survey is 
still relatively new in the sites, especially in an environment which reports frequent staff turnover/ 
changes, which may in part reflect minimal movement in measurement to date.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, in QA5a (2016) when participants were asked to what extent they agreed they would 
continue to use the SafeQuest-CP questionnaire beyond the lifespan of the SPSP-PPC collaborative, 
the median Likert scale response was  ? ? “Agree ?) showing a good motivation to sustain the use and 
impact of the tool.  
 
 
 
 
 
 
Client Outcomes 
 
At this stage of deployment within the program it was considered that examination of service/clinical 
outcomes was premature.  
 
 
 
Conclusions: Engaging in using the tool was thought in some sites as a motivator for further use 
of the survey tool and there is evidence of a wish to continue to use the survey moving forward.  
There are also early signs of some sites changing practice and trying to integrate changes into 
current and evolving systems and procedures but this is still in its infancy.   
0
1
2
3
4
5
6
7
Working
conditions
Communication Leadership Teamwork Safety systems &
learning
Li
k
e
rt
 S
ca
le
 R
e
sp
o
n
se
s
Domain
National Snapshot of SafeQuest-CP Questionnaire Results (Year / Domain)
National snapshot 2015 National Snapshot 2016
1 = Strongly Disagree 
2 = Disagree 
3 = Slightly Disagree 
4 = Neutral 
5 = Slightly Agree  
6 = Agree 
7 = Strongly Agree 
Figure 45: National Snapshot of SafeQuest-CP Questionnaire Results 
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FUTURE DIRECTIONS  
The strategic intent of the SPSP-PPC collaborative is to inform a national implementation programme 
across all community pharmacies (approx. 1250) and dispensing doctor practices in NHS Scotland.  To 
facilitate the national implementation of the SPSP-PPC change packages, the Evaluation Team sought 
to identify a suitable framework for guidance. A number of framework pre-requisites were specified 
and a literature search undertaken which identified around 50 implementation Frameworks designed 
for health services (32, 37, 41).   Analysis if these frameworks against pre-specified criteria identified 
ƚŚĞ/,/ĨƌĂŵĞǁŽƌŬ ‘'ŽŝŶŐƚŽ&Ƶůů^ĐĂůĞ ?ĂƐƐƵŝƚĂďůĞĨŽƌƚhe SPSP-PPC collaborative (37).  The framework 
aims to address the challenges of scaling up new healthcare interventions by offering practical 
guidance. It incorporates guidance on three components; 
x Four sequential stages of scale-up  W (1) the set up phase, (2) developing the scalable unit, (3) 
test of scale up and (4) going to full scale.   
x Adoption mechanisms - which can be described as contextual and environmental factors 
which can affect the implementation process  
x Support Systems  W which offers understanding of the supportive infrastructure optimal to 
scaling up healthcare interventions. 
 
This section of the report pulls together the key lessons drawn from the analysis of results paying 
attention to the components defined in the IHI framework, where appropriate, and any current or 
planned action to support spread of the SPSP-PPC collaborative across NHS Scotland.  
 
Collaborative Learning Approach Delivering Change Packages  
Key lessons  
There is significant learning from the evaluation to help inform how to effectively introduce the Model 
for Improvement (MI) and the underpinning knowledge and skills necessary to support effective and 
efficient delivery of the change packages into community pharmacy/dispensing doctor practices in 
moving forward.  Key lessons to consider:  
x Bringing together participating site leads (Away Team members) across the organisation 
generated a positive reaction, and provided a networking opportunity and motivation to be 
engaged with the SPSP-PPC collaborative 
x The collaborative approach delivered was rated positively by Away Team members with 
regards to the recognised factors of success: expert lead support; collaborative processes; 
teamwork; organisational support   
x Elements of the QI approach including the PDSA cycle documentation process was in some 
sites challenging to maintain routinely in practice 
x Baseline knowledge, understanding and use of the QI approach and tools was initially low but 
rose rapidly through the model of training provision delivered to Away Teams however had 
less impact on Home Teams 
x Involvement of the wider site staff will be important in moving to a sustainable model, and 
further consideration of their learning needs and how best to raise awareness of, and deliver 
training on, the QI approach and change package programmes requires attention.  
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As a direct result of the work of the SPSP-PPC collaborative the Scottish Government have chosen to 
include the Quality Improvement Approach as part of a new NHS Circular  W PCA(P)(2016) entitled 
 “Pharmaceutical Services Supporting Continuous Improvement and Closer Partnership Working ?, 
issued September 2016 (42).    The ambition is to have continuous improvement as an ongoing element 
within the community pharmacy funding settlement moving forward, through introducing an 
incremental approach of building capacity in improvement methodology and practice whilst 
supporting the development of a strong patient safety culture. All community pharmacy contractors 
in NHS Scotland (approximately 1250) will receive a Single Improvement Payment in financial year 
2016/2017 for undertaking three activities as detailed in Figure 46.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activity A within the circular takes forward a modified approach to that delivered through the SPSP-
PPC collaborative. This approach builds upon the NHS Scotland Improvement Hub which includes 
multiple online learning resources (43). The pharmacy contractor and all employed pharmacists are 
being required to complete the identified modules as an initial step to building knowledge and skills 
in quality improvement approaches in practice sites.  These activities will be supported by introducing 
the established Health Board Community Pharmacy Facilitator appointments to the quality 
improvement approach through nationally coordŝŶĂƚĞĚ  “ƚƌĂŝŶŝŶŐ ƚŚĞ ƚƌĂŝŶĞƌƐ ?events, supported 
through a second, NHS circular (44). 
 
 
 
 
 ?Completion of six foundation level modules, each one of which takes one hour. They provide a basic 
introduction to the widely used improvement methodology):
 ?Introduction to our purpose and values 
 ?Introduction to quality and quality improvement 
 ?Introduction to healthcare systems 
 ?Introduction to quality improvement methods 
 ?Lean in healthcare 
 ?Knowledge into practice in healthcare 
Activity A: Understanding Improvement
 ?Completion of two practitioner level modules, each of which takes one hour, and encouraged to create 
space and time for reflective practice and peer discussion in relation to continuous improvement. This 
should include reflection on the Safety Climate Survey):
 ?Creativity and innovation in healthcare 
 ?Evaluating quality improvement
Activity B: Building a Safer Culture- space, time & context
 ?Completion of  this activity by 30th September 2017 followed by discussion of the results in an open and 
supportive way, and should use the findings to identify areas for improvement. 
Activity C: Undertaking the Pharmacy Safety Climate Survey
Figure 46: Deliverables Defined Within NHS Circular PCA(P)(2016) 15 
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High Risk Medicine Care Bundles 
Key lessons  
There is significant learning from the evaluation to help inform further development of the care 
bundles, both in respect to content and implementation. Key lessons to consider:  
x Away Team acceptability of the HRM intervention was low at baseline due to a lack of 
understanding yet over time improved and was maintained through local contextualised 
solutions to implementation. Delivering the care bundle itself was seen as feasible.  
x Delivering the care bundle was feasible.  Some sites developed their own tools to support 
integration into established systems and procedures. Home Team awareness and 
understanding was variable, much stronger for Away Team participants, and this impacted 
on whom in the practice team was delivering the care bundle to patients, often the onus 
lying with the Pharmacist.  
x Confidence levels in the use of QI tools was varied: Care Bundles (high), PDSA Cycles and Run 
Charts (low).  
x The HRM element was seen as appropriate for community pharmacy/dispensing practices, in 
relation to provision of safe and reliable patient care.  Better alignment with other national 
services was proposed in moving forward.  
x The HRM element was seen as fitting well with pre-existing work activities (aside from data 
collection and reporting); delivery remains ongoing in the practice sites (approaching two 
years) with a strong willingness from staff to continue.  
x Feedback on patient satisfaction flagged that application of the HRM Care Bundle on a 
regular basis maybe laborious for some patients; but patients appreciated the 
communication channel the HRM element offered to extend engagement with the practice 
team.  
 
In the context of High Risk Medicines care bundles there has been agreement that the next logical 
step from the care bundle testing within the SPSP-PPC collaborative is to ĚĞǀĞůŽƉƚŚĞ ‘ƐĐĂůĂďůĞƵŶŝƚ ?
prior to larger scale roll out as defined within the IHI ĨƌĂŵĞǁŽƌŬ  ‘'ŽŝŶŐƚŽ&Ƶůů^ĐĂůĞ ?(37).  This is 
currently involving two components: 
x Developing a consolidated Care Bundles though a Consensus Workshop. 
x Developing a Generic High Risk Medicine Care Bundle Process Map to facilitate the next 
phases of scale-up.  
 
Consensus Workshop 
Within the pilot phase, there were two different Warfarin Care Bundles and two different NSAID Care 
Bundles operationalised. At various Steering Group meetings towards the end of the programme a 
desire to develop and further test consolidated care bundles was expressed. The overall aim was to 
consolidate the existing care bundles into a single NSAID Care Bundle, a single Warfarin Care Bundle, 
each with agreed patient cohorts and data collection and measurement plans.  
 
The Nominal Group Technique (NGT) was selected as an appropriate method; it is a structured 
approach to decision-making and consensus generating (45). It involves group interaction, discussion 
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ĂŶĚƚŚĞĂƚƚĂŝŶŵĞŶƚŽĨĐŽŶƐĞŶƐƵƐ ?ĂŶĚŝƚĂůůŽǁƐĨŽƌĞǀĞƌǇďŽĚǇ ?ƐŝŶƉƵƚĞƋƵĂůůǇ- preventing individuals 
overpowering the discussion. The process was believed to facilitate continued stakeholder 
engagement and ownership of the final outcome. 
 
The NGT participants have been purposefully selected based on their involvement in the programme, 
and primarily include the SPSP-PPC Steering Group.   This event is scheduled to run in November 2017, 
led by the evaluation team.    
 
Generic Process Map 
A known barrier to implementation is the lack of compatibility of new interventions with routine 
practice (46-48). Furthermore, in documented community pharmacy quality initiatives, integration 
into practice has been identified as one of six supporting factors (49). In light of this evidence and 
recognizing the need to pay attention to the IHI adoption mechanisms and support system factors we 
have taken the opportunity to focus on understanding how the pilot pharmacies integrated the care 
bundles into routine practice to inform the development of a generic process map which may facilitate 
larger scale roll out as part of a resource toolkit for deployment. The emphasis here was not on 
refinement of the process per se, but to develop an understanding from the pilot phase and use this 
learning to facilitate next steps.   
 
Through a three phased, qualitative case-study methodology (50), depicted in Figure 47 generic 
process map was developed.  
 
Figure 47: Overview of Generic Process Map Development 
 
Through the exploration of variation, five core steps fundamental to successful care bundle delivery 
ǁĞƌĞ ŝĚĞŶƚŝĨŝĞĚ P  ? ? ? ŝĚĞŶƚŝĨǇŝŶŐ ĞůŝŐŝďůĞ ƉĂƚŝĞŶƚƐ ?  ? ? ?ĐůŝŶŝĐĂů ĂƐƐĞƐƐŵĞŶƚ ?  ? ? ? ŚŝŐŚůŝŐŚƚŝŶŐ ƉĂƚŝĞŶƚƐ ?
eligibility, (4) delivering the care bundle to the patients including non-attending patients, and (5) 
documentation. In addition, the process of integrating these five steps into routine practice was also 
identified, shown in Figure 48. The suitability for a whole team approach was also highlighted, as only 
the clinical ĂƐƐĞƐƐŵĞŶƚƐƚĞƉƌĞƋƵŝƌĞĚƉŚĂƌŵĂĐŝƐƚ ?ƐŝŶǀŽůǀĞŵĞŶƚ ?
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Figure 48: Generic Process Map Detailing Integration of Care Bundle into Routine Practice 
 
It has been agreed within the circular NHS PCA(P)(2016) 15 the programme sites will continue to test 
the new consensus care bundles from January to March 2017 (42).  This planned approach should 
enable the following to be achieved over the next few months: the consolidated care bundles to be 
further tested in a different setting (Health Boards who developed the original Warfarin Care Bundle 
to test the new consensus NSAID Care Bundle and vice versa) before proceeding to full scale roll out;  
single consolidated care bundles will offer equality of patient care to all eligible patients, and facilitates 
evaluation of service and clinical outcome measures moving forward; identification of the core stages 
in delivery of the care bundle (generic process map testing) allows for targeted development of 
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resources for national implementation and may facilitate whole team engagement; and, testing the 
concept of developing a generic process map for different HRM areas, may inform adaptability of the 
process to future clinical contexts.  
 
SafeQuest-CP Questionnaire 
Key Lessons  
The patient safety survey tool has now been applied up to twice in the study sites within the SPSP-PPC 
program and there is significant learning from the evaluation undertaken to date to shape how this 
tool could be taken to spread across NHS Scotland community pharmacy and dispensing doctor sites.  
Key lessons to consider:   
x Assurance of anonymity of individuals completing the tool is important, and was especially 
a concern for small sites 
x The underlying safety culture environment within the setting is crucial to success 
x Awareness of the tool and the potential for integration with established systems and 
procedures considering patient safety would facilitate sustained spread 
x The time and resources necessary to apply the tool and discuss the outputs need to be 
acknowledged; there should be recognition that feedback can take multiple forms depending 
on the setting  
x The opportunity to share/benefit from the learning generated by the SPSP-PPC 
collaborative pilot sites (potentially acting as Champions) to new sites should be maximised.   
 
As outlined in Figure 46, the use of the SafeQuest-CP questionnaire will be progressed through the 
NHS Circular PCA(P)(2016) 15 (42).  This will involve all community pharmacies in Scotland 
(approximately 1250) completing the SafeQuest-CP questionnaire by 30th September 2017 and 
following this up with a discussion of the results within the pharmacy team to identify areas for 
improvement. The SPSP-PPC team have produced a series of resources to introduce pharmacy teams 
to the SafeQuest-CP questionnaire including a video and written guide (51). These are based on the 
evidence generated through the SPSP-PPC collaborative and include an important focus on how to 
manage feedback and discussion of results, as this was identified as a key challenge.  The resource 
includes advice on how to organise meetings and provides templates on how to work through the 
culture domains with the team and prepare an action plan as a focus for improvement.    
Given the scale of the spread, from 27 to approximately 1250 sites, it will be important to monitor the 
level of update and engagement with the activity to inform future direction and measure the impact 
on safety culture within these primary care settings. A number of elements could be considered: 
uptake and participation rates, available through the electronic system; sampling/survey of new sites 
using the evaluation tools within the program to capture further lessons on implementation 
approaches for sustained engagement and explore service and client outcomes arising from delivery 
of the anticipated action plans generated by sites over time.  
Medicines Reconciliation Care Bundle 
Key lessons  
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The SPSP-PPC collaborative provides some early insights from the evaluation to guide further 
development and implementation of a Medicines Reconciliation change package into community 
pharmacy/dispensing practices moving forward.  Key lessons to consider:  
x Understanding of Medicines Reconciliation improved amongst Away Team members over 
time and was seen as important, appropriate and acceptable.  
x The major challenge to feasibility was access to the IDL (Immediate Discharge Letter), which 
when resolved enabled delivery of the care bundle in practices.   
x Medicines Reconciliation sustainability is dependent  upon a number of factors: definition 
of the patient cohort; timely and reliable access to IDLs; and appropriate staff involvement 
x The Medicines Reconciliation Care Bundle was delivered across all four Health Boards but the 
patient cohort to whom it was applied varied.  
x The Medicines Reconciliation process and care bundle was satisfactory to patients, and 
seemed particularly beneficial for those patients who are hard to reach, and facilitated an 
open communication channel between the patient, the pharmacy and secondary care 
providers.  
 
The NHS Circular PCA(P)(2016) 15 also provides opportunity for the current study sites to continue 
testing of the Medicines Reconciliation Care Bundle (42).  Discussions are ongoing to consider how 
best to progress the development of this change package.   
 
CONCLUSION 
The SPSP-PPC collaborative has been an ambitious 2yr programme positioned to  “improve patient 
safety by strengthening the contribution of community pharmacy and improving communications 
within the primary care team ? ?dŚĞƉƌŽŐƌĂŵŵĞŚĂƐƐŽƵŐŚƚƚŽĂĐŚŝĞǀĞƚŚŝƐƚŚƌŽƵŐŚƚŚĞĨŽƌŵĂƚŝŽŶŽĨ
a collaborative and use of established improvement tools and approaches focused on three change 
packages: High Risk Medicines, Safety Culture and Medicines Reconciliation.     
 
Delivery of the programme across multiple sites with differing geographies (urban/rural), health 
systems (four distinct localised health care systems) and practice environments (small/medium/large 
chain and independent community pharmacies, plus dispensing practices) has provided the 
opportunity to test both the approach and the delivery of the change packages.   The consequences 
of this diversity have been threefold: firstly, the opportunity to collect, collate and analyse an 
extensive data repository generated through the applied mixed methods evaluation approach over 
the programme duration; secondly, variable response to the level of uptake and use of the three 
change packages with observed  adaptation in the  local practice setting to some extent; and thirdly, 
to generate insight into the potential key adoption mechanisms and support systems that are known 
to be crucial in moving to a successful full scale rollout.     
 
The evaluation approach, integrated within the programme development and review process, has 
afforded the opportunity to provide continuous feedback of learning gained to the SPSP-PPC Steering 
Group. This report consolidates the evidence generated and summarises key lessons for consideration 
in progressing this important patient safety programme.   
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